Archive for the ‘Gene Therapy Doctor’ Category

An unexpected early morning phone call from the hospital is never good news. When Joy Johnson answered, her first thought was that Sharon Birzer, her partner of 15 years, was dead. Her fears were amplified by the voice on the other end refusing to confirm or deny it. Just come in and talk to one of the doctors, she remembers the voice saying.

Johnson knew this was a real possibility. A few weeks earlier, she and Birzer sat in the exam room of a lymphoma specialist at Stanford University. Birzers cancer had grown, and fast first during one type of chemotherapy, then through a second. Out of standard options, Birzers local oncologist had referred her for a novel treatment called chimeric antigen receptor T-cell therapy or CAR-T. Birzer and Johnson knew the treatment was risky. They were warned there was a chance of death. There was also a chance of serious complications such as multi-organ failure and neurological impairment. But it was like warning a drowning person that her lifeboat could have problems. Without treatment, the chance of Birzers death was all but certain. She signed the consent form.

Johnson hung up the phone that early morning and sped to the hospital. She met with a doctor and two chaplains in a windowless room in the cancer ward, where happy photos of cancer alumni smiled down from the walls. This is getting worse and worse, Johnson thought. As she remembers it, the doctor went through the timeline of what happened for 10 minutes, explaining how Birzer became sicker and sicker, before Johnson interrupted with the thought splitting her world in two: I need you to tell me whether shes alive or dead.

Birzer wasnt dead. But she was far from okay. The ordeal began with Birzer speaking gibberish. Then came seizures so severe there was concern she wouldnt be able to breathe on her own. When it took a few different medications to stop Birzer from seizing, her doctors sedated her, put a breathing tube down her throat, and connected her to a ventilator. Now, she was unconscious and in the intensive care unit (ICU).

Birzer was one of the early patients to receive CAR-T, a radical new therapy to treat cancer. It involved removing Birzers own blood, filtering for immune cells called T-cells, and genetically engineering those cells to recognize and attack her lymphoma. CAR-T made history in 2017 as the first FDA-approved gene therapy to treat any disease. After three to six months of follow-up, the trials that led to approval showed response rates of 80 percent and above in aggressive leukemias and lymphomas that had resisted chemotherapy. Patients on the brink of death were coming back to life.

This is something I often dream of seeing but rarely do. As a doctor who treats cancer, I think a lot about how to frame new treatments to my patients. I never want to give false hope. But the uncertainty inherent to my field also cautions me against closing the door on optimism prematurely. We take it as a point of pride that no field of medicine evolves as rapidly as cancer the FDA approves dozens of new treatments a year. One of my biggest challenges is staying up to date on every development and teasing apart what should and shouldnt change my practice. I am often a mediator for my patients, tempering theoretical promises with everyday realism. To accept a research finding into medical practice, I prefer slow steps showing me proof of concept, safety, and efficacy.

CAR-T, nearly three decades in the making, systemically cleared these hurdles. Not only did the product work, its approach was also unique among cancer treatments. Unlike our usual advances, this wasnt a matter of prescribing an old drug for a new disease or remixing known medications. CAR-T isnt even a drug. This is a one-time infusion giving a person a better version of her own immune system. When the FDA approved its use, it wasnt a question of whether my hospital would be involved, but how we could stay ahead. We werent alone.

Today, two FDA-approved CAR-T products called Kymriah and Yescarta are available in more than 100 hospitals collectively across the U.S. Hundreds of clinical trials are tinkering with dosages, patient populations, and types of cancer. Some medical centers are manufacturing the cells on-site.

The FDA approved CAR-T with a drug safety program called a Risk Evaluation and Mitigation Strategy (REMS). As I cared for these patients, I quickly realized the FDAs concerns. Of the 10 or so patients Ive treated, more than half developed strange neurologic side effects ranging from headaches to difficulty speaking to seizures to falling unconscious. We scrambled to learn how to manage the side effects in real time.

Johnson and Birzer, who I didnt treat personally but spoke to at length for this essay, understood this better than most. Both had worked in quality control for a blood bank and were medically savvier than the average patient. They accepted a medical system with a learning curve. They were fine with hearing I dont know. Signing up for a trailblazing treatment meant going along for the ride. Twists and bumps were par for the course.

Cancer, by definition, means something has gone very wrong within a cell has malfunctioned and multiplied. The philosophy for fighting cancer has been, for the most part, creating and bringing in treatments from outside the body. Thats how we got to the most common modern approaches: Chemotherapy (administering drugs to kill cancer),radiation(using high energy beams to kill cancer), and surgery (cutting cancer out with a scalpel and other tools). Next came the genetics revolution, with a focus on creating drugs that target a precise genetic mutation separating a cancer cell from a normal one. But cancers are genetically complex, with legions of mutations and the talent to develop new ones. Its rare to have that one magic bullet.

Over the last decade or so, our approach shifted. Instead of fighting cancer from the outside, we are increasingly turning in. The human body is already marvelously equipped to recognize and attack invaders, from the common cold to food poisoning, even if the invaders are ones the body has never seen before. Cancer doesnt belong either. But since cancer cells come from normal ones, theyve developed clever camouflages to trick and evade the immune system. The 2018 Nobel Prize in Physiology or Medicine was jointly awarded to two researchers for their work in immunotherapy, a class of medications devoted to wiping out the camouflages and restoring the immune systems upper hand. As I once watched a fellow oncologist describe it to a patient: Im not treating you. You are treating you.

What if we could go one step further? What if we could genetically engineer a patients own immune cells to spot and fight cancer, as a sort of best hits of genetic therapy and immunotherapy?

Enter CAR-T. The technology uses T-cells, which are like the bouncers of the immune system. T-cells survey the body and make sure everything belongs. CAR-T involves removing a persons T-cells from her blood and using a disarmed virus to deliver new genetic material to the cells. The new genes given to the T-cells help them make two types of proteins. The first giving the technology its name is a CAR, which sits on the T-cells surface and binds to a protein on the tumor cells surface, like a lock and key. The second serves as the T-cells caffeine jolt, rousing it to activate. Once the genetic engineering part is done, the T-cells are prodded to multiply by being placed on a rocking device that feeds them nutrients while filtering their wastes. When the cells reach a high enough number a typical dose ranges from hundreds of thousands to hundreds of millions they are formidable enough to go back into the patient. Once inside, the cancer provokes the new cells to replicate even more. After one week, a typical expansion means multiplying by about another 1,000-fold.

Practically, it looks like this: A person comes in for an appointment. She has a catheter placed in a vein, perhaps in her arm or her chest, that connects to a large, whirring machine which pulls in her blood and separates it into its components. The medical team set the T-cells aside to freeze while the rest of the blood circulates back into the patient in a closed loop. Then, the hospital ships the cells frozen to the relevant pharmaceutical companys headquarters or transports them to a lab on-site, where thawing and manufacturing takes from a few days to a few weeks. When the cells are ready, the patient undergoes about three days of chemotherapy to kill both cancer and normal cells, making room for the millions of new cells and eradicating normal immune players that could jeopardize their existence. She then gets a day or two to rest. When the new cells are infused back into her blood, we call that Day 0.

I remember the first time I watched a patient get his Day 0 infusion. It felt anti-climactic. The entire process took about 15 minutes. The CAR-T cells are invisible to the naked eye, housed in a small plastic bag containing clear liquid.

Thats it? my patient asked when the nurse said it was over. The infusion part is easy. The hard part is everything that comes next.

Once the cells are in, they cant turn off. That this may cause collateral damage was evident from the start. In 2009 working in parallel with other researchers at Memorial Sloan Kettering Cancer Center in New York and the National Cancer Institute in Maryland oncologists at the University of Pennsylvania opened a clinical trial for CAR-T in human leukemia patients. (Carl June, who led the CAR-T development, did not respond to Undarks interview request.) Of the first three patients who got CAR-T infusions, two achieved complete remission but nearly died in the process. The first was a retired corrections officer named Bill Ludwig, who developed extremely high fevers and went into multi-organ failure requiring time in the ICU. At the time, the medical teams had no idea why it was happening or how to stop it. But time passed. Ludwig got better. Then came the truly incredible part: His cancer was gone.

With only philanthropic support, the trial ran out of funding. Of the eligible patients they intended to treat, the Penn doctors only treated three. So they published the results of one patient in the New England Journal of Medicine and presented the outcomes of all three patients, including Ludwig, at a cancer conference anyway. From there, the money poured in. Based on the results, the Swiss pharmaceutical company Novartis licensed the rights of the therapy.

The next year, six-year-old Emily Whitehead was on the brink of death when she became the first child to receive CAR-T. She also became extremely ill in the ICU, and her cancer was also eventually cured. Her media savvy parents helped bring her story public, making her the poster child for CAR-T. In 2014, the FDA granted CAR-T a breakthrough therapy designation to expedite the development of extremely promising therapies. By 2017, a larger trial gave the treatment to 75 children and young adults with a type of leukemia B-cell acute lymphoblastic leukemia that failed to respond to chemotherapy. Eighty-one percent had no sign of cancer after three months.

In August 2017, the FDA approved a CAR-T treatment as the first gene therapy in the U.S. The decision was unanimous. The Oncologic Drugs Advisory Committee, a branch of the FDA that reviews new cancer products, voted 10 to zero in favor of Kymriah. Committee members called the responses remarkable and potentially paradigm changing. When the announcement broke, a crowd formed in the medical education center of Penn Medicine, made up of ecstatic faculty and staff. There were banners and T-shirts. A remarkable thing happened was the tagline, above a cartoon image of a heroic T-cell. Two months later, in October 2017, the FDA approved a second CAR-T formulation called Yescarta from Kite Pharma, a subsidiary of Gilead Sciences, to treat an aggressive blood cancer in adults called diffuse large B-cell lymphoma, the trial of which had shown a 54 percent complete response rate, meaning all signs of cancer had disappeared. In May 2018, Kymriah was approved to treat adults with non-Hodgkin lymphoma.

That year, the American Society of Clinical Oncology named CAR-T the Advance of the Year, beating out immunotherapy, which had won two years in a row. When I attended the last American Society of Hematology meeting in December 2018, CAR-T stole the show. Trying to get into CAR-T talks felt like trying to get a photo with a celebrity. Running five minutes late to one session meant facing closed doors. Others were standing room only. With every slide, it became difficult to see over a sea of smartphones snapping photos. At one session I found a seat next to the oncologist from my hospital who treated Birzer. Look, she nudged me. Do you see all these non-member badges? I turned. Members were doctors like us who treated blood cancers. I couldnt imagine who else would want to be here. Who are they? I asked. Investors, she said. It felt obvious the moment she said it.

For patients, the dreaded c word is cancer. For oncologists, its cure. When patients ask, Ive noticed how we gently steer the conversation toward safer lingo. We talk about keeping the cancer in check. Cure is a dangerous word, used only when so much time has passed from her cancer diagnosis we can be reasonably certain its gone. But that line is arbitrary. We celebrate therapies that add weeks or months because the diseases are pugnacious, the biology diverse, and the threat of relapse looming. Oncologists are a tempered group, or so Ive learned, finding inspiration in slow, incremental change.

This was completely different. These were patients who would have otherwise died, and the trials were boasting that 54 to 81 percent were cancer-free upon initial follow-up. PET scans showed tumors that had speckled an entire body melt away. Bone marrow biopsies were clear, with even the most sensitive testing unable to detect disease.

The dreaded word was being tossed around could this be the cure weve always wanted?

When a new drug gets FDA approval, it makes its way into clinical practice, swiftly and often with little fanfare. Under the drug safety program REMS, hospitals offering CAR-T were obligated to undergo special training to monitor and manage side effects. As hospitals worked to create CAR-T programs, oncologists like me made the all too familiar transition from first-time user to expert.

It was May 2018 when I rotated through my hospitals unit and cared for my first patients on CAR-T. As I covered 24-hour shifts, I quickly learned that whether I would sleep that night depended on how many CAR-T patients I was covering. With each treatment, it felt like we were pouring gasoline on the fire of patients immune systems. Some developed high fevers and their blood pressures plummeted, mimicking a serious infection. But there was no infection to be found. When resuscitating with fluids couldnt maintain my patients blood pressures, I sent them to the ICU where they required intensive support to supply blood to their critical organs.

We now have a name for this effect cytokine release syndrome that occurs in more than half of patients who receive CAR-T, starting with Ludwig and Whitehead. The syndrome is the collateral damage of an immune system on the highest possible alert. This was first seen with other types of immunotherapy, but CAR-T took its severity to a new level. Usually starting the week after CAR-T, cytokine release syndrome can range from simple fevers to multi-organ failure affecting the liver, kidneys, heart, and more. The activated T-cells make and recruit other immune players called cytokines to join in the fight. Cytokines then recruit more immune cells. Unlike in the early trials at Penn, we now have two medicines to dampen the effect. Steroids calm the immune system in general, while a medication called tocilizumab, used to treat autoimmune disorders such as rheumatoid arthritis, blocks cytokines specifically.

Fortuity was behind the idea of tocilizumab: When Emily Whitehead, the first child to receive CAR-T, developed cytokine release syndrome, her medical team noted that her blood contained high levels of a cytokine called interleukin 6. Carl June thought of his own daughter, who had juvenile rheumatoid arthritis and was on a new FDA-approved medication that suppressed the same cytokine. The team tried the drug, tocilizumab, in Whitehead. It worked.

Still, we were cautious in our early treatments. The symptoms of cytokine release syndrome mimic the symptoms of severe infection. If this were infection, medicines that dampen a patients immune system would be the opposite of what youd want to give. There was another concern: Would these medications dampen the anti-cancer activity too? We didnt know. Whenever a CAR-T patient spiked a fever, I struggled with the question is it cytokine release syndrome, or is it infection? I often played it safe and covered all bases, starting antibiotics and steroids at the same time. It was counterintuitive, like pressing both heat and ice on a strain, or treating a patient simultaneously with fluids and diuretics.

The second side effect was even scarier: Patients stopped talking. Some, like Sharon Birzer spoke gibberish or had violent seizures.Some couldnt interact at all, unable to follow simple commands like squeeze my fingers. How? Why? At hospitals across the nation, perfectly cognitively intact people who had signed up to treat their cancer were unable to ask what was happening.

Our nurses learned to ask a standardized list of questions to catch the effect, which we called neurotoxicity: Where are we? Who is the president? What is 100 minus 10? When the patients scored too low on these quizzes, they called me to the bedside.

In turn, I relied heavily on alaminated booklet, made by other doctors who were using CAR-T, which we tacked to a bulletin board in our doctors workroom. It contained a short chart noting how to score severity and what to do next. I flipped through the brightly color-coded pages telling me when to order a head CT-scan to look for brain swelling and when to place scalp electrodes looking for seizures. Meanwhile, we formed new channels of communication. As I routinely called a handful of CAR-T specialists at my hospital in the middle of the night, national consortiums formed where specialists around the country shared their experiences. As we tweaked the instructions, we scribbled updates to the booklet in pen.

I wanted to know whether my experience was representative. I came across an abstract and conference talk that explored what happened to 277 patients who received CAR-T in the real world, so I emailed the lead author, Loretta Nastoupil, director of the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. Fortuitously, she was planning a trip to my university to give a talk that month. We met at a caf and I asked what her research found. Compared to the earlier trials, the patients were much sicker, she said. Of the 277 patients, more than 40 percent wouldnt have been eligible for the very trials that got CAR-T approved. Was her team calling other centers for advice? They were calling us, she said.

Patients included in clinical trials are carefully selected. They tend not to have other major medical problems, as we want them to survive whatever rigorous new therapy we put them through. Nastoupil admits some of it is arbitrary. Many criteria in the CAR-T trials were based on criteria that had been used in chemotherapy trials. These become standard languages that apply to all studies, she said, listing benchmarks like a patients age, kidney function, and platelet count. But we have no idea whether criteria for chemotherapy would apply to cellular therapy.

Now, with a blanket FDA approval comes clinical judgment. Patients want a chance. Oncologists want to give their patients a chance. Young, old, prior cancer, heart disease, or liver disease without strict trial criteria, anyone is fair game.

When I was making rounds at my hospital, I never wandered too far from these patients rooms, medically prepared for them to crash at any moment. At the same time, early side effects made me optimistic. A bizarre truism in cancer is that side effects may bode well. They could mean the treatment is working. Cancer is usually a waiting game, requiring months to learn an answer. Patients and doctors alike seek clues, but the only real way to know is waiting: Will the next PET scan show anything? What are the biopsy results?

CAR-T was fundamentally different from other cancer treatments in that it worked fast. Birzers first clue came just a few hours after her infusion. She developed pain in her lower back. She described it as feeling like she had menstrual cramps. A heavy burden of lymphoma lay in her uterus. Could the pain mean that the CAR-T cells had migrated to the right spot and started to work? Her medical team didnt know, but the lead doctors instinct was that it was a good sign.

Two days later, her temperature shot up to 102. Her blood pressure dropped. The medical team diagnosed cytokine release syndrome, as though right on schedule, and gave her tocilizumab.

Every day, the nurses would ask her questions and have her write simple sentences on a slip of paper to monitor for neurotoxicity. By the fifth day, her answers changed. She started saying things that were crazy, Johnson explained.

One of Birzer's sentences was guinea pigs eat greens like hay and pizza. Birzer and Johnson owned two guinea pigs, so their diet would be something Birzer normally knew well. So Johnson tried to reason with her: They dont eat pizza. And Birzer replied, They do eat pizza, but only gluten-free.

Johnson remembers being struck by the certainty in her partners delirium. Not only was Birzer confused, she was confident she was not. She was doubling down on everything, Johnson described. She was absolutely sure she was right.

Johnson vividly remembers the evening before the frightening early-morning phone call that brought her rushing back to the hospital. Birzer had said there was no point in Johnson staying overnight; she would only watch her be in pain. So Johnson went home. After she did, the doctor came by multiple times to evaluate Birzer. She was deteriorating and fast. Her speech became more and more garbled. Soon she couldnt name simple objects and didnt know where she was. At 3 a.m., the doctor ordered a head CT to make sure Birzer wasnt bleeding into her brain.

Fortunately, she wasnt. But by 7 a.m. Birzer stopped speaking altogether. Then she seized. Birzers nurse was about to step out of the room when she noticed Birzers arms and legs shaking. Her eyes stared vacantly and she wet the bed. The nurse called a code blue, and a team of more doctors and nurses ran over. Birzer was loaded with high-dose anti-seizure medications through her IV. But she continued to seize. As nurses infused more medications into her IV, a doctor placed a breathing tube down her throat.

Birzers saga poses the big question: Why does CAR-T cause seizures and other neurologic problems? No one seemed to know. My search of the published scientific literature was thin, but one name kept cropping up. So I called her. Juliane Gust, a pediatric neurologist and scientist at Seattle Childrens Hospital, told me her investigations of how CAR-T affects the brain were motivated by her own experiences. When the early CAR-T trials opened at her hospital in 2014, she and her colleagues began getting calls from oncologists about brain toxicities they knew nothing about. Where are the papers? she remembered thinking. There was nothing.

Typically, the brain is protected by a collection of cells aptly named the blood-brain-barrier. But with severe CAR-T neurotoxicity, research suggests, this defense breaks down. Gust explained that spinal taps on these patients show high levels of cytokines floating in the fluid surrounding the spine and brain. Some CAR-T cells circulate in the fluid too, she said, but these numbers do not correlate with sicker patients. CAR-T cells are even seen in the spinal fluid of patients without any symptoms.

What does this mean? Gust interprets it as a patients symptoms having more to do with cytokines than the CAR-T cells. Cytokine release syndrome is the number one risk factor for developing neurotoxicity over the next few days, she said. The mainstay for neurotoxicity is starting steroids as soon as possible. In the beginning we didnt manage as aggressively. We were worried about impairing the function of the CAR-T, she added. Now we give steroids right away.

But the steroids dont always work. Several doses of steroids didnt prevent Birzer from seizing. The morning after Johnsons alarming phone call, after the meeting at the hospital when she learned what had happened, a chaplain walked her from the conference room to the ICU. The first day, Johnson sat by her partners bedside while Birzer remained unconscious. By the next evening, she woke up enough to breathe on her own. The doctors removed her breathing tube, and Birzer looked around. She had no idea who she was or where she was.

Birzer was like a newborn baby, confused and sometimes frightened by her surroundings. She frequently looked like she was about to say something, but she couldnt find the words despite the nurses and Johnsons encouragement. One day she spoke a few words. Eventually she learned her name. A few days later she recognized Johnson. Her life was coming back to her, though she was still suspicious of her reality. She accused the nurses of tricking her, for instance, when they told her Donald Trump was president.

She took cues from the adults around her on whether her actions were appropriate. The best example of this was her I love you phase. One day, she said it to Johnson in the hospital. A few nurses overheard it and commented on how sweet it was. Birzer was pleased with the reaction. So she turned to the nurse: I love you! And the person emptying the trash: I love you! Months later, she was having lunch with a friend who asked, Do you remember when you told me you loved me? Birzer said, Well, I stand by that one.

When she got home, she needed a walker to help with her shakiness on her feet. When recounting her everyday interactions, she would swap in the wrong people, substituting a friend for someone else. She saw bugs that didnt exist. She couldnt hold a spoon or a cup steady. Johnson would try to slow her down, but Birzer was adamant she could eat and drink without help. Then peas would fly in my face, Johnson said.

Patients who experience neurotoxicity fall into one of three categories. The majority are impaired but then return to normal without long-term damage. A devastating handful, less than 1 percent, develop severe brain swelling and die. The rest fall into a minority that have lingering problems even months out. These are usually struggles to think up the right word, trouble concentrating, and weakness, often requiring long courses of rehabilitation and extra help at home.

As Birzer told me about her months of rehab, I thought how she did seem to fall somewhere in the middle among the patients Ive treated. On one end of the spectrum was the rancher who remained profoundly weak a year after his infusion. Before CAR-T, he walked across his ranch without issue; six months later, he needed a walker. Even with it, he fell on a near weekly basis. On the other end was the retired teacher who couldnt speak for a week she would look around her ICU room and move her mouth as though trying her hardest and then woke up as though nothing happened. She left the hospital and instantly resumed her life, which included a recent trip across the country. In hindsight, I remember how we worried more about giving the therapy to the teacher than the rancher, as she seemed frailer. Outcomes like theirs leave me with a familiar humility I keep learning in new ways as a doctor: We often cant predict how a patient will do. Our instincts can be just plain wrong.

I asked Gust if we have data to predict who will land in which group. While we can point to some risk factors higher burdens of cancer, baseline cognitive problems before therapy the individual patient tells you nothing, she confirmed.

So we wait.

Doctors like me who specialize in cancer regularly field heart-wrenching questions from patients. They have read about CAR-T in the news, and now they want to know: What about me? What about my cancer?

So, who gets CAR-T? That leads to the tougher question who doesnt? That depends on the type of cancer and whether their insurance can pay.

CAR-T is approved to treat certain leukemias and lymphomas that come from the blood and bone marrow. Since the initial approval, researchers have also set up new CAR-T trials for all sorts of solid tumors from lung cancer to kidney cancer to sarcoma. But progress has been slow. While some promising findings are coming from the lab and in small numbers of patients on early phase trials, nothing is yet approved in humans. The remarkable responses occurring in blood cancers just werent happening in solid tumors.

Cancer is one word, but its not one disease. Its easier to prove why something works when it works than show why it doesnt work when it doesnt work, said Saar Gill, a hematologist and scientist at the University of Pennsylvania who co-founded a company called Carisma Therapeutics using CAR-T technology against solid tumors. That was his short answer, at least. The longer answer to why CAR-T hasnt worked in solid cancers involves what Gill believes are two main barriers. First, its a trafficking problem. Leukemia cells tend to be easier targets; they bob through the bloodstream like buoys in an ocean. Solid tumors are more like trash islands. The cancer cells stick together and grow an assortment of supporting structures to hold the mound together. The first problem for CAR-T is that the T-cells may not be able to penetrate the islands. Then, even if the T-cells make it in, theyre faced with a hostile environment and will likely die before they can work.

At Carisma, Gill and his colleagues look to get around these obstacles though a different immune cell called the macrophage. T-cells are not the only players of the immune system, after all. Macrophages are gluttonous cells that recognize invaders and engulf them for destruction. But studies have shown they cluster in solid tumors in a way T-cells dont. Gill hopes genetically engineered macrophages can be the stowaways that sneak into solid tumor and attack from the inside out.

Another big challenge, even for leukemias and lymphomas, is resistance, where the cancers learn to survive the CAR-T infusion. While many patients in the trials achieved remission after a month, we now have two years worth of data and the outlook isnt as rosy. For lymphoma, that number is closer to 40 percent. Patients celebrating cures initially are relapsing later. Why?

The CAR-T cells we use target a specific protein on cancer cells. But if the cancer no longer expresses that protein, that can be a big problem, and were finding thats exactly whats happening. Through blood testing, we see that many patients who relapse lose the target.

Researchers are trying to regain the upper hand by designing CAR-Ts to target more than one receptor. Its an old idea in a new frame: An arms race between our medicines and the illnesses that can evolve to evade them. Too much medical precision in these cases is actually not what we want, as it makes it easier for cancer to pinpoint whats after it and develop an escape route. So, the reasoning goes, target multiple pieces at once. Confuse the cancer.

Then theres the other dreaded c word: Cost. Novartis Kymriah runs up to $475,000 while Kite Pharmas Yescarta is $373,000. That covers manufacturing and infusion. Not included is the minimum one-week hospital stay or any complications.

They are daunting numbers. Some limitations on health care we accept maybe the patients are too sick; maybe they have the wrong disease. The wrong cost is not one we as a society look kindly upon. And drug companies shy away from that kind of attention.

Cost origins in medicine are notoriously murky. Novartis, confident in its technology, made an offer to offset the scrutiny in CAR-T. If the treatment didnt work after one month, the company said it wouldnt send a bill.

Not everyone agrees that cost is an issue. Gill, for example, believes the concern is over-hyped. Its not a major issue, he told me over the phone. Look, of course [with] health care in this country, if you dont have insurance, then youre screwed. That is no different when it comes to CAR-T as it is for anything else, he said. The cost conversation must also put CAR-T in context. Gill went on to list what these patients would be doing otherwise months of chemotherapy, bone marrow transplants, hospital stays for cancer-associated complications and the associated loss of income as patients and caregivers miss work. These could add up to far more than a one-time CAR-T infusion. A bone marrow transplant, for example, can cost from $100,000 to more than $300,000. The cancer-fighting drug blinatumomab, also used to treat relapsed leukemia, costs $178,000 a year. Any discussion of cost is completely irresponsible without weighing the other side of the equation, Gill said.

How the system will get on board is another question. Logistics will be an issue, Gill conceded. The first national Medicare policy for covering CAR-T was announced in August 2019, two years after the first product was approved. The Centers for Medicare and Medicaid Services has offered to reimburse a set rate for CAR T-cell infusion, and while this figure was recently raised, it remains less than the total cost. Despite the expansion of medical uses, at some centers referrals for CAR-T are dropping as hospitals worry its a net loss. And while most commercial insurers are covering CAR-T therapies, companies less accustomed to handling complex therapies can postpone approval. Ironically, the patients considering CAR-T are the ones for whom the window for treatment is narrowest. A delay of even a few weeks can mean the difference between a cure and hospice.

This, of course, poses a big problem. A breakthrough technology is only as good as its access. A major selling point of CAR-T besides the efficacy is its ease. Its a one-and-done treatment. Engineered T-cells are intended to live indefinitely, constantly on the alert if cancer tries to come back. Compare that to chemotherapy or immunotherapy, which is months of infusions or a pill taken indefinitely. CAR-T is more akin to surgery: Cut it out, pay the entire cost upfront, and youre done.

Birzer was lucky in this respect. I asked her and Johnson if cost had factored into their decision to try CAR-T. They looked at each other. It wasnt an issue, said Johnson. They remembered getting a statement in the mail for a large sum when they got home. But Birzer had good insurance. She didnt pay a cent.=

One year after Birzers infusion, I met her and Johnson at a coffee shop near their home in San Francisco. They had saved a table. Johnson had a newspaper open. Birzer already had her coffee, and I noticed her hand trembling as she brought it to her mouth. She described how she still struggles to find exactly the right words. She sometimes flings peas. But shes mostly back to normal, living her everyday life. She has even returned to her passion, performing stand-up comedy, though she admitted that at least for general audiences: My jokes about cancer didnt kill.

People handed a devastating diagnosis dont spend most of their time dying. They are living, but with a heightened awareness for a timeline the rest of us take for granted. They sip coffee, enjoy their hobbies, and read the news while also getting their affairs in order and staying on the lookout, constantly, for the next treatment that could save them.

Hoping for a miracle while preparing to die are mutually compatible ideas. Many of my patients have become accustomed to living somewhere in that limbo. It is humbling to witness. They hold out hope for a plan A, however unlikely it may be, while also adjusting to the reality of a plan B. They live their lives; and they live in uncertainty.

I see patients in various stages of this limbo. In clinic, I met a man with multiple myeloma six months after a CAR-T trial that supposedly cured him. He came in with a big smile but then quietly began praying when it was time to view PET results. He asked how the other patients on the trial were doing, and I shared the stats. While percentages dont say anything about an individual experience, theyre also all patients have to go on. When someone on the same treatment dies, its shattering for everyone. Was one person the exception, or a harbinger anothers fate? Who is the outlier?

I look at these patients and think a sober truth: Before CAR-T, all would likely die within six months. Now, imagine taking 40 percent and curing them. Sure, a naysayer might point out, its only 40 percent. Whats the hype if most still succumb to their cancer? But there was nothing close to that before CAR-T. I agree with how Gill described it: I think CAR-T cells are like chemotherapy in the 1950s. Theyre not better than chemotherapy theyre just different. For an adversary as tough as cancer, well take any tool we can get.

There remain many questions. Can we use CAR-T earlier in a cancers course? Lessen the side effects? Overcome resistance? Streamline manufacturing and reimbursement? Will it work in other cancers? Patients will sign up to answer.

For now, Birzer seems to be in the lucky 40 percent. Her one-year PET scan showed no cancer. I thought of our last coffee meeting, where I had asked if she ever worried she wouldnt return to normal. She didnt even pause. If youre not dead, she said, youre winning.

This article was originally published on Undark. Read the original article.

Read the original post:
Behind the Scenes of a Radical New Cancer Cure - Scientific American

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the Phase II NOBILITY study, investigating the safety and efficacy of Gazyva (obinutuzumab) for adults with proliferative lupus nephritis. The study met the primary endpoint with Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrating superiority compared to placebo plus standard of care. Patients treated with Gazyva showed increasing rates of complete renal response (CRR) from week 52 to week 76, with 40% of patients in the Gazyva group achieving CRR, compared to 18% of patients in the placebo group at week 76 (p=0.007). Gazyva additionally met key secondary efficacy endpoints showing improved overall renal response (complete or partial renal responses) and serologic markers of disease activity as compared to placebo. No new safety signals were observed with Gazyva in the study at the time of this analysis. Through week 76, serious adverse events (24% vs. 29% in placebo group) and serious infections (6% vs.18% in placebo group) were not increased with Gazyva. These data will be presented at the 2019 American College of Rheumatology (ACR) Annual Meeting in Atlanta, Georgia, on November 10, 2019 (Abstract 939).

We are very encouraged by the positive results from the NOBILITY study, which suggest that Gazyva may provide a clinically meaningful benefit for adults with proliferative lupus nephritis; a condition for which there is a strong need for more effective and targeted treatment options, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. These results support the continued development of Gazyva for people with lupus nephritis and underscore our longstanding commitment to pursue new treatment options that may benefit the lupus community.

Lupus nephritis is a severe and potentially life-threatening manifestation of systemic lupus erythematosus resulting from inflammation of the kidneys, with proliferative lupus nephritis being the most severe form and associated with high-risk of end-stage renal disease and death. In September 2019, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Gazyva for adults with lupus nephritis based on the Phase II NOBILITY study data. Genentech will initiate a Phase III study for Gazyva in lupus nephritis in 2020.

Phase II data from the NOBILITY study was also presented as a late-breaking oral presentation at the American Society of Nephrologys (ASN) Kidney Week 2019 in Washington, DC, on November 8, 2019 (Abstract FR-OR136).

An audio webcast for analysts and investors on the Phase II NOBILITY study data will be held on Tuesday, November 12, 2019 from 4:30-5:30 p.m. CET / 10:30-11:30 a.m. ET. Further details are available here.

Lupus nephritis overwhelmingly impacts women, particularly young women of color. About 90% of those diagnosed with lupus are women, and African American, Hispanic, Native American and Asian American women are two to three times more likely than Caucasian women to get lupus. Genentech is committed to addressing barriers to clinical trial participation and advancing inclusive research to create new standards for clinical studies. Genentech is taking action to recruit a broader, more diverse population of participants into clinical trials, including diseases such as lupus nephritis, to ensure clinical trial participants more closely reflect those impacted by the disease for which a medicine is being studied. To learn more about Genentechs efforts in this area, please visit https://www.gene.com/inclusiveresearch.

About the NOBILITY Study

The Phase II, randomized, double-blind, placebo-controlled, multi-center study, NOBILITY (NCT02550652), compared the safety and efficacy of Gazyva, combined with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and corticosteroids, to placebo, combined with MMF or MPA and corticosteroids, in adult patients with ISN/RPS 2003 class III or IV proliferative lupus nephritis. The study enrolled 125 people who were randomized to receive Gazyva or placebo infusions on days 1, 15, 168, and 182. The primary endpoint was the proportion of participants who achieved a protocol-defined complete renal response (CRR) at 52 weeks. Key secondary endpoints included overall renal responses (complete or partial renal response) and serologic markers of disease activity, as compared to placebo. Patients were followed in a blinded fashion through week 104, and patients with persistent B-cell depletion are being followed for safety and continued B-cell measurements.

About Lupus Nephritis

Lupus nephritis is a severe and potentially life-threatening disorder of the kidneys. Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus (SLE), an autoimmune disease where a person's own immune system attacks healthy cells and organs, including, in the case of lupus nephritis, the kidneys. This causes kidney inflammation and may lead to blood and/or protein in the urine, high blood pressure, poor kidney function, or kidney failure. An estimated 1.5 million Americans are affected by lupus, with approximately 70% of cases representing SLE. Up to 60% of people with SLE will develop lupus nephritis, and up to 25% of people with the condition develop end-stage renal disease. Lupus overwhelmingly impacts women, particularly young women of color. About 90% of those diagnosed with lupus are women, and African American, Hispanic, Native American and Asian American women are two to three times more likely than Caucasian women to get lupus. Currently, there is no cure for lupus or lupus nephritis.

About Gazyva

Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found only on certain types of B-cells. It is thought to work by attacking targeted cells both directly and together with the body's immune system. Gazyva is part of a collaboration between Genentech and Biogen. Combination studies investigating Gazyva with other approved or investigational medicines, including cancer immunotherapies and small molecule inhibitors, are underway across a range of blood cancers.

Gazyva Indications

Gazyva (obinutuzumab) is a prescription medicine used:

Important Safety Information

The most important safety information patients should know about Gazyva

Patients must tell their doctor right away about any side effect they experience. Gazyva can cause side effects that can become serious or life-threatening, including:

Who should not receive Gazyva:

Patients should NOT receive Gazyva if they have had an allergic reaction (e.g., anaphylaxis or serum sickness) to Gazyva. Patients must tell their healthcare provider if they have had an allergic reaction to obinutuzumab or any other ingredients in Gazyva in the past.

Additional possible serious side effects of Gazyva:

Patients must tell their doctor right away about any side effect they experience. Gazyva can cause side effects that may become severe or life threatening, including:

The most common side effects of Gazyva in CLL were infusion reactions, low white blood cell counts, low platelet counts, low red blood cell counts, fever, cough, nausea, and diarrhea.

The safety of Gazyva was evaluated based on 392 patients with relapsed or refractory NHL, including FL (81%), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) (a disease for which Gazyva is not indicated), who did not respond to or progressed within six months of treatment with rituximab product or a rituximab product-containing regimen. In patients with follicular lymphoma, the profile of side effects that were seen were consistent with the overall population who had NHL. The most common side effects of Gazyva were infusion reactions, low white blood cell counts, nausea, fatigue, cough, diarrhea, constipation, fever, low platelet counts, vomiting, upper respiratory tract infection, decreased appetite, joint or muscle pain, sinusitis, low red blood cell counts, general weakness and urinary tract infection.

A randomized, open-label multicenter trial (GALLIUM) evaluated the safety of Gazyva as compared to rituximab product in 1,385 patients with previously untreated follicular lymphoma (86%) or marginal zone lymphoma (14%). The most common side effects of Gazyva were infusion reactions, low white blood cell count, upper respiratory tract infection, cough, constipation and diarrhea.

Before receiving Gazyva, patients should talk to their doctor about:

Patients should tell their doctor about any side effects.

These are not all of the possible side effects of Gazyva. For more information, patients should ask their doctor or pharmacist.

Gazyva is available by prescription only.

Report side effects to the FDA at (800) FDA-1088, or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.

Please visit http://www.Gazyva.com for the Gazyva full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Original post:
Genentech's Gazyva (obinutuzumab), in Combination With Standard of Care, More Than Doubles the Percentage of Lupus Nephritis Patients Achieving...

Your vision may change as you get older, but it can also change much sooner than you think if you are not careful.

These are some ways to keep your eyes seeing longer.

From looking at TV to looking outside at nature, your eyes focus on 50 different objects per second. But your eyes aren't perfect; they can run into problems, for example, if you stare at your phone too long.

"That's high-energy visible light, but it's harmful, and that's what causes the digital eye strain," Florida ophthalmologist Dr. Alan Mendelsohn said.

Experts say if you feel weary, just take a break. If you are not careful, this could lead to red eyes and possibly pink eye.

"Vision becomes blurry, eyes become fatigued, sometimes red. It's very frequent to start getting headaches," Mendelsohn said.

To reduce the irritation, take a cool or warm towel to your eyes.

But not every cause is so easily fixed. Lazy eye, which causes vision to be weaker, requires surgery, and so does uveitis, which causes inflammation in the middle layer of your eye and cataracts.

"It's almost like having a stone inside your eye, and breaking that up sometimes requires a lot of energy. That energy is not good to the eye," said Dr. Sean Lanchulev, a New York eye and ear doctor.

If you don't take care of cataracts, that could lead to night blindness.

Finally, watch out for the sun. Not protecting your eyes could lead to excess tearing or floaters, which could be a sign of retinal detachment. So, wear those sunglasses for style and protection.

Contact wearers, beware! Do not wet them in your mouth, as it could lead to infection, and be sure that they fit properly to protect your eyes from being scratched.

RESEARCH SUMMARYPROTECTING YOUR SIGHT REPORT #2690

BACKGROUND: Around 1.3 billion people around the world live with some form of distance or near vision impairment. Regarding distance vision, 188.5 million have mild vision impairment, 217 million have moderate to severe vision impairment, and 36 million people are blind. When it comes to near vision, 826 million people live with a near vision impairment. Having good ocular health means that vision is at least 20/20 or better with or without correction, and the eyes are disease-free. Ophthalmologists can provide total eye care, from examinations and vision correction to the diagnosis and treatment of disease through medication and surgery. By getting regular exams and discussing family history, your doctor is better able to anticipate, prevent, and treat eye disease. Not wearing your prescribed eyeglasses or contacts will not cause disease of the eye, but it can cause discomfort by eyestrain, headaches, or possibly injury brought on by the lack of safe vision. Constant exposure to ultraviolet rays can result in photochemical eye damage and wearing safety glasses and protective goggles while playing sports or working with hazardous or airborne materials lowers your risk for eye injury, damage to vision, and complete loss of sight. (Source: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment and https://my.clevelandclinic.org/health/articles/8560-ocular-health)

MOST COMMON EYE DISEASES AND TREATMENTS: Macular degeneration is the damage to the central portion of retina, known as the macula. There are no definite signs and symptoms in earlier stages of macular degeneration other than gradual or sudden change in the quality of your vision followed by appearance of straight lines as distorted. There are some prescription medications helpful with macular degeneration in preventing the growth of abnormal blood vessels within the eye. Cataracts are another common eye problem. Symptoms can include blurred, clouded or dim vision; problem seeing at night; and problem seeing through light and glare. Surgery is the only effective treatment, which involves removal and replacement of cloudy lens with an artificial one. Glaucoma is an eye condition where the eye's optic nerve is damaged, getting worse over time. It results in pressure buildup within the fluid in your eye, which can potentially damage the optic nerve responsible for transmitting images to your brain. From eye drops to pills, traditional surgery and laser surgery, or even a combination of these methods, an experienced eye doctor would recommend any treatment if it is focused on preventing vision loss. (Source: https://irisvision.com/most-common-eye-problems-signs-symptoms-and-treatment/)

GENE THERAPY FOR EYES: Scientists researching a form of inherited blindness in children called Leber's congenital amaurosis recently had success in a clinical trial that improved the vision of children. The trial was preceded by 30 years of research by Jean Bennett and her husband, Al Maguire, at the Scheie Eye Institute of the University of Pennsylvania, as well as other scientists at Penn and around the world. The gene, which is called RPE65, is injected into the eye, under the retina, in an operating room procedure. It enters retinal cells because it is packaged into a safe virus called adeno-associated virus (AAV). Neither the naturally occurring AAV nor the genetically modified version designed to carry the RPE65 gene into people causes disease. The genetically modified AAV was able to significantly restore vision in blind children, enabling them to complete tasks such as walking through a maze without bumping into soft objects, or catching a ball. The retinal RPE65 gene therapy is a breakthrough that will pave the way for gene therapies treating several other retinal diseases, including age-related macular degeneration (AMD), retinitis pigmentosa, and choroideremia.

Read the original post:
Protecting your sight: What you need to know - WNDU-TV

Maria Todd would probably prefer that I write this story about well, anyone else but her. When I first interviewed her and began with the warm-up question of how long shes been researching and teaching biology at Southwestern (the answer is 18 years, since 2001), she very quickly shifted focus to talking about a remarkable undergraduate she taught years ago who is now an oncologist. When she publishes her research, she gives credit to every person who sends her samples because naming them as contributors will, she says, help them get grantsand if theyre getting grants, that helps the whole community. If youre lucky enough to be one of her students or have a cup of tea with her, youll notice that she exhibits a generosity of spirit and that quintessential self-deprecatory Anglo-Irish sensibility that immediately draws you in.

And if you didnt know any better, youd almost never guess that this utterly unpretentious, quietly funny, and genuinely delightful individual is an expert in molecular biology and genetics who has made significant contributions to the progress of cancer research.

Dr. Maria ToddThe evolution of a scientist

A born biologist whose first memory is of crawling down the garden path behind her London home and being fascinated by ants and stones and leaves, Todd recalls that her early love of science was the product of curiosity and exploration. I remember as a child just staring at leaves and their veins, and my parents would allow me to dissect plants and flowers with kitchen knives, she says. Id look at a beautiful flower, and then I would dissect it to see what was inside. I had to understand how it worked. Im always appreciative of the beauty of nature, but I want to understand the mechanisms behind it.

With the loving encouragement of her parents, Todd analyzed specimens she discovered in London parks and by the seaside, experimented with chemistry sets at home, and tinkered with gadgets her father would bring home from his work as an electronics engineer. She eventually enrolled as an undergraduate at the University of Sussex, where Todd originally hoped to specialize in conservation biology and ecology, following in the footsteps of her hero, Jane Goodall. But a first-year course on molecular and population genetics captured her imagination. I knew then, at 19 years old, that this would revolutionize medicine, and I was completely seduced, she recounts. It changed my life. So she traded romantic visions of a future examining ferns on the moors of England for a more fitting career at the lab bench studying genetic engineering.

Her studies would continue during a Ph.D. program at Cambridge University, where she lived for one year in the former home of the father of evolutionary thinking. It was amazing to walk into the drawing room and think, This is where Charles Darwin sat and read his newspapers and worked on the Origin of Species, and here am I, a little 20-something geneticist, sitting in the same window seat perhaps where he sat and looking out onto the grounds, she recalls. It was a very magical experience. She then adds with a laugh, The rest of the accommodation was not magical and is best forgotten. Todd admits that she did sometimes feel rather intimidated while at Cambridge, where she was one of only two women in her medical research cohort and worked in a lab flanked by a pair of Nobel Prize winners. Like so many graduate students, she was periodically afflicted with impostor syndrome, wondering whether her admission to the program had been some sort of mistake or even a cruel sociological experiment. But once she began to build a community among other women scientists at the university, her confidence grew, and she knew that she and her colleagues did, in fact, belong.

The importance of good questions

Todd shares stories like these with her Southwestern students, bringing profound empathy to her teaching and mentorship of students. Most of my time is spent reassuring students, reminding them that theyre here for a reason, that they are good enough to be here, that they will excel here, that they are making a really valuable contribution to this community of learning, that we want them here, [and] that were learning from them just as they learn from us, she says. I always encourage students to ask questions and to share their ideas because their ideas might be the next great breakthrough. Its this approach to teaching that has understandably earned Todd multiple honors throughout her years at SU, including theExemplary Teaching Award from the Board of Higher Education and Ministry of the United Methodist Church and the Southwestern University Teaching Award.

As one might expect of the limelight-shy biology professor, Todd prefers that the camera's focus remain on her students, like Shi Solis '20 , rather than on her.Shi Solis 20, one of Todds current research assistants, can attest that her mentor has been a delight to work with. A methods course with Todd inspired the English major to add biology as her second major, but even more than her coursework, Solis feels that the productive failure of trial and error that characterizes any laboratory setting has really expanded her understanding of biology. Working with Dr. Todd is the best. Shes an angel, Solis remarks. I feel like we came in, and we werent super prepared in what it was like to do research, but shes the best teacher. Even if we dont know anything, she makes us feel that this is a learning environmentthat every minute in the lab is a learning experience.

Biology major Anthony Seek 20 agrees that the lab experience, even with all its mental hurdles, has been pretty awesome because its pushed him to consider not just the what but also the why of cell biology: I wanted to do this before I came here, and Im really excited I got the opportunity to do this and work with Dr. Todd. Shes amazing. I sat in on one of her classes before I came [to SU], and it was great. Shes the best person to work with.

Todds appreciation for Solis and Seek is conspicuous as she praises them for being such independent thinkers and doers. She says that working with undergraduates is fabulous and lovely because they bring youthful enthusiasm; they bring their curiosity. And something that I think is very special about undergraduates is that they ask questions that are quite basic, fundamental questions, and these are the best questions to ask in science. She explains that as more advanced researchers delve deeper into their fields, they tend to think of more sophisticated, complicated questions. But the best science is when we ask very straightforward questions, and students will do that, kind of pulling me up a little [because] maybe I had made an assumption about something . They also ask questions about mechanisms and cellular processes that really keep me on my toes in terms of staying up to date with the literature. And unlike how labs are often portrayed on television, Todd observes that laboratories are communities; no scientist works in isolation. Were highly collaborative, and were highly social creatures . Our students bring life and heart to the lab.

A common but understudied cancer

When students like Seek and Solis apply to work in Todds lab at Southwestern, they have to be highly conscientious, precise, and detail oriented. Thats because theyll be working with complex instruments and techniques that are difficult to learn and require weeks to months of practice to master, or, conversely, theyll be focusing for long periods on techniques that arent necessarily difficult but can be quite tedious.

Those students must possess physical and mental fortitudenot to mention a sense of respect for their materialsbecause they are working with cancer cells that are older than they are.

Todd and her students are studying uterine cancer, which, according to the nonprofit World Cancer Research Fund International, is the sixth most commonly occurring cancer in women (only breast, colorectal, lung, cervical, and thyroid cancers have higher incidences worldwide). More than 382,000 new cases of uterine cancer were reported in 2018, and approximately 76,000 patients die from the disease each year.

Elliot Hershbergn 18 and Sid Pradeep 17 worked alongside Professor Maria Todd in summer 2016.

Although uterine cancer is the most common gynecological cancer in the U.S., it is, paradoxically, also the least studied compared with ovarian, cervical, vaginal, and vulvar malignancieswhich is just one reason Todd and her longtime collaborator, fellow Southwestern Professor of Biology and Garey Chair in Biology Maria Cuevas, switched their research efforts from breast to uterine cancer several years ago while putting together an application for a National Institutes of Health grant. Todd believes its one of those cancers thats often overlooked by researchers because uterine cancer doesnt have the same advocacy groups that breast and ovarian cancers have enjoyed for the past 15 years. Those cancers have benefited from better research funding and more media coverage, likely because uterine cancer occurs less frequently than breast cancer does (one in 25 women versus one in seven, respectively) and is much easier to treat than ovarian cancer, which is often diagnosed too late to benefit from conventional therapies.

Todd says she and Cuevas were also compelled to refocus their research energies because they found something very startling and very striking: women of all races have about the same incidence of uterine cancer, but the mortality rate for African-American women with uterine cancer is 2-1/2 times that of all other women with the same disease. We were completely blown away, Todd recalls. Why is it that the uterine cancer rate is not higher in African-American women but they die at much higher rates?

Todd and Cuevas knew there were many possible answers: Perhaps African-American women were not being diagnosed early enough because of limited access to healthcare. Maybe cultural distrust between African-American women patientsof all socioeconomic classesand their primarily white male doctors was preventing those women from advocating for their own care. And/or perhaps implicit bias was keeping patients from receiving sufficiently aggressive treatment. But these would be sociological responses and therefore beyond the scope of Todd and Cuevass research. From a biological standpoint, however, the pair could investigate which kinds of uterine cancer African-American women were being diagnosed with: Was it the more treatable endometrial cancer (i.e., malignancy of the lining of the uterus), or was it the more difficult-to-treat myometrial cancer (i.e., malignancy of the muscular wall of the uterus)? And if they were to look at tumor samples from women across racial identities, would they see differences in the ability of cancer cells to stay adhered to one another, or would those cells break off more frequently, making it easier for tumors to migrate through the bloodstream and spread (i.e., metastasize) to a different part of the body?

From cancer research to (better) cancer treatment

To help answer such questions about what causes cancer to spread throughout the body, Todd and her undergraduate research assistantspositions made possible by her funding as Southwesterns first Ed and Suzanne Morrow Ellis Term Chairwork with immortalized uterine tumors from women. That is, normal cells eventually stop dividing, grow old, and die; cancer cells, however, have short-circuited that aging process, so they can grow and replicate in perpetuity. So when patients have a tumor removed, researchers can actually continue to grow and examine immortal cell lines derived from that tumor. Todd says, I say that to the students: Just think about what it is that youre handling here in these flasks. These are cancer cells that are immortal, and they will outlive us and your children and your grandchildren. So we do treat them with a certain amount of reverence, actually.

With all due reverence, Solis, Seek, and Todd are studying claudin-3 and claudin-4, just two members of a family of 24 tight-junction proteins that create watertight seals between adjacent cells and help hold those cells together. Although one might expect that having high levels of something called tight-junction proteins would mean that the connections between cells would be even stronger, it turns out that claudin-3 and -4 are abnormally elevated in uterine cancer cells, and that disproportion of proteins actually makes it easier for malignant cells to shear off, spread to another organ, and grow secondary tumors. Todd believes that down the road, if she and her fellow researchers can correlate high levels of claudin-3 and -4 with certain stages of uterine cancer, that correlation can prove useful not just as a diagnostic marker but also as a prognostic one. That is, a doctor could tell a patient how much cancer is in the body and better predict how the cancer will behave, including how it will respond to treatment.

Anthony Seek 20, one of Todd's current research assistants, looks forward to applying his SU lab experience to a future career in pediatric oncology.

But most exciting to meand something that my lab and my students are working onare the possible treatment applications, Todd shares. She and her collaborators have been able to use a molecule known as small interference RNA to decrease the excessive amounts of claudin-3 and -4 to normal levels, which prevents the uterine cancer cells from migrating or moving across membranes as quickly. The hope, then, is that by decreasing the levels of these proteins, scientists will eventually be able to stop uterine tumors from metastasizing.

Thats obviously my goal as a cancer researcher and I think the goal of most people who go into cancer research, Todd says. We might not see those clinical applications in our working lives, possibly not even in our lives, but we build on one anothers work. Shes hopeful that gene therapies similar to those she and her students are experimenting with will one day complement conventional cancer treatments such as surgery, chemotherapy, and radiation. Or rather, given the physical and emotional trauma of surgery and the side effects and risks of chemotherapy and radiationwhich can damage DNA, have adverse effects on neighboring healthy cells, and lead to mutations that cause secondary cancersTodd adds, Im hopeful that in our childrens generation, gene therapy will be part of the treatment program, and by the time they have children, gene therapy will be the major tailored form of therapy and we will eliminate chemotherapy drugs or radiation altogether.

In April 2020, Todd and Cuevas will present their research at the annual meeting of the American Association for Cancer Research, where the theme will be Turning Science into Lifesaving Cure. Todd looks forward to sharing their latest findings with their scholarly colleagues, and shes thankful for her Ellis Term Chair funding because it will support her travel to the conference and because it means that the research we can do at Southwestern is comparable to that at a large R1 [research] institution, and were really excited about that. But she and Cuevas are also dedicated to translating their knowledge in ways that will benefit their students beyond academic or professional development. In a biology class, its not just about preparing for medical school or graduate school or teaching or industry; its about learning about our own health, our own journey, and how our bodies change on a continuous basis, Todd explains. Its just so important from an intellectual standpoint to understand the structures, the functions, and the mechanisms. But its also important from a very human perspective to understand the emotional component, the biological component, and the psychological component that contribute to our own well-being.

Read more:
Researching the Future of Cancer Treatment - Southern Newsroom

Ilana Yurkiewicz, a physician and medical journalist at Stanford University, explains why CAR-T is only used in patients with certain cancers and tries to answer why they havent yet been shown to work against solid tumors in an UnDark article. Public health news is on breast cancer tests, fecal matter transplants, Zantac recalls, white male life expectancy, skin rashes, growing up with HIV, a retracted HIV study, live-streaming a mammogram, and how to get a good night's sleep, as well.

The Washington Post:Science Author Digs Into The Story About A Revolutionary Cancer Treatment Used In ImmunotherapyIn 2017, CAR-T therapy made waves as the first gene therapy to be approved by the Food and Drug Administration. In a fascinating article for Undark, Ilana Yurkiewicz, a physician at Stanford University, plunges into the fraught history and future of a cancer treatment thats as radical as it is risky. Unlike chemotherapy or radiation, which attack cancer directly, CAR-T engineers patients immune cells so they can do it themselves. (Blakemore, 11/2)

Bloomberg:Blood Test To Detect Breast Cancer Could Be Five Years AwayA blood test that may be able to detect breast cancer up to five years before symptoms develop could be available by 2025 if development is fully funded, U.K. researchers said. Doctors at the Centre of Excellence for Autoimmunity in Cancer at the University of Nottingham compared blood samples from 90 patients being treated for breast cancer with the same number from a control group without the disease to measure the bodys immune response to substances produced by tumor cells. Theyre now testing samples from 800 patients for nine markers and they expect the accuracy of the test to improve. (Marley, 11/3)

Stat:FDA To Consider New Evidence, Risks Behind Fecal Matter TransplantsOn Monday, the Food and Drug Administration will host its first formal discussion about fecal microbiome transplants in years less than a week after a paper in the New England Journal of Medicine disclosed new details about the first death ever conclusively linked to the procedure, often abbreviated to FMT. The Monday meeting, which will be happening at the FDAs headquarters in White Oak, Md., will cover the safety and effectiveness of FMT as a treatment for repeated (and potentially fatal infections) of Clostridium difficile bacteria. (Sheridan, 11/1)

Stat:FDA: Zantac Does Not Form A Carcinogen, But Some Pills Should Be RecalledAfter running simulated testing, the Food and Drug Administration says it has not found evidence that Zantac and similar heartburn medicines form a possible carcinogen in patient stomachs or small intestines. Nonetheless, the agency also indicated some of the medicines contain higher than acceptable levels of NDMA, and asked manufacturers to voluntarily withdraw those pills. The move marks the first time the FDA has suggested drug makers should recall their heartburn medicines, which are called ranitidines, after opening a probe several weeks ago. (Silverman, 11/1)

CBS News:Life Expectancy For American Men Drops For A Third YearLife expectancy for American men dropped for a third consecutive year, with the National Center for Health Statistics citing an increase in so-called "deaths of despair," such as the rise in drug overdose deaths.The average lifespan of men in the U.S. dipped to 76.1 years in 2017 (the latest data available), amounting to a four-month decline in life expectancy since 2014. The findings shed additional light on economic research into the sharp increase in recent years in deaths from overdoses and suicides among white men with less education. (Picchi, 10/31)

NPR:Rashes Can Look Very Different On Different Shades Of SkinWhen Ellen Buchanan Weiss' son was about a year old, he broke out in a rash little bumps that appeared to be hives. So Buchanan Weiss did what a lot of new parents do: She turned to the Internet to find images that matched the rash she was seeing on her little boy. "I'm trying to figure out would I be paranoid if I went to the doctor at this point? Is that a reasonable thing to do? So I started googling it," says Buchanan Weiss, who lives with her family in Raleigh, N.C. (Prichep, 11/4)

The New York Times:Armed With A New Laptop, He Is On A Path To A DegreeWhen he was growing up, Warren Williams wanted nothing more than to play baseball and watch Scooby-Doo. I just wanted to be normal, like other kids, he said. But his health often took the joy out of his childhood. Mr. Williams, 26, was born with H.I.V. One of his earliest memories is from when he was 4: A mass had developed in his chest and he was rushed to a hospital to have open-heart surgery. The doctors gave him a stuffed Barney the dinosaur to keep by his side on the operating table. (Aridi, 11/3)

The Associated Press:Scientists Retract Study Suggesting Mutation Shortens LifeScientists have retracted a study that appeared to show people may live shortened lives if they carry a DNA mutation that reduces their chance of HIV infection. The study focused on people who carry a specific mutation in both copies of a gene called CCR5. It was published in June in the journal Nature Medicine and covered by news outlets including The Associated Press. (11/1)

The Washington Post:Ali Meyer Records Breast Cancer Diagnosis Live On Facebook For KFOR NewsAli Meyer live-streamed her first mammogram with other women in mind. The veteran journalist was wary of making herself the center of the story, she remembers, but she wanted to remind people to schedule their own appointments so they could catch breast cancer early. Then a nurse came in to say the radiologist would prefer to see Meyer with the camera off. In private, the doctor told Meyer she would need more imaging. At 40 years old, she realized, she might have cancer. (Knowles, 11/2)

NPR:How To Fall Asleep: These Daytime Habits Will HelpIf turning back the clock an hour for the end of daylight saving time leaves you feeling jangly, imagine the toll that chronic sleep loss can take on your health. The evidence has piled up. We all need good sleep. And our bodies crave regular routine. Without it, we set up ourselves for increased risk of anxiety, depression, weight gain, even dementia. (Aubrey, 11/3)

See the rest here:
Physician Goes Behind The Scenes To Write Compelling Story About Treating Patients With New Cancer Gene Therapy - Kaiser Health News

Humanigen is developing a portfolio of cell and gene therapies for the treatment of cancers through its novel GM-CSF gene-knockout platforms

() said Wednesday that two abstracts on its promising key drug candidate lenzilumab will be presented at the upcoming annual meeting of the American Society of Hematology, in Florida.

The Burlingame, California, companys lenzilumab, is a recombinant monoclonal antibody that neutralizes a substance that promotes growth of white blood cells, but is also tied to inflammations that can occur during CAR-T therapies and lead to side effects.

Pre-clinical work shows lenzilumab is effective in preventing the side effects and may make the CAR-T therapies more effective, according to Humanigen.

In a statement, the clinical-stage biopharmaceutical company said the two abstracts are focused on granulocyte-macrophage colony-stimulating factor (GM-CSF) gene knockout and GM-CSF neutralization with lenzilumab, the company's proprietary Humaneered anti-human-GM-CSF immunotherapy.

Both abstracts have been accepted for presentation at the American Society of Hematology on December 9, at the Orange County Convention Center, in Orlando, Florida.

Humanigen said that using a xenograft model for relapsed acute lymphoblastic leukemia (ALL), which is a type of cancer of the blood and bone marrow that affects white blood cells, treatment with GM-CSF k/o CART19 resulted in improved overall survival compared to wildtype CART19.

The lack of myeloid cells in this model pointed to an intrinsic effect of GM-CSF on CAR-T cells, said the company.

"These results strongly indicate that CAR-T cells increase expression of GM-CSF receptor subunits when activated, resulting in modulation of CAR-T function, said Humanigen CEO Durrant.

Collectively, these results illuminate a novel mechanism for a direct modulatory effect of GM-CSF on activated CAR-T cells that helps to explain the improved survival with GM-CSF neutralization or knockout," he added.

Durrant, a medical doctor and MBA who assumed the role of CEO in March 2016, said the results of the company sponsored phase I study reinforce the favorable safety profile of lenzilumab even in patients with chronic myelomonocytic leukemia (CMML), a rare type of blood cancer,who have undergone several cycles of immunosuppressive therapy.

"As with all prior lenzilumab clinical trials, no serious treatment related adverse events were observed," said Durrant.

Throughout the study there were no reported instances of dose limiting toxicities or adverse events grade 3 or higher related to the study drug. Additionally, of four subjects with NRAS mutations at screening, three either achieved clinical benefit or had clinical meaningful bone marrow myeloblast reductions, he added.

Humanigen is developing a portfolio of next-generation cell and gene therapies for the treatment of cancers through its novel GM-CSF neutralization and gene-knockout platforms.

The companys immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the companys proprietary anti-human-GM-CSF immunotherapy, which is its lead product candidate.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

See the original post here:
Humanigen"s abstracts on lenzilumab to be presented at the American Society of Hematology - Proactive Investors USA & Canada

CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ --New clinical data from Sanofi's oncology and rare blood disorders portfolios and pipelines will be featured, including four oral presentations and 18 posters, at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition from December 7-10 in Orlando, FL.

"Blood cancers and rare blood disorders account for some of the most challenging diseases to treat, and patients often have limited therapeutic options," said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. "Drawing upon our deep expertise in hematology, and one of the industry's more robust research and development programs actively working to address numerous hematologic conditions, we are excited to present new data at ASH that we believe demonstrate our commitment to advancing science and improving the lives of patients we serve."

Advancing the understanding of multiple myeloma in difficult-to-treat populationsIsatuximab: In the area of multiple myeloma, analyses from the pivotal ICARIA-MM trial for isatuximab, an investigational anti-CD38 monoclonal antibody, will highlight depth of response and associated long-term outcomes (abstract #3185), health-related quality of life (abstract #1850), and outcomes in an elderly patient population (abstract #1893). The ICARIA-MM clinical trial serves as the basis of a Biologic License Application for isatuximab for the treatment of relapsed/refractory multiple myeloma, which is currently under review by the U.S. Food and Drug Administration with a target action date for a decision of April 30, 2020. A Marketing Authorization Application for isatuximab was also accepted for review by the European Medicines Agency in the second quarter of 2019. Read more about our oncology data at ASH.

Striving to address unmet needs for people with rare blood disorders Cold Agglutinin Disease and Immune Thrombocytopenic Purpura:New analyses of transfusion practices in the U.S. (abstract #3559) and mortality risks associated with cold agglutinin disease (CAD) (abstract #4790) will underscore the seriousness of this rare and debilitating hemolytic anemia. Sutimlimab, an investigational monoclonal antibody designed to inhibit C1s, is being investigated as a potential first-in-class treatment for CAD in two pivotal Phase 3 studies. An oral presentation on sutimlimab will also explore its potential in immune thrombocytopenic purpura (ITP) patients without adequate response to two or more prior therapies (abstract #898). ITP represents a second indication being investigated for sutimlimab.

Hemophilia:Final data from a Phase 1 study (abstract #625) of BIVV001 (rFVIIIFc-VWF-XTEN) evaluating the safety and pharmacokinetics of repeated dosing will be shared in an oral presentation. BIVV001 is the first and only investigational von Willebrand (VWF)-independent factor VIII therapy that is designed to provide high sustained factor activity and extend protection from bleeds with once weekly dosing for people with hemophilia A. A Phase 3 study of BIVV001 is expected to be initiated by year-end. BIVV001 is being developed in collaboration with Sobi.

Additional analysis of the ongoing Phase 2 open-label extension study (abstract #1138) of fitusiran, a potential first-in-class, once-monthly, fixed-dose subcutaneously administered RNA interference therapeutic targeting antithrombin (AT) will also be shared. Fitusiran is the first and only monthly investigational therapy in Phase 3 development for the treatment of both hemophilia A and B, with and without inhibitors.

Hemoglobinopathies:New pre-clinical and clinical research on our pipeline of investigational, zinc finger nuclease ex vivo gene-edited cell therapies for sickle cell disease (BIVV003) and beta thalassemia (ST-400) will be shared in multiple presentations. BIVV003 and ST-400 are being developed in collaboration with Sangamo Therapeutics, Inc.

Acquired Thrombotic Thrombocytopenic Purpura;Additional presentations include results from studies on Cablivi (caplacizumab-yhdp), our first-in-class approved treatment, in combination with plasma exchange and immunosuppressive therapy, for adult patients with acquired thrombotic thrombocytopenic purpura (aTTP).

Oncology Poster Presentations:

Isatuximab

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis (Dr. Fredrik Schjesvold; Saturday, December 7, 2019: Poster Presentation, 5:30-7:30 p.m. ET)

Depth of Response and Response Kinetics in the ICARIA-MM Study of Isatuximab/Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (Dr. Cyrille Hulin; Sunday, December 8, 2019: Poster Presentation, 6:00-8:00 p.m. ET)

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab plus Pomalidomide and Dexamethasone: ICARIA-MM Study (Katherine Houghton; Saturday, December 7, 2019: Poster Presentation, 5:30-7:30 p.m. ET)

Exposure-response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma (Dr. Fatiha Rachedi; Saturday, December 7, 2019: Poster Presentation, 5:30-7:30 p.m. ET)

The Relationship Between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 studies (Dr. Paul Richardson; Sunday, December 8, 2019: Poster Presentation, 6:00-8:00 p.m. ET)

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, ICARIAMM (Dr. Greg Finn; Sunday, December 8, 2019: Poster Presentation, 6:00-8:00 p.m. ET)

Rare Blood Disorders Oral and Poster Presentations:

Cold Agglutinin Disease and Immune Thrombocytopenic Purpura

Inhibition of the Classical Pathway of Complement With Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients Without Adequate Response to Two or More Prior Therapies - #898 - Monday, December 9, 2019,6:15 PM 7:45 PM(ET) Oral Presentation - Room W307

Cold Agglutinin Disease Transfusion Practices in the United States: An Electronic Medical RecordBased Analysis- #3559 - Monday, December 9, 2019, 6:00 PM 8:00 PM (ET)

Mortality Among Patients With Cold Agglutinin Disease in the United States: An Electronic Medical Record (EMR)Based Analysis - #4790 (abstract only)

Hemophilia

Phase 1 Repeat Dosing with BIVV001: The First Investigational Factor VIII Product to Break through the Von Willebrand FactorImposed Half-Life Ceiling - #625 Monday, December 9, 2019 10:30 AM 12:00 PM (ET) - Oral presentation - Room W415A

Cryo-EM Structure of BIVV001 Reveals Coagulation Factor VIII-Von Willebrand Factor D'D3 Interaction Mode- #94- Saturday, December 7, 2019, 9:30 AM 11:00 AM (ET) - Oral presentation Room W414AB

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia A or B with or without Inhibitors: Management of Acute Bleeding Events #1138 - Saturday, December 7, 2019, 5:30 PM - 7:30 PM(ET)

Patients' and Caregivers' Preferences for Different Hemophilia A Treatment Attributes- #2122 - Saturday, December 7, 2019, 5:30 PM - 7:30 PM (ET)

Acquired Thrombotic Thrombocytopenic Purpura

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study- #1093 - Saturday, December 7, 2019, 5:30 PM 7:30 PM (ET)

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity#2366 - Sunday, December 8, 2019, 6:00 PM - 8:00 PM (ET)

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen- #2365 -Sunday, December 8, 2019, 6:00 PM 8:00 PM (ET)

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies - #4908 (abstract only)

Sickle Cell Disease and Beta Thalassemia

Genetic Activation of NRF2 By KEAP1 Inhibition Induces Fetal Hemoglobin Expression and Triggers Anti-Oxidant Stress Response in Erythroid Cells- #210 - Saturday, December 7, 2019, 2:00 PM 3:30 PM (ET) Oral Presentation Room W414B

Zinc Finger Nuclease-Mediated Disruption of the BCL11A Erythroid Enhancer Results in Enriched Biallelic Editing, increased Fetal Hemoglobin, and Reduced Sickling in Erythroid Cells Derived from Sickle Cell Disease Patients- #974 - Saturday, December 7, 2019, 5:30 PM 7:30 PM (ET) Joint with Sangamo

MetAP2 Inhibition Modifies Hemoglobin S (HbS) to Delay Polymerization and Improve Blood Flow in Sickle Cell Disease- #2260 - Sunday, December 8, 2019, 6:00 PM 8:00 PM (ET)

Differential Efficacy of Anti-Sickling and Anti-Inflammatory Mechanisms in a Fluorescent Intravital Microscopy Dorsal Skinfold Vaso-occlusion Model in Sickle Cell Disease Townes Mice, #2264 - Sunday, December 8, 2019, 6:00 PM 8:00 PM (ET)

Characterization of a genetically engineered HUDEP2 cell line harboring a sickle cell disease mutation as a potential research tool for preclinical Sickle Cell Disease Drug Discovery- #3559 - Monday, December 9, 2019, 6:00 PM 8:00 PM (ET)

Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia #3544 Monday, December 9, 2019, 6:00 8:00 PM (ET) Joint with Sangamo

Identification of Novel Variants Associated with Fetal Hemoglobin Levels in Healthy Donors (the INTERVAL study) - #2243 - Sunday, December 8, 201, 6:00 PM - 8:00 PM (ET)

Rare Disease Presentations:

Gaucher Disease

Response to Oral Eliglustat in Adults with Gaucher Disease Type 1: Results from 4 Completed Clinical Trials - #4859 (abstract only)

About isatuximabIsatuximab, an investigational anti-CD38 monoclonal antibody, targets a specific epitope on the CD38 receptor and is designed to trigger multiple, mechanisms of action that are believed to directly promote programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on multiple myeloma cells and cell surface receptors, making it a potential target for antibody-based therapeutics such as isatuximab.

Isatuximab is an investigational agent and its safety and efficacy have not been evaluated by the U.S. FDA, the European Medicines Agency, or any other regulatory authority.

About SutimlimabSutimlimab is a C1s inhibitor that received breakthrough therapy designation and is currently being investigated for the treatment of CAD in Phase 3 clinical trials. A humanized, monoclonal antibody, sutimlimab is designed to target C1s, a serine protease within the C1-complex in the classical complement pathway of the immune system, which directly impacts the central mechanism of hemolysis in CAD. Similarly, the classical complement pathway has been shown to contribute to the physiopathology of immune thrombocytopenic purpura (ITP). With a unique mechanism of action and high target specificity, sutimlimab is designed to selectively inhibit disease processes by upstream blockade of the classical complement pathway while maintaining activity of the alternative and lectin complement pathways, which are important for immune surveillance and other functions.

Sutimlimab has not been approved by the FDA, EMA or any other regulatory authority for any indication and no conclusions can or should be drawn regarding the safety or effectiveness of this investigational therapeutic.

About BIVV001BIVV001 (rFVIIIFc-VWF-XTEN) is a novel and investigational recombinant factor VIII therapy that is designed to provide high sustained factor activity and extend protection from bleeds with prophylaxis dosing of once weekly for people with hemophilia A. BIVV001 builds on the company's innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN polypeptides to extend its time in circulation. BIVV001 was granted orphan drug designation by the Food and Drug Administration in August 2017 and the European Commission in June 2019. BIVV001 is being developed in collaboration with Sobi.

BIVV001 has not been approved by the FDA, EMA or any other regulatory authority for any indication and no conclusions can or should be drawn regarding the safety or effectiveness of this investigational therapeutic.

About FitusiranFitusiran is potential first-in-class investigational, once-monthly, subcutaneously administered RNA interference therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia A and B, with and without inhibitors. Fitusiran also has the potential to be used for rare bleeding disorders. Fitusiran is designed to lower levels of AT with the goal of promoting sufficient thrombin generation to restore hemostasis and prevent bleeding. Fitusiran utilizes Alnylam's ESC-GalNAc conjugate technology, which enables subcutaneous dosing with increased potency and durability. The clinical significance of this technology is under investigation.

Fitusiran has not been approved by the FDA, EMA or any other regulatory authority for any indication and no conclusions can or should be drawn regarding the safety or effectiveness of this investigational therapeutic.

About BIVV003BIVV003 is an investigational ex vivo gene-edited cell therapy for the treatment of people with sickle cell disease being developed in collaboration with Sangamo Therapeutics, Inc. BIVV003 is a non-viral cell therapy that involves gene editing of a patient's own hematopoietic stem cells (HSCs) using zinc finger nuclease (ZFN) technology to address underlying disease pathophysiology. A Phase 1/2 clinical trial to assess the safety, tolerability, and efficacy of BIVV003 in adults with sickle cell disease has been initiated. Sanofi and Sangamo collaborate on a similar second program, ST-400, an investigational ex vivo gene-edited cell therapy, for the treatment of adults with beta-thalassemia. The safety, efficacy and tolerability ST-400 is currently being evaluated in a Phase 1/2 clinical trial.

BIVV003 has not been approved by the FDA, EMA or any other regulatory authority for any indication and no conclusions can or should be drawn regarding the safety or effectiveness of this investigational therapeutic.

About CabliviCablivi should be administered upon initiation of plasma exchange therapy, and in combination with immunosuppressive therapy, based on a diagnosis of aTTP. Cablivi is first administered as an 11 mg intravenous injection prior to plasma exchange, followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1. During the daily plasma exchange period and 30 days following daily plasma exchange, patients will take daily 11 mg subcutaneous injections. If after the initial treatment symptoms of the underlying disease are unresolved the treatment can be further extended for a maximum of 28 days. Subcutaneous injection can by administered by a patient/caregiver following proper training.

Cablivi was developed by Ablynx, which was acquired by Sanofi in 2018. Cablivi was approved in the European Union in August 2018 and in the United States in February 2019. Cablivi is part of the company's rare blood disorders franchise within Sanofi Genzyme, the specialty care global business unit of Sanofi.

CABLIVI IMPORTANT SAFETY INFORMATION

What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Who should not take CABLIVI?

Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.

Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.

You may have a higher risk of bleeding if you have a bleeding disorder (i.e Hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.

CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.

The most common side effects includenosebleed, headache and bleeding gums.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

Click here for full prescribing information.

Please visit http://www.cablivi.com.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2018. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

SOURCE Sanofi

http://www.sanofi.us

See the article here:
New data to be presented at ASH 2019 highlight Sanofi's commitment to treat challenging blood cancers and rare blood disorders - PRNewswire

NORTH PLATTE When Levi Thoene was just past six months old, his parents were told he had a rare genetic condition that meant he probably wouldnt reach his second birthday.

Called spinal muscular atrophy, it meant his body couldnt produce enough of a protein that certain nerve cells in his spinal cord need to survive. The condition leads to weakened muscles, including those needed for vital functions like breathing and swallowing.

On Tuesday, Levi turned 2. And in defiance of his earlier prognosis, his parents are seeing signs that hes making gains.

He can now sit up for 15 minutes or more, said mom Morgan Thoene (pronounced Tay-nee) of Ralston. Hes moving his arms and hands more, and he can do more to signal his wants and needs. His cough is stronger, and hes starting to say words, including no, the staple of toddler vocabulary.

Brandon Thoene, left, and Morgan, right, sit with their son Levi sit up during a visit to his doctor at Children's Hospital on Friday, October 18, 2019. Levi, who has spinal muscular atrophy, a month ago received a new gene therapy called Zolgensma and has been recently able to sit up on his own for the first time.

Anything he does is a surprise, and a blessing, that hes doing it as well as he is, said Brandon Thoene, his dad.

A month ago, Levi became the first child in Nebraska to receive a new gene therapy for spinal muscular atrophy called Zolgensma.

Approved by the Food and Drug Administration in May, it made headlines as one of the first gene therapies with the potential to stop the progression of possibly cure a genetic condition.The one-time treatment also comes with a price tag of $2.1 million.

About 1 in 11,000 babies are born with SMA, according to Cure SMA, an advocacy group. There are four main types, with Type 1, the version Levi has, being the most serious of those and the most common.

Before starting the new treatment, Levi had been getting a different therapy called Spinraza, the first drug available to treat the condition.

While Spinraza gives a defective gene in SMA patients an assist, Zolgensma replaces it, said Dr. Geetanjali Rathore, neurology division chief and director of the neuromuscular clinic at Childrens Hospital & Medical Center in Omaha.

No studies have yet been done to compare the two drugs. While plenty of questions remain unanswered, including about the therapies' long-term performance, both are preventing progression of the disease and resulting in improvements, Rathore said.

Dr. Geetanjali Rathore examines Levi Thoene just before his second birthday at Children's Hospital on Friday, October 18, 2019. Thoene has spinal muscular atrophy and recently received a new gene therapy called Zolgensma.

As a result, doctors for the first time have treatments to offer patients and their families, beyond feeding tubes, ventilators and other supportive care.

I think thats huge, thats huge for us and the SMA population, said Rathore, who well remembers her first SMA patient. A beautiful, 6-month-old girl and her parents first child, she was too old for the early Spinraza trials available at the time. She didnt survive her first year.

Last week, Rathore saw Levi for his one-month follow-up since starting the gene therapy. Hes also getting weekly lab tests to check for any side effects and make sure the treatment isnt affecting his liver or heart.

While its still early days, Rathore said shes very pleased with the progress Levi is making. Hes had no side effects and his lab tests are stable.

I am hoping to continue to see much more improvement, she said. Doctors typically see more measurable motor milestones starting at three months after treatment. At six months, they'll do a formal assessment of motor function.

Brandon Thoene, left, fist-bumps his son Levi during a visit to his doctor at Children's Hospital on Friday, October 18, 2019. Levi, who has spinal muscular atrophy, a month ago received a new gene therapy called Zolgensma and has been recently able to sit up on his own for the first time.

Meantime, the availability of treatments is creating new urgency to begin treatment for SMA as soon as possible, before the lack of the needed protein leads to permanent loss of neurons and function.

Unpublished data presented at medical conferences indicates that very young children treated before they develop symptoms all are doing extremely well, developing almost normally, Rathore said.

That calls for earlier diagnosis. Federal health officials added SMA to their list of recommended screenings for newborns in 2018.

The Nebraska Newborn Screening Advisory Committee voted in March to recommend adding SMA to the states newborn screening panel, the tests all babies are given at birth. State health officials anticipate that legislation to require the screening will be introduced in January.Ten states, including Missouri and Minnesota, already have implemented the testing,according to Cure SMA. Iowawilldecide whether to add it in 2021, pending successful completion of a pilot project expected to start next summer.

Rathore, who spoke in favor of adding the test, said the SMA screening can be performed using the same heel-prick blood sample now collected from newborns before they leave the hospital.

The tests, which now check for more than 30 conditions, look for conditions that would not be apparent just by looking at a baby and that can be treated effectively if identified early. Theyre credited with saving babies lives each year and preventing neurological and other developmental delays.

Morgan Thoene said the family plans to push the Nebraska Legislature to add SMA to the panel. She writes about Levis journey on the Facebook group, Life of Levi.

Morgan Thoene, left, comforts her son Levi during a visit to his doctor at Children's Hospital on Friday, October 18, 2019. Levi, who has spinal muscular atrophy, a month ago received a new gene therapy called Zolgensma and has been recently able to sit up on his own for the first time.

Starting therapy before symptoms develop, she said, could head them off. When Levi was diagnosed in April 2018, the Thoenes, both teachers at area schools, knew nothing about the condition. Levi had been hospitalized beginning in March for failure to thrive. He wasnt gaining weight, he didnt cry very loud and his cough was weak. He certainly wasnt as active as his older brother, Elliot, now 5.

Levi began receiving Spinraza, which the FDA approved in 2016, shortly after he was diagnosed. The drug must be injected into the fluid surrounding the spine every four months indefinitely. The cost is estimated at $750,000 for the first year and at $375,000 a year thereafter. Children's so far has treated 18 patients with that drug.

After Zolgensma was approved by the FDA, staff at Children's staff worked hard to get it OK'd internally for use at the hospital, Rathore said. It's federally approved for children under age 2. Levi, who started it Sept. 20, made it just under the wire.

"Spinraza was great because it allowed him to get a lot of gains," Morgan Thoene said. "But this has produced even more."

The gene therapy, given intravenously, is delivered by a virus that has had its genetic material removed. It's replaced with the gene that codes for the lacking protein. But rather than integrating with the patient's DNA, it sits on the side and goes to work to increase production of the protein.

In Levi's case, the costs were shared by Blue Cross Blue Shield of Nebraska and Medicaid.

Multiple studies, she said, found that the cost of caring for patients with SMA Type 1 think ventilators, wheelchairs, hospitalizations significantly outpaced the annual cost of Spinraza. Those studies haven't yet been done yet for Zolgensma, but the therapy is expected to be cost effective in the long term, particularly if it proves to be a one-time therapy.

Efforts are under way to expandboth treatments to more kids. Children's is on the list to become a center for trials of Zolgensma in children older than 2 who have less severe forms of the disease.

The hospital also has begun a study to gauge improvements in quality of life in such patients. That will focus on more subtle but still important changes such as whether patients can eat by themselves and how much help they need to move. It's new territory, Rathore said, because the focus with SMA patientshas for so long been on survival.

The Thoenes celebrated Levi's big milestone at home, just the four of them. They planned tomark the occasion with extended family and friends Sunday with a gathering at an area pizzeria.

For now, they're celebrating the progress he's made.Said Morgan Thoene, "He's doing fantastic."

Continue reading here:
Boy, 2, first in Nebraska to receive $2.1 million therapy for rare disorder. 'He's doing fantastic' - Kearney Hub

Nathaly Sweeney, a neonatologist at Rady Children's Hospital-San Diego and researcher with Rady Children's Institute for Genomic Medicine, attends to a young patient in the hospital's neonatal intensive care unit. Jenny Siegwart/Rady Children's Institute for Genomic Medicine hide caption

Nathaly Sweeney, a neonatologist at Rady Children's Hospital-San Diego and researcher with Rady Children's Institute for Genomic Medicine, attends to a young patient in the hospital's neonatal intensive care unit.

When Nathaly Sweeney launched her career as a pediatric heart specialist a few years ago, she says, it was a struggle to anticipate which babies would need emergency surgery or when.

"We just didn't know whose heart was going to fail first," she says. "There was no rhyme or reason who was coming to the intensive care unit over and over again, versus the ones that were doing well."

Now, just a few years later, Sweeney has at her fingertips the results of the complete genome sequence of her sickest patients in a couple of days.

That's because of remarkable strides in the speed at which genomes can be sequenced and analyzed. Doctors who treat newborns in the intensive care unit are turning to this technology to help them diagnose their difficult cases.

Sweeney sees her tiny patients in the neonatal intensive care unit of Rady Children's Hospital in San Diego. Doctors there can figure out what's wrong with about two-thirds of these newborns without a pricey DNA test. The rest have been medical mysteries.

"We had patients that were lying here in the hospital for six or seven months, not doing very well," she says. "The physicians would refer them for rapid genome sequencing and would diagnose them with something we didn't even think of!"

Rady's Institute for Genomic Medicine, which has been pioneering this technology, has now sequenced the genomes of more than 1,000 newborns.

In a building across the street from the hospital, three $1 million sequencing machines form the core of the operation. Technicians tending to the NovaSeq 6000s can put DNA from babies (and often their parents) into the machine in the late afternoon and have a complete genome sequence back by 11 a.m. or noon the next day, says clinical lab scientist Luca Van der Kraan.

That fact is worth repeating: An entire genome is decoded in about 16 hours.

Kasia Ellsworth is one of the experts waiting in a nearby office to analyze the information. That task has shrunk from months to typically just four hours, thanks to increasingly sophisticated software.

Ellsworth inputs the baby's symptoms into the software, which then spits out a long list of genetic variants that might be related to the illness. She scrolls down the screen.

"I'm looking through a list of those variants and then basically deciding whether something may be truly contributing to the disease or not," she says.

About 40% of the time, a gene stands out, giving doctors a tentative diagnosis. Follow-up tests are often requested, and those can take several days. But in the meantime, doctors can sometimes act on the information they have in hand.

When she or a colleague makes a diagnosis, "You always feel very relieved, very happy and excited," she says. "But at the same time you kind of need to put it in perspective. What does it mean for the family, for the patient, for the clinician as well?"

Often it's a sense of relief. And for a minority of cases, it can affect the baby's treatment.

"We now are at the point where I think the evidence is overwhelming that a rapid genome sequence can save a child's life," says Dr. Stephen Kingsmore, the institute's director and the driving force behind this revolution.

By his reckoning, the results change the way doctors manage these cases about 40% of the time.

Treatments are available for only a small share of these rare diseases. In other cases, the information can help parents and doctors understand what's wrong with their baby even if there is no treatment or learn whether death is inevitable. "And there it's a very different conversation," Kingsmore says. "We help guide parents through picking an appropriate point at which to say enough is enough" and to end futile treatments.

Of course, Kingsmore highlights the happier outcomes. One example is a bouncy girl named Sebastiana, now approaching her third birthday.

As a newborn, Sebastiana Manuel was diagnosed with a rare disease after rapid genome sequencing. She is seen here at 11 months of age. Jenny Siegwart/Rady Children's Institute for Genomic Medicine hide caption

As a newborn, Sebastiana Manuel was diagnosed with a rare disease after rapid genome sequencing. She is seen here at 11 months of age.

He showed off her case recently in front of the Global Genes conference, a meeting of families with rare genetic conditions.

"She was critically ill in our intensive care unit," he tells the audience, "and in a couple of days we gave the doctors the answer. It's Ohtahara syndrome. It comes with this specific therapy. And she hasn't had a seizure in 2 1/2 years. She doesn't take any medication."

The audience applauds enthusiastically at an outcome that sounds miraculous. But when you meet Sebastiana and her mother, Dolores Sebastian, a more complicated story emerges.

Ohtahara syndrome isn't actually what made Sebastiana ill it's a term doctors use to describe newborn seizures. Those are actually a symptom of deeper brain issues. That was apparent the day she was born.

"She was acting weird and screaming and crying and turning purple and we weren't sure why," her mother says.

The hospital where Sebastiana was born rushed her to the neonatal intensive care unit, across town at Rady. She was having frequent seizures. The following days were a nightmare for Sebastian and her husband.

"I can't even describe it," she says. "I always keep on saying that at that moment I was kind of like dead, but I was walking."

The hospital ran a battery of tests to look for severe brain damage. They couldn't get to the bottom of it.

"They came in and offered us the genomic testing," Sebastian said. "They never told us how quick it would be."

She was surprised when the results were back in four days. The doctor told her they had identified a gene variant that can trigger seizures as well as do other harm to the brain.

"He said this is how we're going to go ahead and change her medications now and treat her," she says. And that made a "huge difference, [an] amazing difference."

Sebastiana was already on a medication that was helping control her seizures, but they sedated her to the extent that she needed a feeding tube. On the new medication, carbamazepine, she was alert and able to eat, and her seizures were still under control. Sebastian says her daughter is still taking that drug.

Controlling her seizures isn't a cure. Children who have this genetic variant, in a gene called KCNQ2, can have a range of symptoms from benign to debilitating. Sebastiana falls somewhere in between. For example, she has only a few words in her vocabulary as she approaches the age of 3.

"She took her first steps when she was 2 years old, so she's delayed in some things," Sebastian says, "but she's catching up very quickly. She has [physical therapy]; she's going to start speech therapy. She gets a lot of help but everything's working."

Sebastiana Manuel (second from left) with members of her family: Domingo Manuel Jr. (from left), Dolores Sebastian and Tony Manuel. Jenny Siegwart/Rady Children's Institute for Genomic Medicine hide caption

Sebastiana Manuel (second from left) with members of her family: Domingo Manuel Jr. (from left), Dolores Sebastian and Tony Manuel.

KCNQ2 variants are the most common genetic factor in epilepsy, causing about a third of all gene-linked cases and about 5% of all epilepsies. Sebastiana's case could have been diagnosed with a less expensive test. For example, Invitae geneticist Dr. Ed Esplin says his company offers a genetic screen for epilepsy that has a $1,500 list price and a two-week turnaround.

Rady's whole-genome test costs $10,000, Kingsmore says. But it casts a wider net, so it might provide useful information if a baby's seizures are caused by something other than epilepsy.

And Kingsmore says his test costs about as much as a single day in the NICU. "In some babies we avoid them being in the intensive care unit literally for months," he says.

Kingsmore and colleagues have published some evidence that their approach is cost-effective, based on an analysis of 42 cases.

Even so, most insurance companies and state Medicaid programs are still balking at the cost. Kingsmore says private donors are helping support this effort at Rady, which sequences about 10% of the babies in the NICU, and at more than a dozen others scattered from Honolulu to Miami. They send their samples to Rady for analysis.

Kingsmore is pushing to expand his network in the next few years, to reach 10,000 babies at several hundred children's hospitals.

Other providers are also starting to offer whole-genome sequencing. But Dr. Isaac Kohane, chair of the department of biomedical informatics at Harvard Medical School, worries that the technology is too unreliable.

Knowledge of genes and disease is evolving rapidly, so these analyses run the risk of either missing a diagnosis or making a mistaken one. Kohane says there's still a lot of dubious information there a typical person has 10 to 40 gene variants that the textbooks incorrectly identify as causing disease.

Kohane is part of a medical network that helps diagnose people with baffling diseases. A study from 2018 found "a third of the patients who actually come to us already had full genome sequences and interpretations," Kohane says. "They were just not correct."

Even so, Kohane sees this use in the NICU as a relatively fruitful use of gene sequencing. "This is one of the few areas where I think the Human Genome Project is really beginning to pay off in health care," he says, "but buyer beware, it's not something ready to be practiced in every hospital." (He supports the work at Rady in fact, he is a science adviser.)

Kingsmore is already looking ahead. "We want to solve the next bottleneck, which is, 'I don't have a great treatment for this baby,' " he says. That's a far greater challenge, and it's especially difficult for a mutation that has altered a baby's development in the womb. Those problems may often not be reversible.

Kingsmore is undeterred. "It's going to be an incredibly exciting time in pediatrics," he says.

You can contact NPR science correspondent Richard Harris at rharris@npr.org.

Read the original here:
Genome Sequencing In NICU Can Speed Diagnosis Of Rare Inherited Diseases : Shots - Health News - NPR

The new horror flick on Netflix, Eli, released just in time for Halloween, borrows from The Exorcist and Rosemarys Baby, with touches of The Shining. And it all takes place in what looks like Downton Abbey with the cleaning staff gone.

Eli works; its scary. But the set-up using gene therapy gone awry is unfortunate, superfluous, and even offensive. (Beware, spoilers ahead)

The film opens with 11-year-old Eli dreaming about being able to go outside without his hazmat suit and breathing without his skin reddening and blistering. He awakens and hes inside, in a bubble.

David was diagnosed, four years earlier, with a rare formof severe combined immune deficiency (SCID). It slashes his ability to make the antibodies that protect against infection, unleashes inflammation that reddens his skin, while at the same time turns his immune system against his own tissues, an autoimmune response.

The parents, caring Rose and weirdo Paul, bundle Eli up to take him to a doctor whos going to cure him with a new treatment. Once at the supposedly clean Downton Abbey haunted house, Eli has a decontamination shower.

When the boy meets the doc, she explains that his immune system makes too many bad immunoglobulins, using that word instead of antibodies because it sounds more technical.Eli quickly responds, spouting out that he has mutations in the RAG1 and RAG2 genes (recombination-activating genes).

Elis body cant make the enzymes that mix and match antibody parts, and the proportions of a bunch of immune system cells and proteins go out of whack. His condition is also called Omenn syndrome.

Dr. Horn has two nurses, and all three of them wear purple uniforms.

Good news! Dr. Horn will administer viral gene therapy! I will make you better, like my other patients, she assures the boy.

Rose gingerly begins to unwrap the blue layers that encase her son, bending down and looking like Laura Dern examining dino poo in Jurassic Park or Princess Leia releasing the hologram from R2D2. Mom and boy can finally hug!!!

At night, the house creaks. Eli wanders the spooky halls, glimpsing kids in the windows, mirrors, and reflections, including ghostly girls who look like the twins at the end of the hallway in The Shining.

A redheaded girl outside, Sadie Sink, apparently escaped from playing Max on Stranger Things, seems real.

Im allergic to the world, Eli tells her. Not exactly.

The next morning, Dr. Horn blames Elis ghost sightings on a side effect from immunosuppressants. Why is she trying to suppress an immune system already so impaired?

Next Eli, who looks so much like Tom Petty that I expected him to shriek I Wont Back Down, is strapped down to a table with a contraption holding his head in place, as Dr. Frankenstein asks her nurses to take a reading.

Dr. Horn at first seems to have gotten the basic idea of gene therapy correct: introducing a working copy of the mutant gene aboard viruses into stem cells from bone marrow. And poof! Like a magic trick! itll work, she proclaims.

She proceeds to extract a hunk of pinkish gunk after drilling into a bone, as the immobilized boy twists and grimaces on the table. Satisfied, the doc plops the glob into a Petri dish.

It burns! Eli shrieks.

That means its working, replies the doc. Within seconds, the doctored viruses have apparently hit their targets.

Then Eli awakens. It all seems a dream, but its foreshadowing.

A ghost appears in a bloody nightgown.

The house breathes at night.

A scrawny, dagger-nailed hand grabs Eli and the apparition turns into his father.

When Eli writes his name on a window, the letters rearrange to spell Lie, like Redrum becoming Murder in the mirror in The Shining. Later on, with the E written like a 3, Eli scratched into various furniture surfaces in the house becomes 317317317. What can it mean?

When Eli reports these events, Dr. Horn barks, Its the medication, as if sophisticated gene therapy has suddenly become as mundane as a tab of Tylenol. Shell have to lower the dosage because the second of the three treatments is coming up.

Treatment 2 is indeed brutal. Eli is held in a contraption like the one Hannibal Lecter wears to keep him from eating people and his head bolted like hes Frankenstein.

Were confident that the gene therapy virus is correcting the mutation, Dr. Horn declares, adding that this will burn a little bit, as she presumably delivers more.

When Eli turns red and screams, she assures him that this is supposed to happen. The virus is penetrating the blood-brain barrier, as if said barrier is a superhighway requiring that the bolts hold his head still.

I was speechless.

Barrier refers to the blood vessels in the brain that are closed to large molecules, which keeps toxins out. A widely-used gene therapy vector, AAV9 (adeno-associated virus 9), has been known for a decade to naturally cross the barrier. And that doesnt require torture hardware.

Heres a photo of one of the kids I write about receiving AAV9 gene therapy for a rare neurological disease through an intravenous delivery in her hand!

The doc then attributes Elis reaction to his body initially rejecting the new cells, like any transplant. But if his gene therapy consists of viruses traipsing across the blood-brain barrier, where did cells suddenly come from? Is it the doctoring of stem cells from bone marrow that was in Elis dream, or delivering viruses into the bloodstream?

Elis nocturnal adventures continue. Hes pushed and pulled from unseen forces as the floor turns transparent, revealing scary medical people. As he keeps bellowing the doc orders Haldol and his mom pushes Valium.

The mysterious 317 opens a key pad to an inner sanctum, which looks like the set of the second Indiana Jones film. We see insects alighting, so the place was never a clean room after all.

Eli finds a notebook with case histories of the past patients and the pieces start to fit. Perry. Agnes. Lucas.

After treatment 2, the kids eyes look haunted, their complexions gray, like Eli. After treatment 3, their heads exploded.

Then the religion clues start to fall out.

Eli discovers a photo of nuns that includes his medical team. A huge iron cross sheaths a dagger. The surgical table with Eli across it resembles Christ on the cross.

One reviewer posits that the plot is about gay conversion, pointing to a scene in which Eli literally crawls out of a closet to tell his parents the truth.

The action speeds up and twists as treatment 3 looms.

Dr. Horn dons religious garb, makes the sign of the cross, flings holy water, and babbles about Jesus and the archangel. The boy, having discovered the medical records, has become a liability.

I thought I could cure Eli. The gene therapy would have worked, if he wasnt so strong. But he cant leave here! the enraged doc yells.

But when Eli is tied down and Dr. Crazy is coming at him with the dagger pulled from the cross, he suddenly summons his inner Regan MacNeil (from The Exorcist) and stops the knife in mid-air, turns it around, and forces the doctor to stab herself. She mutters may you find peace and forgiveness in the name of the Lord, channeling Father Damien KarrasThe power of Christ compels you! as he attempts to exorcise Regan.

With the plunging of the dagger, Eli, red-eyed and screaming, rips off his restraints. His parents are thrown to the floor while the nurses and the doc, somehow still living with the dagger in her chest, try to leave.

But Eli, like Anthony in the cornfield episode of the Twilight Zone, points at them and they turn in unison and then elevate, like Regan rising from her bed. The purple ones then float around the room in an eerie circle emanating an unearthly blue glow, as if theyre on one of those centripetal force amusement park rides.

A conspiracy revealed

It turns out that all are in on whats happening, even the nice-seeming mom. And Eli realizes hes never been sick.

What has she been putting inside me? What have you been putting inside me? he shrieks at his parents, conjuring images of Rosemarysdevil spawn.

At that the nurses and doc suddenly flip upside down, the horror equivalent of Regans rotating head, and slam to the floor.

What am I?

Our son.

Eli sets the nurses and doc on fire.

Are you my dad?

I prayed every day! answers dad.

Prayed to whom? the boy bellows.

The Lord didnt answer me, but your father did, Rose utters mysteriously.

And we know.

Eli never had a SCID. Its a twist on Munchausen Syndrome by Proxy, the cause of his symptoms the holy water that mom and then doc sprinkled on him.

But the ultimate cause? Dad is the devil. At that realization, Eli makes his dads head explode.

The other kids, whose bodies indeed turn up, were Elis half-siblings, even Haley. Dad the Devil got around.

Eli is fun, fast and scary. But why did the writers have to tarnish gene therapy? Why use a genetic disease at all? And especially an ultra rare one? I cant help but wonder what motivated the writers to do this.

Ive devoted the past decade to learning about families who have rare genetic diseases and have kids who have had, or wish they could have, gene therapy, writing about them, and accompanying some of them on their journeys.

In addition to my posts here and at my blog DNA Science, I wrote the only book on gene therapy, The Forever Fix, which chronicles the efforts of a few families. The first gene therapy was FDA-approved in late 2017. The technology has indeed been like the mythical phoenix bird, arising from the ashes.

For the families, I resent the use of gene therapy as a plot point.

After viewing the film the other night, I did a final Facebook check. The first thing that popped up: a photo of an exquisite child, on a page for families dealing with Sanfilippo syndrome, a devastating neurological condition.

The boy was now free of the cruel disease, free to be at peace. He was 11. Elis age.

Genetic disease, and especially attempts to treat it, shouldnt be the stuff of horror films.

Ricki Lewis is the GLPs senior contributing writer focusing on gene therapy and gene editing. She has a PhD in genetics and is a genetic counselor, science writer and author of The Forever Fix: Gene Therapy and the Boy Who Saved It, the only popular book about gene therapy. BIO. Follow her at her website or Twitter @rickilewis

Continue reading here:
Viewpoint: Netflix's new horror movie 'Eli' is a fright. But why did they have to 'tarnish gene therapy'? - Genetic Literacy Project

Two decades ago, a patient with HER2-positive breast cancer had a single targeted drug option. Now a plethora of new and emerging treatments fill the landscape.

BY Meeri N. Kim, Ph.D.

Over the summer, Gulley had noticed a hard lump in her right breast. Having experienced fibroadenomas benign, noncancerous breast lesions in the past, she mostly ignored it. During Gulleys annual gynecological exam in November, even her doctor didnt seem too concerned but asked her to keep an eye on it for the next few weeks. When the lump hadnt gone away by December, Gulley scheduled a mammogram and ultrasound.Although I didnt officially get the diagnosis until January 2018, they were already 100% sure that it was cancer, says Gulley, now 33. I have no family history of breast cancer whatsoever, and I thought at the time that breast cancer was always hereditary, so it was very shocking. Getting that news is really overwhelming, and I had no idea what was to come.

Because of her young age, her doctors wanted to start treatment right away. They took three biopsies, which revealed a subtype of breast cancer known as HER2 positive. Women with HER2-positive breast cancers have tumors with higher levels of a growth-promoting protein called HER2, which stands for human epidermal growth factor receptor 2. As a result, these cancers grow and spread more aggressively than other types of breast cancer. About one out of every five breast cancers has extra copies of the HER2 gene (known as gene amplification) that leads to an overexpression (high levels) of the HER2 protein.

Jennifer Campisano received a diagnosis of HER2- positive breast cancer in 2011, also at an early age. HER2- positive status is more common among younger patients with breast cancer, with mutation incidence at 29.9% in patients ages 15 to 29 and 25.5% in those ages 30 to 39. When Campisano was 32, she and her husband, Chris, had their first child, a boy named Quinn. When he was just 3 1/2 months old, Campisano noticed a walnut-size lump in her right breast.

After two OB-GYNs told her it was probably nothing, she eventually saw a surgeon who sent her straight to the radiology department for a mammogram and ultrasound.

In my head, I still wasnt thinking cancer, but the radiologist told me, Im 99% sure this is cancer, says Campisano, who lives in Phoenix. After the biopsies, they called me and confirmed that it was HER2-positive breast cancer. It was rough. I had to wean my son overnight, which was really painful.

Fortunately, the treatment landscape for this type of disease has evolved considerably over the past two decades, with the development of drugs that target the HER2 protein. Even today, treatment options continue to emerge for patients like Campisano and Gulley, who both received newer agents as part of their regimens for earlier-stage disease and remain cancer-free.

In the past, HER2-positive breast cancer was known as a more aggressive disease with a worse prognosis than HER2-negative breast cancer, says Dr. Janice Lu, clinical professor of medicine at the University of Southern California Norris Comprehensive Cancer Center. But with the development and approval of five drugs now that specifically target HER2, being HER2 positive is no longer any worse for patients than being HER2 negative.

In clinical trials, researchers are testing several other agents for HER2-positive breast cancer with a high likelihood of approval by the Food and Drug Administration (FDA). They are mostly focused on treating patients in the metastatic setting, meaning the disease has spread beyond the breast, and those whose disease is resistant to more commonly used drugs.

A LARGE TOOLBOX OF TREATMENTSIn 1987, oncologist Dr. Dennis Slamon at UCLA discovered that the HER2 protein was present at high levels in certain breast cancers. The protein is also found on the surface of normal breast cells, but some breast cancer cells have 40 to 100 times more HER2, which stimulates the tumor cells to divide and grow. This overexpression of HER2, which became known as HER2 positivity, was linked to a higher likelihood of metastasis and relapse in patients, along with a decrease in overall survival, or the length of life measured from the start of treatment.After this discovery, Slamon and his colleagues had a novel idea: What if HER2 proteins activity could be blocked? Shouldnt that, in theory, halt the aggressive growth of the cancer cells? This train of thought led to the groundbreaking development and FDA fast-track approval of the first drug to target HER2 in 1998. In fact, it was the first drug to target a protein that contributes to the development and growth of any cancer: Herceptin (trastuzumab).

Herceptin is a monoclonal humanized antibody, a laboratory-created molecule that attaches to cancer cells, inhibits the growth factor function of HER2 and attracts attack by the immune system. In a phase 3 clinical trial, adding Herceptin to chemotherapy was associated with more responses, longer time until cancer progression and better survival in patients with metastatic HER2-positive breast cancer compared with chemotherapy alone. In 2006, it was approved with chemotherapy for use after surgery, to help prevent recurrence, in earlier-stage HER2-positive breast cancers.

Herceptin is generally well-tolerated, causing mild to moderate side effects such as muscle aches, dizziness, headache, fever/chills and runny nose. However, it does come with a small risk of cardiotoxicity especially for women who were also treated with anthracycline chemo- therapy which usually manifests as cardiac dysfunction, primarily a condition known as cardiomyopathy, which can lead to congestive heart failure.

We are getting long-term data on outcomes with trastuzumab after its FDA approval 20-plus years ago, and today if women are diagnosed with HER2-positive breast cancer, we can tell them their prognosis is as good as those with HER2- negative disease, says Dr. Sara Hurvitz, a medical oncologist at UCLA. Although trastuzumab has leveled the playing field, it isnt a cure for 100% of patients by any means. For early-stage cancer that recurs as metastatic disease, trastuzumab can improve outcomes and help patients live with the disease, but it does not cure, for the most part.

More recently, patients have also benefited from a newer HER2-targeting therapy called Perjeta (pertuzumab), which was approved in 2012. Similar to Herceptin, Perjeta is a monoclonal antibody that attaches to HER2 receptors on the surface of breast cancer cells and prevents them from receiving growth signals. It targets a different area on the HER2 receptor than Herceptin, which means it can act as a complementary treatment or serve as an alternative therapy for Herceptin-resistant disease.

This drug is used in both earlier-stage and metastatic HER2-positive breast cancers.

For women with early-stage HER2-positive breast cancer, the standard of care is currently chemotherapy plus Herceptin. Typical chemotherapy regimens include AC-TH, or Adriamycin (doxorubicin) and Cytoxan (cyclophos- phamide), followed by a taxane that is given concurrently with Herceptin. Recently, it has become more common to use TCHP, which includes docetaxel and carboplatin given concurrently with Herceptin and Perjeta.

This minimizes the cardiac risks associated with Adriamcyin along with Herceptin. Patients on either regimen will end with Herceptin (and Perjeta if used with chemotherapy) after completing the chemotherapy portion, such that a full year of antibody therapy is given.

In the metastatic setting, the standard of care for initial treatment is a combination of Herceptin, chemotherapy and Perjeta. Studies have found that 15% to 25% of patients with early-stage, HER2-positive breast cancer eventually experience metastatic recurrence after initial treatment. Then, the prognosis is poor, with most recurrences involving incurable metastatic disease, although some patients can survive for many years with their cancer controlled by several available medications.

In the metastatic setting, were not curing the vast majority of patients with HER2-positive disease, and resistance does occur, says Dr. Sara Tolaney, associate director of the SusanF. Smith Center for Womens Cancers at Dana-Farber Cancer Institute in Boston. But patients continue to live longer because they can go from one treatment to the next. There are now multiple options to go to as resistance develops, and there are also clever ways to overcome resistance.

In 2012, Campisano started the TCH regimen along with surgery and radiation therapy. When it looked like her cancer recurred, her doctors gave her newly approved Perjeta, along with Herceptin and chemotherapy. Less than a week after her 2018 wedding, Gulley was also treated with Perjeta in conjunction with the AC-TH regimen following her mastectomy. The agent had already been approved for more than five years to treat both metastatic HER2-positive breast cancer and early-stage disease prior to surgery, and in 2017 it won approval to be given after surgery for early-stage disease.

I was on Perjeta for a year, and my doctors warned me about diarrhea being a common side effect, Gulley says. I definitely noticed that in the beginning of treatment, but my body got used to it, I guess, because at the end of the year, I wasnt as bad. I used over-the-counter Imodium and things like that to combat it.

With the combination of Perjeta and Herceptin, Campisano experienced very mild side effects itchy skin and a runny nose but they were nothing compared to how she felt during chemotherapy. Unfortunately, her scans still showed what looked like cancer after her initial treatment, so she started on Kadcyla (ado-trastuzumab emtansine, also known as T-DM1).

Kadcyla is a type of antibody-drug conjugate, an emerging class of agents comprised of an antibody linked to a highly potent anti-cancer drug. They combine the heat-seeking ability of targeted therapy with the cancer-killing power of chemotherapy. In 2013, Kadcyla was approved for patients with metastatic HER2- positive breast cancer who were previously treated with Herceptin and taxanes. Earlier this year, it gained approval for use in the adjuvant (postsurgical) setting for early-stage disease. Common side effects include fatigue, nausea, bone and joint pain, muscle pain and constipation.

In the phase 3 KATHERINE study, Kadcyla given after surgery significantly reduced the risk of invasive breast cancer recurrence or death from any cause by 50% compared with Herceptinin patients who had residual disease after neoadjuvant (presurgical) therapy. An analysis showed that of 1,486 patients in the trial, 165 in the Herceptin group and 91 in the Kadcyla group had experienced invasive disease or death. In addition, at three years, 88.3% of those who took Kadcyla versus 77% of those who took Herceptin were free of invasive disease.

Campisano took Kadcyla for almost three years. In 2016, a lung biopsy revealed that what had appeared to be cancer in her lungs was actually an autoimmune disease that can mimic cancer on scans. She was taken off treatment and finally tested cancer-free. Even if she didnt need T-DM1, she refers to it as a wonder drug.

Another option in both early-stage and metastatic HER2- positive breast cancer is Nerlynx (neratinib). In early-stage disease, the drug is approved for extended postsurgical therapy after chemotherapy and Herceptin to reduce the risk of recurrence. Nerlynx is a kinase inhibitor, which blocks enzymes that promote cell growth. Specifically, it inhibits the activity of HER2 and other enzymes in its family. In a phase 3 clinical trial, 94% of those who took Nerlynx experienced no disease progression over two years versus 91% in a placebo group. Common side effects included diarrhea, vomiting and nausea.

The results from a more recent phase 2 trial showed that combining Nerlynx with a chemotherapy drug called capecitabine has an effect on patients with HER2-positive breast cancer who have brain metastases.

Neratinib is notable because it has activity with HER2- positive brain metastases, which occurs in about 50% of patients with metastatic disease, Tolaney says. It already has FDA approval in the adjuvant setting for patients who have completed a year of trastuzumab, and it will likely get approval in the near future for the metastatic setting based on the results of the trial.

Finally, the kinase inhibitor Tykerb (lapatinib) was approved in 2007 for the first-line treatment of HER2-positive metastatic breast cancer, first with the chemotherapy Xeloda (capecitabine) and later with the hormone-blocking drug letrozole for postmenopausal women with hormone-driven breast cancer that over- expresses the HER2 receptor. A 2009 study showed that adding Tykerb was associated with a 5.2-month increase in median time without disease progression compared with taking letrozole alone (8.2 months with the drug combination versus 3.0 months with letrozole only).

NEW DRUGS HOLD PROMISEPatients have a lot of options, and there are multiple new therapies in clinical trials, some of which are very prom- ising, Hurvitz says. Three in particular deserve mention: tucatinib, a pill that appears to be safer than neratinib and lapatinib because it doesnt cause as much diarrhea; DS-8201, another antibody-drug conjugate with a different chemo payload than Kadcyla; and margetuximab, which is similar to trastuzumab.

All three investigational agents have shown tremendous promise in fighting HER2-positive disease and are expected to gain FDA approval in the near future. The HER2CLIMB trial is currently investigating tucatinib, a HER2-specific tyrosine kinase inhibitor, with Herceptin andcapecitabine in patients with metastatic HER2-positive breast cancer. It can penetrate the blood-brain barrier better than antibody drugs like Herceptin and Perjeta and demonstrated abrain-specific response in five of 12 patients with brain metastases. Hurvitz expects tucatinibto gain FDA approval within the next six to 12 months.

DS-8201 (trastuzumab deruxtecan) links Herceptin with a chemotherapeutic drug a topoisomerase inhibitor called deruxtecan, which interrupts DNA replication in cancer cellsand is guided more specifically to HER2-positive cells while mostly sparing normal cells.

The FDA granted this experimental antibody-drug conjugate breakthrough therapy designation, expediting its development and review, as a potential treatment for patients with HER2-positive, locally advanced or metastatic breast cancer who have been previously treated with Herceptin and Perjeta and have disease progression after T-DM1. In a phase 1 study, 54.5% of HER2-positive women treated with DS-8201 saw their cancer respond to the drug.

DS8201 is an up-and-coming drug that everyone is very excited about. It delivers a different payload into the cancer cell than TDM-1 and also uniquely allows for the bystander effect, Tolaney said. This means that some of the drug that enters one cancer cell can pass through its cell membrane into neighboring cancer cells, which then kills them.

A more recently studied monoclonal antibody, margetuximab, has been described as an optimized version of Herceptin. A section of the antibody was engineered to better engage the immune system in fighting the disease. In the phase 3 SOPHIA trial, patients with metastatic HER2-positive breast cancer who took the investigational drug with chemotherapy had a median progression-free survival of 5.8 months compared with 4.9 months for those treated with Herceptin and chemotherapy.

These new drugs are rising stars in the metastatic setting, and many other agents are currently being tested, Lu says. Patients with HER2-positive breast cancer should discuss with their doctors what is the standard of care, next steps for treatment, any clinical trials that are potentially available and, of course, possible side effects.

Although they continue to adjust to a new normal after cancer, Gulley and Campisano are grateful to be cancer-free and hopeful about the growing availability of treatment options for their disease. Gulley had a left-side mastectomy in February of this year, after a mammogram revealed calcifications in her remaining breast. She was also put into a chemical menopause at age 33, which means hot flashes, night sweats and fatigue.

After my wedding, instead of going on a honeymoon, I started my chemotherapy. This has all been such a whirlwind, Gulley said. Being newly married, its really hard. Menopause has a lotof bad side effects, sexually and otherwise. That fear of recurrence is always there too, but Im so thankful for the two medicines that were available to treat me.

Campisano also went through early menopause, induced by chemotherapy. She eventually emerged from that menopause and, surprisingly, became pregnant with her second child. But the chaos of having a newborn, then a cancer diagnosis and treatment, followed by another baby left her physically and mentally exhausted.

I dont think I had time to process anything in the beginning. My husband and I had not even been married three years when I was diagnosed, and today Im left with range-of-motion issues, body image issues, a bilateral mastectomy and post-traumatic stress disorder, Campisano says. I know that we dont have a cure for metastatic HER2-positive breast cancer, but its wonderful that these new drugs do work for some people.

Read the rest here:
From One to Many: The Growing Treatment Landscape of HER2-Positive Breast Cancer - Curetoday.com

Dr Mukesh Batra, the owner of Dr Batras clinics.

Mitchelle DSouza, Sub-editor/Reporter

The founder and chairman of Dr Batras group of companies, Dr Mukesh Batras name has become a byword for homeopathy.

The pioneering Indian doctor-cum-entrepreneur has built a legacy which includes a network of clinics, day-care aesthetic centres, and health and wellness products.

We caught up with Dr Batra at his Healthcare City clinic in Dubai, where he spoke at length about the workings of homeopathy and introduced us to the new Geno-Homeopathy treatment launched by the brand.

Can you explain what homeopathy treatment is for those who dont have a clear understanding? How does it work in comparison to conventional medicine?

Theres actually a misconception that its not well known. For emergencies and conventional problems, allopathy is the go-to. Like a heart attack, surgeries, gunshot wounds and so on.

However, homeopathy is safe for anything that is chronic and long lasting such as psychosomatic problems like stress, anxiety, and depression related issues; allergies, skin and hair problems.

We treat a wide range of illnesses such as asthma, arthritis, anxiety, depression, backache, cervical spondylitis, kidney stones in primary stage, warts, piles, PCOD, nasal polyps etc.

It has no side-effects and is completely painless and non-invasive. It goes to the root of the problem, nipping it in the bud, rather than just supressing it temporarily with pain killers.

"People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

Is it true that homeopathy is slower in addressing an ailment in comparison to allopathy?

Its partly true, but not entirely. If you come to allopathy for a chronic sinus problem, you pop a pill and supress it. Similarly for a skin allergy, an ointment will supress the symptoms. The moment you stop, it flares up again.

So when you look at suppression, it is quick in allopathy, but thats not a cure. In conventional medicine, treatment is as slow as homeopathy or maybe even slower

For instance, a patient may be supressing his/her migraine or skin problem for the last 10 years with allopathy by taking pain killers and anti-inflammatories but without a proper solution.

However, if he/she were to take homeopathy for just 10 months, it would cure it, and hence that makes it much faster and effective as it gets to the root of the cause.

The reason it may feel seemingly long is because most illnesses are chronic, long-standing and deep-rooted.

Geno-Homeopathy treatment employs a gene test to predict, pre-empt and treat an illness. Charles Bertram/TNS

Can you give us an insight into the new Geno-Homeopathy treatment launched in the UAE?

As you may be aware, genetic DNA studies have been around for some years and have become more popular off late, thanks to Angelina Jolie creating awareness by positively testing herself for a cancer gene.

This helps predict and pre-empt an illness. How this works is that you have genes that are inherited, with 99.9 per cent of them being normal. But 0.1 per cent genes can be faulty and that percentage decides what diseases we carry.

A gene is like a finger print, it never changes. So just like you would use your finger print or pupil for identity, this is used for gene mapping through a simple sputum test. Now that 0.1 percentage gene decides how healthy I can be and which diseases I am likely to suffer from.

So with Geno-Homeopathy we can now analyse those 0.1 per cent genes. We completed one year in India in September and did 15,000 cases of genetic mapping.

This technique gives you your disease propensity and can tell you, for example, whether youll go bald five or 10 years from now; if youre prone to heart attack or diabetes it will tell you when youre likely to get it.

Post an analysis, a homeopathic treatment is offered to the patient to treat a condition. So this can be almost life-saving and is now within peoples reach in the UAE.

Angelina Jolie found out through genetic testing similar to Geno-Homeopathy that she is at a high risk of developing breast cancer.Marechal Aurore/TNS

There are a lot of cynics out there who question the scientific basis of homeopathy. What do you have to say to that?

A research we conducted three to four years ago found that a majority of people in Indian metros were taking homeopathy as the first choice of treatment. Pharma is growing at 10 per cent while homeopathy is growing at 30 per cent all over the world.

People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

To give you a little perspective, there are around 300 people dying of drug reaction in America alone everyday which is equal to a Boeing crash. But it doesnt get as much attention, which can be pinned on the strong medical lobby.

So theres a gradual shift happening from allopathy to homeopathy not just in India but all over the world.

That being said, there are a lot of cynics and the lobbies that plant various stories. In spite of all this homeopathy is growing exponentially. The proof of the pudding is in eating it, so people should give it a try before denouncing it.

See the article here:
Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today

The statistics are all too clear Black women in the U.S. are 42% more likely to die from breast cancer than white women, according to 2016 findings from the American Cancer Society. In fact, one in nine African-American women will be diagnosed with the disease in her lifetime. These numbers are far more frightening when you consider that Black women are often subject to discriminatory practices that impact the care they receive from medical professionals. Yet every day, Black women who find themselves face-to-face with this battle suit up and fight like hell. And many of them are winning.

Dr. April Spencer, the founder of Dr. Spencer Global Breast Health & Wellness Center in Atlanta and a Know Your Girls ambassador, spoke to ESSENCE exclusively about just how much breast cancer is impacting Black women and girls. What makes African-American women unique is that the younger women, defined as women before the age of 45, have the highest rate of new breast cancer incidents, she says. That is alarming, and it is what makes our desire to [encourage] Black women to receive mammograms and testing even more significant.

Reducing your risk of breast cancer involves several factors, and Dr. Spencer breaks it all down for us, simple as ABC.

A Is For Awareness

You need to be aware of your body, your breasts, and what they feel like. Be aware of changes to your breast size, shape and changes to the skin underneath your arms. Ive had lots of patients diagnosed with breast cancer who didnt suspect it because they didnt have a lump.

B Is For Behavior

There are things that women can do to lower their risk of breast cancer. They including maintaining a healthy weight, exercising daily and limiting alcoholic intake. In terms of your culinary choices, be mindful of what youre eating. Theres no magic bullet in terms of the best diet, but there has been lots of research on the benefits of a Mediterranean diet, which is high in healthy fats like olive oil, and unsaturated fat like salmon. Every time you sit down [to eat], youre either feeding disease or fighting disease. Also, women who have undergone menopause should limit their use of hormone therapy, as it can increase your risk.

C Is For Chemoprevention

Chemoprevention is just some women that may have the breast cancer gene may not be prepared to do a surgical option like removing their breast or removing their ovaries, but there are certain medications that can block the hormone estrogen that has been known to feed breast cancer, and so those medications, they have risks, so its important to talk to your doctor about the risk versus benefit of taking those medications, but that can lower the risk as well.

So ABC. Awareness of the body, B is behavior, and C is chemoprevention.

This article originally appeared in the October 2019 issue of ESSENCE Magazine, on newsstands now.

The rest is here:
Dr. April Spencer's ABC's Of Breast Cancer Prevention - Essence

I never imagined every woman in my family would get breast cancer. It started in 1998 when my aunt was diagnosed at 58-years-old. In 2010, my mom was diagnosed at 65. Two years later, my cousin (my aunts daughter) was diagnosed at 42 with Stage 1 Triple Negative breast cancer, the most aggressive and fastest-growing type. Had it been discovered just a year later, it would have grown to Stage 4. I joined the club in 2014, just two weeks shy of my 35th birthday. All four of us tested negative for the BRCA gene mutation.

In the simplest terms, thats code fortheBReastCAncer geneand is split into two categories: BRCA1 and BRCA2. Though we all have BRCA genes, they are believed to increase a persons chances of developing the disease when mutated. Dr. Sunil Hingorani, a family friend and pancreatic cancer specialist, once told me It doesnt mean there isnt a gene link, it just means they havent found the gene yet.Eek. Then I thought, Oh, maybe theyll name it after us. Cool. Wait. Nope, not cool.

After being told we werent BRCA gene mutation carriers, I morphed into a boob spy named Erin Boobivich to investigate exactly what the culprit was. My cousin believes it has something to do withthe water in Connecticut. Not only had each of us lived there for at least 30 years prior to our diagnosis (Boobivich knows her number-crunching); its also home to some of the countryshighest breast cancer rates. My brother thinks the microwave we grew up using is to blame. My mom thinks my aunt got it from eating too much barbecue. Im convinced it has something to do with potato chips. (What?! Theyre a carcinogen! I read an article once and now I dont eat potato chips). Okay, thats the extent of my research, but it could be all or any of those things, plus a bag of genes.

Reasoning aside, whats really worth sharing goes beyond statistics. Ultimately,breast cancercompletely changed our lives collectively and individually. And while its important to share the commonalities weaved throughout, our individual experiences carry lessons that should be amplified, too.

My aunt, who left India for America in the 70s, was diagnosed withHER2 neu positive, a very aggressive type of breast cancer. She had a lumpectomy (aka breast-conserving surgery that removes abnormal tissue) and more than 20 lymph nodes removed to determine if it had spread throughout her body. This was followed by debilitating chemotherapy that left her extremely ill for months. From the outside, you could never tell she was in pain because her sense of humor made cancer seem fun. She was always upbeat and cracking super inappropriate jokes, like the one where she called me in 2003 and joked her cancer was back, then cackled loudly and said she was kidding.Ha. Ha.

During chemo, she chose not to wear a wig, and insteadwore headwrapsand proudly flew bald. She just didnt seem to care. Her hair never really grew back. If you ask my aunt to take a picture with you today, she will refuse, claiming she hates pictures. The truth is cancer changes how you feel about your body. Her hair didnt grow back to its former glory, but thankfully, neither did her cancer. She just hit her 21 year clear MRI on October 8, 2019.

My moms cancer washormone-based. She was told by a doctor that she would need a lumpectomy, radiation and chemotherapy. Our family friend Dr. Hingorani insisted she go toDana Farber, a renowned cancer institute in Boston, for a second opinion. My mom balked at it, but my father and Hingorani insisted. Its a good thing she listened. The doctors there confirmed chemotherapy wouldnt be beneficial. At all. Had she gone through with it, she would have lost her hair and who knows what else. forNo. Benefit. At. All. With that being said, get second opinions. Get thirds. Make sure you have all the info you need.

By the way, after her lumpectomy and radiation, Mom was put onArimidex, a drug specifically for post-menopausal women to reduce the risk of cancer coming back. She just hit 9 years clear and was told on October 9, 2019 that she no longer needs to take it.

My cousin was diagnosed in November 2012 in early November and went through at least 5 biopsies well into 2013. Because her cancer was especially aggressive, a combo of lumpectomy, radiation, and chemotherapy was the only choice. At the time her children were 11, 9 and 7 years old, respectively.

At our Christmas dinner, a month before she began chemotherapy, I remember asking if I could get a picture of her, my aunt and the kids with my new camera. Priya responded, Sure, since itll be the last time I have hair like this. And she was right. Her hair has never returned to what it was that day.

She endured 8 rounds of chemo within 4 months and each infusion took 4 to 6 hours. We took turns accompanying her to Boston. Her husband, Douglas, did the first round. But when he tried to unplug the chemo machine to charge his Blackberry, lets just say he wasnt invited to return.

Priyas hair fell out, her nails turned blue, and her eyebrows disappeared. My cousin is a very strong and stoic individual to a fault. She never wanted to admit she was in pain or needed help. I understood. With three young children, she didnt want them to feel unsafe or think that their mother was dying. One morning she couldnt protect them from what was going on, and while they were having breakfast, she fainted in the pantry. Thankfully, Douglas wasnt charging his Blackberry, ran to the pantry, and moved the kids out of the kitchen so he could help her. He was scared. So were the kids.

She was told that chemotherapy would only improve her chance of no recurrence by 3-5%. It seems like nothing right? But with three kids, she said she would do whatever was necessary. Today, shes 7 years clear. But in addition to her hair thinning, chemo also affected her brainspecifically her attention span and memory. It took her two years to be able to get through a long book again. And like a lot of women, chemo threw her into early menopause at just 43.

My mother and I got the exact same type of cancer. Same boob. Same exact spot. Like mother, like daughter. The only difference was age; my diagnosis came much earlier in life (30 years before Mom, to be exact.) It sucked. I always thought Id have children of my own. Unfortunately, this diagnosis changed that.

Prior to getting the bad news, everyone in my family begged me to get screened; specifically, after my cousins diagnosis. I finally did a year later. I thought there was no way I could to get cancer at such a young age. Thats what we all thought.

But then they saw something on my right boob. After two mammograms, 1 ultrasound and a biopsy, I got an all-clear. Phew. Relief. No cancer. But then something strange happened. In my right underarm, I got a swelling that was extremely painful. So on Christmas day, my uncle drove me around to see if we could find an urgent care center. The doctor who had previously ordered my biopsy, asked for an MRI. It revealed everything was fine on the right breastand a tumor on the left. The latter was missed on two mammograms and an ultrasound.

My mom said when I called her on March 4, 2014 to break the news, it was one of the most shocking moments in her life. I remember bursting into tears and Im not a crier. That doctor told me, So listen, you can get a lumpectomy, radiation, maybe chemo. Or you can just get a mastectomy and not have to worry about any of that. Wow. (That was the most glossed-over statement that was ever said to me). My cousin called Dr. Alexandra Heerdt, her breast surgeon atMemorial Sloan Kettering Cancer Center, who later told me a mastectomy wasnt something shed recommend.

By the time my lumpectomy was done on April 9, 2014, I had been through 2 mammograms, 2 ultrasounds, and 3 biopsies. Two days after my surgery, I developed cording, despite only having 3 sentinel nodes removed. Its a traumatic reaction your body has when the muscles and nerves in that same area wrap around each other. It was one of the most painful experiences of my life and took 5 months of physical therapy to treat.

Radiation nukes everything. The doctors told me if I ever had kids, I wouldnt be able to breastfeed on my left side. It also charred my boob and literally turned it black. Thankfully, my cancer had not spread, so chemotherapy was eliminated. However, I had to go on a drug (like Mom) to inhibit the hormones that caused my cancer in the first place.

My doctor initially recommended shutting down my ovaries for 5 years. What the ever loving?! Yes, thats correct. He went over the side effects, which include but arent limited to hair loss, decreased libido, and joint pain. No thanks. So I talked to Dr. Rachel Freedman, my other doctor at Dana Farber (who also happens to be my cousins oncologist). She said the research wasnt there to confirm ovarian shutdown as the best option. Instead, she recommended I start withTamoxifenand if a new study was done on ovarian shutdown, I could switch. A few weeks later, a new study became available and my main oncologists recommendation aligned with Dr. Freedmans.

He also said pregnancy is a hormone storm for your body. You cant for at least 5 years. That was probably the hardest thing to hear. I chose to not freeze my eggs, because quite frankly, getting rid of cancer and going through treatment was enough to deal with at the time. I worry that I will regret this decision.

This year, I hit 5 years clear. I will have to take Tamoxifen for a total of 10 years, or until Im 46. Ill probably enter menopause shortly before or after that. It sucks. Thankfully, Tamoxifen hasnt thrown me intoearlymenopause; at least not yet. For this reason, I actually get excited for the period I used to curse each month. As long as Im still getting it, maybe theres still a chance I can have kids.

My cousin Priya has two daughters, Bella, age 16 and Emma, age 14. About 2 months ago, we were out to lunch with my Aunt Veena, their grandmother. The topic ofbreast cancercame up, and Emma, Bella and I made some jokes as our family is apt to do. My aunt looked horrified, and Emma lightly said, What Nani? We know were probably going to get it.

I hope they never join this club. And with research and progress over the next few years, maybe they wont. Today, all of us are diligently scanned and have annual MRIs and mammograms. I have blood tests every 3 months. And when we get clear tests, we text our family group chat to report the news because were all scared on some level. The fear that its going to come back never goes away. Sometimes, the further I get from it, the more I fear I experience.

So cancer does change things. A lot. But with a good boob squad friends, family, and doctors it will be ok. My friends saved me when I was going through all of this. In fact, this post-it my friend Marisa found on her desk from 2014 says it all. (Seriously, if you get cancer, you can get your friends to do stuff for you). And remember, every day they are discovering new genes and new treatments. So get your mamms, maams.

View post:
Every Woman in My Family Had Breast Cancer & None of Us Have the BRCA Gene Mutation - SheKnows

Healthcare is an industry that is currently being transformed using the latest technology, so it can meet the challenges it is facing in the 21st century. Technology can help healthcare organizations meet growing demand and efficiently operate to deliver better patient care. Here are 9 technology trends that will transform medicine and healthcare in 2020.

The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020

AI and Machine Learning

As the world population continues to grow, and age, artificial intelligence, and machine learning offer new and better ways to identify disease, diagnose conditions, crowdsource and develop treatment plans, monitor health epidemics, create efficiencies in medical research and clinical trials, and make operations more efficient to handle the increased demands on the healthcare system. By 2020, medical data will double every 73 days. McKinsey estimates that there could be $100 billion in annual savings for medicine and pharma by leaning on big data as well as the artificial intelligence and machine learning tools to process it. Artificial intelligence algorithms powered by recent advances in computational power learn from the data and can predict the probability of a condition to help doctors provide a diagnosis and treatment plans. Ultimately, AI and machine learning can assist with many clinical problems as long as governing and regulatory bodies can determine how to regulate the use of algorithms in healthcare.

Robotics

When it comes to life or death, would you trust a robot with yours? Currently, collaborative robotssuch as the da Vinci surgical robot are already assisting humans with tasks in the operating room. However, the potential for robots in healthcare expands beyond surgical uses. With tremendous growth expected in the industrythe global medical robotics market is expected to reach $20 billion by 2023theres no doubt that robots used in healthcare will continue to conduct more varied tasks. These already include helping doctors examine and treat patients in rural areas via telepresence," transporting medical supplies, disinfecting hospital rooms, helping patients with rehabilitation or with prosthetics, and automating labs and packaging medical devices. Other medical robots that are promising include a micro-bot that can target therapy to a specific part of the body, such as radiation to a tumor or clear bacterial infections.

Computer and Machine Vision

Training computers to "see" the world and understand visual input is no small feat. Since there has been significant progress in machine vision, there are more ways computers and machine vision are being used in medicine for diagnostics, viewing scans and medical images, surgery, and more. Machine vision is helping doctors definitively know how much blood a woman loses in childbirth so that appropriate care can be given to reduce the mortality of mothers from post-partum hemorrhaging. Computers provide accurate intel, while previously this was a guessing game. The applications where computers are being used to view CT scans to detect neurological and cardiovascular illnesses and spot tumors in X-ray images are growing rapidly.

Wearable Tech

Wearable fitness technology can do much more than tell you how many steps you walk each day. With more than 80% of people willing to wear wearable tech, there are tremendous opportunities to use these devices for healthcare. Today's smartwatches can not only track your steps but can monitor your heart rhythms. Other forms of wearable devices are ECG monitors that can detect atrial fibrillation and send reports to your doctor, blood pressure monitors, self-adhesive biosensor patches that track your temperature, heart rate, and more. Wearable tech will help consumers proactively get health support if there are anomalies in their trackers.

Genomics

Artificial intelligence and machine learning help advance genomic medicinewhen a person's genomic info is used to determine personalized treatment plans and clinical care. In pharmacology, oncology, infectious diseases, and more, genomic medicine is making an impact. Computers make the analysis of genes and gene mutations that cause medical conditions much quicker. This helps the medical community better understand how diseases occur, but also how to treat the condition or even eradicate it. There are many research projects in place covering such medical conditions as organ transplant rejection, cystic fibrosis, and cancers to determine how best to treat these conditions through personalized medicine.

3D Printing

Just as it's done for other industries, 3D printing enabled prototyping, customization, research, and manufacturing for healthcare. Surgeons can replicate patient-specific organs with 3D printing to help prepare for procedures, and many medical devices and surgical tools can be 3D printed. 3D printing makes it easier to cost-effectively develop comfortable prosthetic limbs for patients and print tissues and organs for transplant. Also, 3D printing is used in dentistry and orthodontics.

Extended Reality (Virtual, Augmented and Mixed Reality)

Extended reality is not just for entertainment; its being used for important purposes in healthcare. The VR/AR healthcare market should reach $5.1 billion by 2025. Not only is this technology extremely beneficial for training and surgery simulation, but it's also playing an important part in patient care and treatment. Virtual reality has helped patients with visual impairment, depression, cancer, and autism. Augmented reality helps provide another layer of support for healthcare practitioners and aided physicians during brain surgery and reconnecting blood vessels. In mixed reality, the virtual and real worlds are intertwined, so it provides important education capabilities for medical professionals as well as to help patients understand their conditions or treatment plans.

Digital Twins

A digital twin is a near real-time replica of something in the physical worldin healthcare, that replica is the life-long data record of an individual. Digital twins can assist a doctor in determining the possibilities for a successful outcome of a procedure, help make therapy decisions, and manage chronic diseases. Ultimately, digital twins can help improve patient experience through effective, patient-centric care. The use of digital twins in healthcare is still in its early stages, but its potential is extraordinary.

5G

As the capabilities for healthcare centers to provide care in remote or under-served areas through telemedicine increase, the quality and speed of the network are imperative for positive outcomes. 5G can better support healthcare organizations by enabling the transmission of large imaging files so specialists can review and advise on care; allow for the use of AI and Internet of Things technology; enhance a doctor's ability to deliver treatments through AR, VR and mixed reality; and allow for remote and reliable monitoring of patients.

These technologies offer incredible opportunities to provide better healthcare to billions of people and make help our healthcare systems cope with the ever-increasing demands.

Originally posted here:
The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020 - Forbes

Photo courtesy of Bacan Family

Brynlee Bacan, five, was diagnosed with Rett Syndrome when she was 18 months old.

Posted: Friday, November 1, 2019 10:59 am

Community awareness and a local familys strength By Kelly Riibe Leadercourier-times.com

Nicole Bacan, of McCook Lake, is seeing purple this month and not just because her three daughters attend Dakota Valley. October is Rett Syndrome Awareness Month and it is recognized by wearing the schools popular purple color. Raising awareness means a lot to Bacan and her husband, Brett, because their youngest daughter, Brynlee, was diagnosed with Rett Syndrome in 2016.

Its considered a neurodevelopmental disease or disorder, and it is a mutation of a gene, Bacan detailed. Its the MECP2 gene on the X chromosome. And that apparently makes a protein, and its in the brain, and it goes to all the systems, which is why all the systems are affected.

Rett Syndrome is rare and usually found in girls. Babies with Rett typically do not show signs of concern until they are six-12 months, or older, and begin to miss or lose ground with developmental milestones.

We didnt notice anything until she was almost one and not crawling yet, Bacan recalled. So we knew that there was something physically that we were missing. We talked to our doctor. We got set up with early intervention services with physical therapy coming into the home. And then the physical therapist actually was the one who had noticed that she [Brynlee] had a little bit of a head tremor when she would stand her up... and thats indicative of neurological stuff.

See full story in this weeks Dakota Dunes / North Sioux City Times.

Posted in News on Friday, November 1, 2019 10:59 am.

See more here:
Community awareness and a local family's strength - Leadercourier-times.com

This page requires Javascript.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm(96? {6G: %9@6?6 H2D ;FDE A2DE D:I >@?E9D @=5[ 9:D A2C6?ED H6C6 E@=5 96 925 2 C2C6 86?6E:4 4@?5:E:@? E92E >62?E 96 AC@323=J H@F=5?E C6249 9:D D64@?5 3:CE952J]k^Am

kAmr2==65 DA:?2= >FD4F=2C 2EC@A9J[ :E >62?E 9:D 3@5J 4@F=5?E AC@5F46 6?@F89 @7 2 AC@E6:? E92E 46CE2:? ?6CG6 46==D 😕 9:D DA:?2= 4@C5 ?665 E@ DFCG:G6] %96 4@?5:E:@? =625D E@ H62<6?65 >FD4=6D[ :?4=F5:?8 E9@D6 ?66565 7@C G:E2= 7F?4E:@?D =:<6 3C62E9:?8 2?5 DH2==@H:?8]k^Am

kAm~? %F6D52J[ {6G: EFC?65 a] p?5 😕 567:2?46 @7 9:D 62C=:6C AC@8?@D:D[ 9:D A2C6?ED 2C6 D66:?8 D:8?D E92E 96D >2<:?8 82:?D]k^Am

kAmw6 42? ?@H D:E FA 7@C `d >:?FE6D @C >@C6[ D2:5 >@> |@C82? %9@6?6 WAC@?@F?465 %2J?66X @7 #2=DE@?] w6D >@G:?8 9:D 2C>D 2?5 92?5D >@C6[ 2?5 96 42? 5@ >@C6 E@ D:8?2= 9:D H2?ED 2?5 ?665D] w:D 4@F89 😀 DEC@?86C[ 2?5 96D DE2CE:?8 E@ D2J H@C5D[ :?4=F5:?8 ?@[ E96 DE2A=6 @7 E@55=6C G@423F=2CJ]k^Am

Brandon Thoene, left, and Morgan, right, sit with their son Levi sit up during a visit to his doctor at Children's Hospital on Friday, October 18, 2019. Levi, who has spinal muscular atrophy, a month ago received a new gene therapy called Zolgensma and has been recently able to sit up on his own for the first time.

kAmp?JE9:?8 96 5@6D 😀 2 DFCAC:D6[ 2?5 2 3=6DD:?8[ E92E 96D 5@:?8 :E 2D H6== 2D 96 :D[ D2:5 qC2?5@? %9@6?6[ 9:D 525]k^Am

kAmp >@?E9 28@[ {6G: 3642>6 E96 7:CDE 49:=5 😕 }63C2D<2 E@ C646:G6 2 ?6H 86?6 E96C2AJ 7@C DA:?2= >FD4F=2C 2EC@A9J 42==65 +@=86?D>2]k^Am

kAmpAAC@G65 3J E96 u@@5 2?5 sCF8 p5>:?:DEC2E:@? 😕 |2J[ :E >256 9625=:?6D 2D @?6 @7 E96 7:CDE 86?6 E96C2A:6D H:E9 E96 A@E6?E:2= E@ DE@A E96 AC@8C6DD:@? @7 A@DD:3=J 4FC6 kDEC@?8mk^DEC@?8m2 86?6E:4 4@?5:E:@?]%96 @?6E:>6 EC62E>6?E 2=D@ 4@>6D H:E9 2 AC:46 E28 @7 Sa]` >:==:@?]k^Am

Get the latest health headlines and inspiring stories straight to your inbox.

kAmp3@FE ` 😕 ``[___ 323:6D 2C6 3@C? H:E9 $|p[ 244@C5:?8 E@ rFC6 $|p[ 2? 25G@424J 8C@FA] %96C6 2C6 7@FC >2:? EJA6D[ H:E9 %JA6 `[ E96 G6CD:@? {6G: 92D[ 36:?8 E96 >@DE D6C:@FD @7 E9@D6 2?5 E96 >@DE 4@>>@?]k^Am

kAmq67@C6 DE2CE:?8 E96 ?6H EC62E>6?E[ {6G: 925 366? 86EE:?8 2 5:776C6?E E96C2AJ 42==65 $A:?C2K2[ E96 7:CDE 5CF8 2G2:=23=6 E@ EC62E E96 4@?5:E:@?]k^Am

kAm(9:=6 $A:?C2K2 8:G6D 2 56764E:G6 86?6 😕 $|p A2E:6?ED 2? 2DD:DE[ +@=86?D>2 C6A=246D :E[ D2:5 sC] v66E2?;2=: #2E9@C6[ ?6FC@=@8J 5:G:D:@? 49:67 2?5 5:C64E@C @7 E96 ?6FC@>FD4F=2C 4=:?:4 2E r9:=5C6?D w@DA:E2= U2>Aj |65:42= r6?E6C 😕 ~>292]k^Am

kAm}@ DEF5:6D 92G6 J6E 366? 5@?6 E@ 4@>A2C6 E96 EH@ 5CF8D] (9:=6 A=6?EJ @7 BF6DE:@?D C6>2:? F?2?DH6C65[ :?4=F5:?8 23@FE E96 E96C2A:6DV =@?8E6C> A6C7@C>2?46[ 3@E9 2C6 AC6G6?E:?8 AC@8C6DD:@? @7 E96 5:D62D6 2?5 C6DF=E:?8 😕 :>AC@G6>6?ED[ #2E9@C6 D2:5]k^Am

Dr. Geetanjali Rathore examines Levi Thoene just before his second birthday at Children's Hospital on Friday, October 18, 2019. Thoene has spinal muscular atrophy and recently received a new gene therapy called Zolgensma.

kAmpD 2 C6DF=E[ 5@4E@CD 7@C E96 7:CDE E:>6 92G6 EC62E>6?ED E@ @776C A2E:6?ED 2?5 E96:C 72>:=:6D[ 36J@?5 7665:?8 EF36D[ G6?E:=2E@CD 2?5 @E96C DFAA@CE:G6 42C6]k^Am

kAmx E9:?< E92ED 9F86[ E92ED 9F86 7@C FD 2?5 E96 $|p A@AF=2E:@?[ D2:5 #2E9@C6[ H9@ H6== C6>6>36CD 96C 7:CDE $|p A2E:6?E] p 362FE:7F=[ e>@?E9@=5 8:C= 2?5 96C A2C6?ED 7:CDE 49:=5[ D96 H2D E@@ @=5 7@C E96 62C=J $A:?C2K2 EC:2=D 2G2:=23=6 2E E96 E:>6] $96 5:5?E DFCG:G6 96C 7:CDE J62C]k^Am

kAm{2DE H66<[ #2E9@C6 D2H {6G: 7@C 9:D @?6>@?E9 7@==@HFA D:?46 DE2CE:?8 E96 86?6 E96C2AJ] w6D 2=D@ 86EE:?8 H66<=J =23 E6DED E@ 4964< 7@C 2?J D:56 67764ED 2?5 >2<6 DFC6 E96 EC62E>6?E :D?E 27764E:?8 9:D =:G6C @C 962CE]k^Am

kAm(9:=6 :ED DE:== 62C=J 52JD[ #2E9@C6 D2:5 D96D G6CJ A=62D65 H:E9 E96 AC@8C6DD {6G: 😀 >2<:?8] w6D 925 ?@ D:56 67764ED 2?5 9:D =23 E6DED 2C6 DE23=6]k^Am

kAmx 2> 9@A:?8 E@ 4@?E:?F6 E@ D66 >F49 >@C6 :>AC@G6>6?E[ D96 D2:5] s@4E@CD EJA:42==J D66 >@C6 >62DFC23=6 >@E@C >:=6DE@?6D DE2CE:?8 2E E9C66 >@?E9D 27E6C EC62E>6?E] pE D:I >@?E9D[ E96JV== 5@ 2 7@C>2= 2DD6DD>6?E @7 >@E@C 7F?4E:@?]k^Am

Brandon Thoene, left, fist-bumps his son Levi during a visit to his doctor at Children's Hospital on Friday, October 18, 2019. Levi, who has spinal muscular atrophy, a month ago received a new gene therapy called Zolgensma and has been recently able to sit up on his own for the first time.

kAm|62?E:>6[ E96 2G2:=23:=:EJ @7 EC62E>6?ED 😀 4C62E:?8 ?6H FC86?4J E@ 368:? EC62E>6?E 7@C $|p 2D D@@? 2D A@DD:3=6[ 367@C6 E96 =24< @7 E96 ?66565 AC@E6:? =625D E@ A6C>2?6?E =@DD @7 ?6FC@?D 2?5 7F?4E:@?]k^Am

kAm&?AF3=:D965 52E2 AC6D6?E65 2E >65:42= 4@?76C6?46D :?5:42E6D E92E G6CJ J@F?8 49:=5C6? EC62E65 367@C6 E96J 56G6=@A DJ>AE@>D 2== 2C6 5@:?8 6IEC6>6=J H6==[ 56G6=@A:?8 2=>@DE ?@C>2==J[ #2E9@C6 D2:5]k^Am

kAm%92E 42==D 7@C 62C=:6C 5:28?@D:D] u656C2= 962=E9 @77:4:2=D 25565 $|p E@ E96:C =:DE @7 C64@>>6?565 D4C66?:?8D 7@C ?6H3@C?D 😕 a_`g]k^Am

kAm%96 }63C2D<2 }6H3@C? $4C66?:?8 p5G:D@CJ r@>>:EE66 G@E65 😕 |2C49 E@ C64@>>6?5 255:?8 $|p E@ E96 DE2E6D ?6H3@C? D4C66?:?8 A2?6=[ E96 E6DED 2== 323:6D 2C6 8:G6? 2E 3:CE9] $E2E6 962=E9 @77:4:2=D 2?E:4:A2E6 E92E =68:D=2E:@? E@ C6BF:C6 E96 D4C66?:?8 H:== 36 :?EC@5F465 😕 y2?F2CJ]%6? DE2E6D[ :?4=F5:?8 |:DD@FC: 2?5 |:??6D@E2[ 2=C625J 92G6 :>A=6>6?E65 E96 E6DE:?8[k2 9C67lQ9EEADi^^HHH]4FC6D>2]@C8^?6H3@C?D4C66?:?87@CD>2^Q E2C86ElQ03=2?A=6E:@? @7 2 A:=@E AC@;64E 6IA64E65 E@ DE2CE ?6IE DF>>6C]k^Am

kAm#2E9@C6[ H9@ DA@<6 :? 72G@C @7 255:?8 E96 E6DE[ D2:5 E96 $|p D4C66?:?8 42? 36 A6C7@C>65 FD:?8 E96 D2>6 966=AC:4< 3=@@5 D2>A=6 ?@H 4@==64E65 7C@> ?6H3@C?D 367@C6 E96J =62G6 E96 9@DA:E2=]k^Am

kAm%96 E6DED[ H9:49 ?@H 4964< 7@C >@C6 E92? b_ 4@?5:E:@?D[ =@@< 7@C 4@?5:E:@?D E92E H@F=5 ?@E 36 2AA2C6?E ;FDE 3J =@@<:?8 2E 2 323J 2?5 E92E 42? 36 EC62E65 67764E:G6=J :7 :56?E:7:65 62C=J] %96JC6 4C65:E65 H:E9 D2G:?8 323:6D =:G6D 6249 J62C 2?5 AC6G6?E:?8 ?6FC@=@8:42= 2?5 @E96C 56G6=@A>6?E2= 56=2JD]k^Am

kAm|@C82? %9@6?6 D2:5 E96 72>:=J A=2?D E@ AFD9 E96 }63C2D<2 {68:D=2EFC6 E@ 255 $|p E@ E96 A2?6=] $96 HC:E6D 23@FE {6G:D ;@FC?6J @? E96 u2463@@< 8C@FA[ {:76 @7 {6G:]k^Am

Morgan Thoene, left, comforts her son Levi during a visit to his doctor at Children's Hospital on Friday, October 18, 2019. Levi, who has spinal muscular atrophy, a month ago received a new gene therapy called Zolgensma and has been recently able to sit up on his own for the first time.

kAm$E2CE:?8 E96C2AJ 367@C6 DJ>AE@>D 56G6=@A[ D96 D2:5[ 4@F=5 9625 E96> @77] (96? {6G: H2D 5:28?@D65 😕 pAC:= a_`g[ E96 %9@6?6D[ 3@E9 E62496CD 2E 2C62 D49@@=D[

kAm{6G: 3682? C646:G:?8 $A:?C2K2[ H9:49 E96 usp 2AAC@G65 😕 a_`e[ D9@CE=J 27E6C 96 H2D 5:28?@D65] %96 5CF8 >FDE 36 :?;64E65 :?E@ E96 7=F:5 DFCC@F?5:?8 E96 DA:?6 6G6CJ 7@FC >@?E9D :?567:?:E6=J] %96 4@DE 😀 6DE:>2E65 2E Sfd_[___ 7@C E96 7:CDE J62C 2?5 2E Sbfd[___ 2 J62C E96C627E6C] r9:=5C6?VD D@ 72C 92D EC62E65 `g A2E:6?ED H:E9 E92E 5CF8]k^Am

kAmp7E6C +@=86?D>2 H2D 2AAC@G65 3J E96 usp[ DE277 2E r9:=5C6?VD DE277 H@C<65 92C5 E@ 86E :E ~zV5 :?E6C?2==J 7@C FD6 2E E96 9@DA:E2=[ #2E9@C6 D2:5] xEVD 7656C2==J 2AAC@G65 7@C 49:=5C6? F?56C 286 a] {6G:[ H9@ DE2CE65 :E $6AE] a_[ >256 :E ;FDE F?56C E96 H:C6]k^Am

kAmQ$A:?C2K2 H2D 8C62E 3642FD6 :E 2==@H65 9:> E@ 86E 2 =@E @7 82:?D[Q |@C82? %9@6?6 D2:5] QqFE E9:D 92D AC@5F465 6G6? >@C6]Qk^Am

kAm%96 86?6 E96C2AJ[ 8:G6? :?EC2G6?@FD=J[ 😀 56=:G6C65 3J 2 G:CFD E92E 92D 925 :ED 86?6E:4 >2E6C:2= C6>@G65] xEVD C6A=2465 H:E9 E96 86?6 E92E 4@56D 7@C E96 =24<:?8 AC@E6:?] qFE C2E96C E92? :?E68C2E:?8 H:E9 E96 A2E:6?EVD s}p[ :E D:ED @? E96 D:56 2?5 8@6D E@ H@C< E@ :?4C62D6 AC@5F4E:@? @7 E96 AC@E6:?]k^Am

kAmx? {6G:VD 42D6[ E96 4@DED H6C6 D92C65 3J q=F6 rC@DD q=F6 $9:6=5 @7 }63C2D<2 2?5 |65:42:5]k^Am

kAm|F=E:A=6 DEF5:6D[ D96 D2:5[ 7@F?5 E92E E96 4@DE @7 42C:?8 7@C A2E:6?ED H:E9 $|p %JA6 ` E9:?< G6?E:=2E@CD[ H966=492:CD[ 9@DA:E2=:K2E:@?D D:8?:7:42?E=J @FEA2465 E96 2??F2= 4@DE @7 $A:?C2K2] %9@D6 DEF5:6D 92G6?VE J6E 366? 5@?6 J6E 7@C +@=86?D>2[ 3FE E96 E96C2AJ 😀 6IA64E65 E@ 36 4@DE 67764E:G6 😕 E96 =@?8 E6C>[ A2CE:4F=2C=J :7 :E AC@G6D E@ 36 2 @?6E:>6 E96C2AJ]k^Am

kAmt77@CED 2C6 F?56C H2J E@ 6IA2?53@E9 EC62E>6?ED E@ >@C6 <:5D] r9:=5C6?VD :D @? E96 =:DE E@ 364@>6 2 46?E6C 7@C EC:2=D @7 +@=86?D>2 😕 49:=5C6? @=56C E92? a H9@ 92G6 =6DD D6G6C6 7@C>D @7 E96 5:D62D6]k^Am

kAm%96 9@DA:E2= 2=D@ 92D 368F? 2 DEF5J E@ 82F86 :>AC@G6>6?ED 😕 BF2=:EJ @7 =:76 😕 DF49 A2E:6?ED] %92E H:== 7@4FD @? >@C6 DF3E=6 3FE DE:== :>A@CE2?E 492?86D DF49 2D H96E96C A2E:6?ED 42? 62E 3J E96>D6=G6D 2?5 9@H >F49 96=A E96J ?665 E@ >@G6] xEVD ?6H E6CC:E@CJ[ #2E9@C6 D2:5[ 3642FD6 E96 7@4FD H:E9 $|p A2E:6?EDkDEC@?8mk^DEC@?8m92D 7@C D@ =@?8 366? @? DFCG:G2=]k^Am

kAm%96 %9@6?6D 46=63C2E65 {6G:VD 3:8 >:=6DE@?6 2E 9@>6[ ;FDE E96 7@FC @7 E96>] %96J A=2??65 E@>2C< E96 @442D:@? H:E9 6IE6?565 72>:=J 2?5 7C:6?5D $F?52J H:E9 2 82E96C:?8 2E 2? 2C62 A:KK6C:2]k^Am

kAmu@C ?@H[ E96JVC6 46=63C2E:?8 E96 AC@8C6DD 96VD >256]kDEC@?8mk^DEC@?8m$2:5 |@C82? %9@6?6[ Qw6VD 5@:?8 72?E2DE:4]Qk^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmkDA2?m|2EE96H t=6586 2?5 9FD32?5 t==:@E s@F896CEJA=2? E@ 6IA=2:? 96C k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^J62C@=58C6E?2H@>2?8:G6D3:CE9E@8C2?549:=5G:2:G7^2CE:4=607_ehba4g7b76de67hgg7e46``5gdbbd3]9E>=Q E2C86ElQ03=2?D D96 42? F?56CDE2?5i E92E 96C 8C2?5>@E96C 7FC?:D965 E96 82C56? H96C6 D96 8C6H[ 2?5 E92E 96C 2F?E[ {62 *C:36[ 86?6C@FD=J DFAA=:65 E96 D665D]k^DA2?mk^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm~?6 A@E9@=6 5:5 2 A2DD6?86C 2 72G@C H96? E96 2>3F=2?46 96 H2D 😕 DECF4< :E[ 244@C5:?8 E@ 7:CDE C6DA@?56CD] vC6E?2 7:C67:89E6CD H6C6 E2<:?8 2 >2? DF776C:?8 496DE A2:? 2?5 2 9:89 962CE C2E6 E@ E96 9@DA:E2=] (9:=6 6? C@FE6 E@ {2<6D:56 w@DA:E2=[ E96 2>3F=2?46 9:E 2 A@E9@=6] %96 ;@=E C6EFC?65 E96 A2E:6?ED k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^A@E9@=6;@=ED>2?D962CEC2E63242=@?^2CE:4=6046`ef272fa5fd444g72a7hdfg4cbh`b6]9E>=Q E2C86ElQ03=2?2=k^2m]k^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm%9@F89E E@ 36 3C2:? 5625[ 5@4E@CD E@@< 7@C>6C rC6:89E@? q=F6;2JD A=2J3JA=2J 2??@F?46C %] $4@EE |2CC @77 =:76 DFAA@CE] q67@C6 9:D 72>:=J D6EE=65 @? 2 7F?6C2= 9@>6[ E96J 564:565 E@ D66 E96:C 525 @?6 >@C6 E:>6] (96? E96J 8@E E96C6[ k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^5@4E@CDE@@<7@C>6C4C6:89E@?2??@F?46C@77=:76DFAA@CE2?52^2CE:4=6065d5a_bc33f4dh35g2ea3_fh675f`df`]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmkDA2?mz2C=2 !6C6K H2D aa H66:=J 2?5 5@4E@CD <6AE 96C @? =:76 DFAA@CE]k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^52JD27E6C?63C2D<2H@>2?H2D564=2C653C2:?562596CD@?^2CE:4=602a3c_efahfd6d7echafabbbafac3ghfe]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAms2C?:D92 {255 ?6G6C :>28:?65 $?2A492E H@F=5 96=A D2G6 96C =:76 27E6C D96 DF776C65 2 DEC@<6] qFE ?665:?8 2 AC64:D6 E:>6=:?6 @7 6G6?ED[ 5@4E@CD 2?5 72>:=J C6=:65 @? 2 A@DE @? E96 A9@?6 2AA 2?5 H6C6 k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^E92?292H@>2?86ED=:76D2G:?8DEC@<6>65:4:?6H:E9^2CE:4=60d7eec2chg2c_dacbh72_22cgf`egd4b`]9E>=Q E2C86ElQ03=2?65:42E:@? 😕 E:>6k^2m]k^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm{:?5D6J 2?5 s6C6< %6E6?VD EC:A=6ED 2C6 @?6 :? 2 >:==:@?] {:E6C2==J] %96 }63C2D<2 r:EJ 4@FA=6VD E9C66 52F89E6CD[ 3@C? :? =2E6 yF?6 a_`f[ 2C6 :56?E:42= 2?5 H6C6 4@?46:G65 H:E9@FE 76CE:=:EJ EC62E>6?ED] %96 8:C=D H6C6 E96 k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^:E;FDE3=6H@FC>:?5D:56?E:42=EC:A=6ED3@C?E@?63C2D<2^2CE:4=60e_6hcgh_e6ea``6fhaf5b747`434fb37]9E>=Q E2C86ElQ03=2?6?VD w@DA:E2=] %96 7:CDE D6E[ 2=D@ 8:C=D[ k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^F?492CE65E6CC:E@CJ:56?E:42=EC:A=6EDH6C627:CDE7@C5@4E@CD2?5^2CE:4=60g2ec4`6g`h37da5a3cb26_cch`g4fch7]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm(92E >2<6D y2>6J s@F82==VD 962=E9 DE@CJ F?FDF2= 😀 9:D EC62E>6?E A=2?] s@F82==[ H9@VD =682==J 3=:?5[ FD6D 2 DA64:2= A2:C @7 8=2DD6D E@ D66] w6VD D66? 9:D H:76 z2?5:46[ 9:D EH@ 52F89E6CD[ 2?5 ?@H[ k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^?63C2D<2?2E:G6H9@D=682==J3=:?5D66D9FD<6CDA=2J7@C^2CE:4=60hb4d6`gb`c_adafch3d4g7a`gb37b6c7]9E>=Q E2C86ElQ03=2? E96 wFD<6CDk^2m]k^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAms@4E@CD 5:28?@D65 E96 A2C2=JD:D E92E H2D 4C66A:?8 FA yFDE:? r96?:6CVD =68D 2D vF:==2:?q2CC6 DJ?5C@>6] xE H@F=5 364@>6 D@ D6C:@FD E92E E96 ~>292 >2? H@F=5 ?62C=J =@D6 4@?D4:@FD?6DD H9:=6 D4C62>:?8 3642FD6 @7 E96 A2:?] %96 DJ?5C@>6 H2D k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^7:CDEEC@F3=6H2=<:?8E96?A2C2=JD:DE96?9@CC:7:4A2:?2?@>292?^2CE:4=60agh`74e_64ffdeb335fh__5fb3g`h`34]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmz6?K6 |6DD>2?VD 366? 5:28?@D65 H:E9 D6G6C2= 49C@?:4 :==?6DD6D] $@>6E:>6D 96C 962CE C2E6 4=:>3D[ D6:KFC6D D6?5 96C E@ E96 7=@@C 2?5 >:8C2:?6D =62G6 96C 😕 E96 52C<] p?5 @?6 @7 E96 2:=>6?ED 42FD6D E96 `fJ62C@=5 E@ 92G6 k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^:?DA:C2E:@?^=:?4@=?E66?:D2==6C8:4E@2=>@DE6G6CJE9:?8:?4=F5:?8DF?=:89E49@4@=2E6^2CE:4=607e52646f6bb3d_5d275e_a6e_da7bcef]9E>=Q E2C86ElQ03=2?@DE 6G6CJE9:?8k^2m]k^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm%96 D<:? @? $92C2? qCJD@?VD =68 H2D 3=24< 7C@> =24< @7 4:C4F=2E:@?] $96 76=E ?@E9:?8 3FE 2 D92CA[ DE233:?8 A2:?] %96 =68 H2D 5625[ 2?5 96C 36DE @AE:@? H2D 2>AFE2E:@?] qCJD@? 3@F?465 324< 2?5 k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^D96=@DE2=68E@6D2?52966=?@HD96^2CE:4=60h5g67de_g_26d_6d24e3_`2gah_h2245]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmr92D6 %:6>2?? 92D 925 ?F>6C@FD DFC86C:6D 😕 9:D J@F?8 =:76[ :?4=F5:?8 E96 2>AFE2E:@? @7 9:D =67E 2C>] %96 ~>292 3@J 92D 2 4@?5:E:@? E92E 42FD6D EF>@CD D@>6E:>6D 36?:8?[ D@>6E:>6D 42?46C@FD E@ 7@C> @? 9:D 3@5J] %@ 3@@DE 9:D DA:C:ED 27E6C 2>AFE2E:@?[ E96 !2A:==:@? u:C6 s6A2CE>6?E k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^J62C@=5H:E92>AFE2E652C>?2>659@?@C2CJA2A:==:@?7:C67:89E6C^2CE:4=60bae6673dh456d3f4g6d5377b4ae`f2d5]9E>=Q E2C86ElQ03=2?65 r92D6 2? 9@?@C2CJ 7:C67:89E6Ck^2m]k^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm(6D=6J (@@5D 32EE=65 962CE 5:D62D6 7@C a_ J62CD] w6V5 C24<65 FA ?:?6 962CE 2EE24F=E:A=6 DFC86C:6D 2?5 @?6 962CE EC2?DA=2?E] w6 H2D E:C65 @7 9@DA:E2=D] %:C65 @7 496DE A2:?] %:C65 @7 766=:?8 E:C65] (@@5D H2D =F4292]4@>^=:G6H6==?63C2D<2^H:E92?@E96C?6H962CE:@H2>2?86ED2D64@?5D64@?5^2CE:4=60h7776257eb2gd52ag_b6gb5`ga5cf5gb]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm&C>: q2DF H2D D6E E@ H2=< 24C@DD E96 DE286 E@ C646:G6 96C 5@4E@C2E6] qFE 7:G6 52JD 367@C6 E96 46C6>@?J[ E96 E96?b_J62C@=5 DF776C65 2 >2;@C DEC@<6] xE =67E 96C A2C2=JK65 @? 96C C:89E D:56 2?5 DECF88=:?8 E@ DA62<] p7E6C E9C66 J62CD @7 :?E6?D6 C6923[ k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^:?DA:C2E:@?^F?>4DEF56?EDF776C652>2;@CDEC@<62EE9C66J62CD=2E6C^2CE:4=604e`55ga_a_25d2c63eabgg_`gf6ag224]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmp>36C zF5C?2 H2D?VE DFC6 D96V5 36 23=6 E@ 92G6 2 49:=5 @7 96C @H?] p7E6C EH@ <:5?6J EC2?DA=2?ED[ 5@4E@CD 82G6 E96 ~>292 H@>2? 2 =2F?5CJ =:DE @7 A@E6?E:2= AC68?2?4J 4@>A=:42E:@?D] zF5C?2 2?5 9FD32?5 p52> H6:8965 E96:C @AE:@?D 2?5[ 😕 $6AE6>36C a_`g[ k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^:ED2ECF64:C4=6@7=:7627E6CEC2?DA=2?ED<:5?6J^2CE:4=60bfh5dh`cc446df5bhb5f362dg552gg__]9E>=Q E2C86ElQ03=2?65 2 323J 3@Jk^2m]k^Am

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm$F6 '6?E6:496C DE2CE65 H92E H@F=5 36 E96 =2C86DE D:?8=69@DA:E2= =:G:?85@?@C <:5?6J EC2?DA=2?E 492:? :? }63C2D<2 9:DE@CJ] }:?6 =:G:?8 5@?@CD k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^962=E9^27E6CEC2?DA=2?E492:?5@?@CD>66EE9@D6H9@D6=:G6DE96JD2G65^2CE:4=60_3cc6`c`2372d2a3h7eab``b7dhfb7d4]9E>=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmy@6 }@=2? 4@F=5?VE E2<6 9:D D@? y2>6DV A2:? 2H2J] qFE 96 4@F=5 7:?5 2 H2J E@ D92C6 :E] }@=2? 8@E 2 E2EE@@ E92E 2C4965 24C@DD 9:D 9625[ ;FDE =:<6 9:D D@?VD D42C] y2>6D H2D 3@C? H:E9 2 92?57F= @7 2:=>6?ED[ :?4=F5:?8 @?6 E92E C68F=2C=J k2 9C67lQ9EEADi^^HHH]@>292]4@>^=:G6H6==?63C2D<2^5@4E@CD92G6E@C6D92A69:DD@?DD=Q E2C86ElQ03=2?

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAmsC] y6??:76C w2C?6JkDA2?mFD65 E@ 62E A:KK2 D2?D >62E @C 4966D6] $96 4@F=5?VE 255 >:=< E@ 96C 4@7766] $96 925 E@ 49@<6 5@H? 2 D92<6=:<6 7@C>F=2 E@ DFAA=6>6?E 96C 5:6E] $96 H2D 5:28?@D65 H:E9 2 C2C6[ 86?6E:4 4@?5:E:@? 27E6C 3:CE9] qFE E92?292]4@>^=:G6H6==?63C2D<2^962=E9^C2C65:D62D6>62?E62E:?8D92<6DE92EE2DE65=:<642E7@@5^2CE:4=60bheae`hbb6`3de53hgbeaf77hg3a5f7_]9E>=Q E2C86ElQ03=2?

Follow this link:
Boy, 2, first in Nebraska to receive $2.1 million therapy for rare disorder. 'He's doing fantastic' - Omaha World-Herald

Scroll To See More Images

I never imagined every woman in my family would get breast cancer. It started in 1998 when my aunt was diagnosed at 58-years-old. In 2010, my mom was diagnosed at 65. Two years later, my cousin (my aunts daughter) was diagnosed at 42 with Stage 1 Triple Negative breast cancer, the most aggressive and fastest-growing type. Had it been discovered just a year later, it would have grown to Stage 4. I joined the club in 2014, just two weeks shy of my 35th birthday. All four of us tested negative for the BRCA gene mutation.

In the simplest terms, thats code for the BReast CAncer gene and is split into two categories: BRCA1 and BRCA2. Though we all have BRCA genes, they are believed to increase a persons chances of developing the disease when mutated. Dr. Sunil Hingorani, a family friend and pancreatic cancer specialist, once told me It doesnt mean there isnt a gene link, it just means they havent found the gene yet. Eek. Then I thought, Oh, maybe theyll name it after us. Cool. Wait. Nope, not cool.

After being told we werent BRCA gene mutation carriers, I morphed into a boob spy named Erin Boobivich to investigate exactly what the culprit was. My cousin believes it has something to do with the water in Connecticut. Not only had each of us lived there for at least 30 years prior to our diagnosis (Boobivich knows her number-crunching); its also home to some of the countrys highest breast cancer rates. My brother thinks the microwave we grew up using is to blame. My mom thinks my aunt got it from eating too much barbecue. Im convinced it has something to do with potato chips. (What?! Theyre a carcinogen! I read an article once and now I dont eat potato chips). Okay, thats the extent of my research, but it could be all or any of those things, plus a bag of genes.

Reasoning aside, whats really worth sharing goes beyond statistics. Ultimately, breast cancer completely changed our lives collectively and individually. And while its important to share the commonalities weaved throughout, our individual experiences carry lessons that should be amplified, too.

My aunt, who left India for America in the 70s, was diagnosed with HER2 neu positive, a very aggressive type of breast cancer. She had a lumpectomy (aka breast-conserving surgery that removes abnormal tissue) and more than 20 lymph nodes removed to determine if it had spread throughout her body. This was followed by debilitating chemotherapy that left her extremely ill for months. From the outside, you could never tell she was in pain because her sense of humor made cancer seem fun. She was always upbeat and cracking super inappropriate jokes, like the one where she called me in 2003 and joked her cancer was back, then cackled loudly and said she was kidding. Ha. Ha.

During chemo, she chose not to wear a wig, and instead wore headwraps and proudly flew bald. She just didnt seem to care. Her hair never really grew back. If you ask my aunt to take a picture with you today, she will refuse, claiming she hates pictures. The truth is cancer changes how you feel about your body. Her hair didnt grow back to its former glory, but thankfully, neither did her cancer. She just hit her 21 year clear MRI on October 8, 2019.

My moms cancer was hormone-based. She was told by a doctor that she would need a lumpectomy, radiation and chemotherapy. Our family friend Dr. Hingorani insisted she go to Dana Farber, a renowned cancer institute in Boston, for a second opinion. My mom balked at it, but my father and Hingorani insisted. Its a good thing she listened. The doctors there confirmed chemotherapy wouldnt be beneficial. At all. Had she gone through with it, she would have lost her hair and who knows what else. for No. Benefit. At. All. With that being said, get second opinions. Get thirds. Make sure you have all the info you need.

By the way, after her lumpectomy and radiation, Mom was put on Arimidex, a drug specifically for post-menopausal women to reduce the risk of cancer coming back. She just hit 9 years clear and was told on October 9, 2019 that she no longer needs to take it.

My cousin was diagnosed in November 2012 in early November and went through at least 5 biopsies well into 2013. Because her cancer was especially aggressive, a combo of lumpectomy, radiation, and chemotherapy was the only choice. At the time her children were 11, 9 and 7 years old, respectively.

At our Christmas dinner, a month before she began chemotherapy, I remember asking if I could get a picture of her, my aunt and the kids with my new camera. Priya responded, Sure, since itll be the last time I have hair like this. And she was right. Her hair has never returned to what it was that day.

She endured 8 rounds of chemo within 4 months and each infusion took 4 to 6 hours. We took turns accompanying her to Boston. Her husband, Douglas, did the first round. But when he tried to unplug the chemo machine to charge his Blackberry, lets just say he wasnt invited to return.

Priyas hair fell out, her nails turned blue, and her eyebrows disappeared. My cousin is a very strong and stoic individual to a fault. She never wanted to admit she was in pain or needed help. I understood. With three young children, she didnt want them to feel unsafe or think that their mother was dying. One morning she couldnt protect them from what was going on, and while they were having breakfast, she fainted in the pantry. Thankfully, Douglas wasnt charging his Blackberry, ran to the pantry, and moved the kids out of the kitchen so he could help her. He was scared. So were the kids.

She was told that chemotherapy would only improve her chance of no recurrence by 3-5%. It seems like nothing right? But with 3 kids, she said she would do whatever was necessary. Today, shes 7 years clear. But in addition to her hair thinning, chemo also affected her brainspecifically her attention span and memory. It took her two years to be able to get through a long book again. And like a lot of women, chemo threw her into early menopause at just 43.

My mother and I got the exact same type of cancer. Same boob. Same exact spot. Like mother, like daughter. The only difference was age; my diagnosis came much earlier in life (30 years before Mom, to be exact.) It sucked. I always thought Id have children of my own. Unfortunately, this diagnosis changed that.

Prior to getting the bad news, everyone in my family begged me to get screened; specifically, after my cousins diagnosis. I finally did a year later. I thought there was no way I could to get cancer at such a young age. Thats what we all thought.

But then they saw something on my right boob. After two mammograms, 1 ultrasound and a biopsy, I got an all-clear. Phew. Relief. No cancer. But then something strange happened. In my right underarm, I got a swelling that was extremely painful. So on Christmas day, my uncle drove me around to see if we could find an urgent care center. The doctor who had previously ordered my biopsy, asked for an MRI. It revealed everything was fine on the right breastand a tumor on the left. The latter was missed on two mammograms and an ultrasound.

My mom said when I called her on March 4, 2014 to break the news, it was one of the most shocking moments in her life. I remember bursting into tears and Im not a crier. That doctor told me, So listen, you can get a lumpectomy, radiation, maybe chemo. Or you can just get a mastectomy and not have to worry about any of that. Wow. (That was the most glossed-over statement that was ever said to me). My cousin called Dr. Alexandra Heerdt, her breast surgeon at Memorial Sloan Kettering Cancer Center, who later told me a mastectomy wasnt something shed recommend.

By the time my lumpectomy was done on April 9, 2014, I had been through 2 mammograms, 2 ultrasounds, and 3 biopsies. Two days after my surgery, I developed cording, despite only having 3 sentinel nodes removed. Its a traumatic reaction your body has when the muscles and nerves in that same area wrap around each other. It was one of the most painful experiences of my life and took 5 months of physical therapy to treat.

Radiation nukes everything. The doctors told me if I ever had kids, I wouldnt be able to breastfeed on my left side. It also charred my boob and literally turned it black. Thankfully, my cancer had not spread, so chemotherapy was eliminated. However, I had to go on a drug (like Mom) to inhibit the hormones that caused my cancer in the first place.

My doctor initially recommended shutting down my ovaries for 5 years. What the ever loving?! Yes, thats correct. He went over the side effects, which include but arent limited to hair loss, decreased libido, and joint pain. No thanks. So I talked to Dr. Rachel Freedman, my other doctor at Dana Farber (who also happens to be my cousins oncologist). She said the research wasnt there to confirm ovarian shutdown as the best option. Instead, she recommended I start with Tamoxifen and if a new study was done on ovarian shutdown, I could switch. A few weeks later, a new study became available and my main oncologists recommendation aligned with Dr. Freedmans.

He also said pregnancy is a hormone storm for your body. You cant for at least 5 years. That was probably the hardest thing to hear. I chose to not freeze my eggs, because quite frankly, getting rid of cancer and going through treatment was enough to deal with at the time. I worry that I will regret this decision.

This year, I hit 5 years clear. I will have to take Tamoxifen for a total of 10 years, or until Im 46. Ill probably enter menopause shortly before or after that. It sucks. Thankfully, Tamoxifen hasnt thrown me into early menopause; at least not yet. For this reason, I actually get excited for the period I used to curse each month. As long as Im still getting it, maybe theres still a chance I can have kids.

My cousin Priya has two daughters, Bella, age 16 and Emma, age 14. About 2 months ago, we were out to lunch with my Aunt Veena, their grandmother. The topic of breast cancer came up, and Emma, Bella and I made some jokes as our family is apt to do. My aunt looked horrified, and Emma lightly said, What Nani? We know were probably going to get it.

I hope they never join this club. And with research and progress over the next few years, maybe they wont. Today, all of us are diligently scanned and have annual MRIs and mammograms. I have blood tests every 3 months. And when we get clear tests, we text our family group chat to report the news because were all scared on some level. The fear that its going to come back never goes away. Sometimes, the further I get from it, the more I fear I experience.

So cancer does change things. A lot. But with a good boob squad friends, family, and doctors it will be ok. My friends saved me when I was going through all of this. In fact, this post-it my friend Marisa found on her desk from 2014 says it all. (Seriously, if you get cancer, you can get your friends to do stuff for you). And remember, every day they are discovering new genes and new treatments. So get your mamms, maams.

Visit link:
Every Woman in My Family Had Breast Cancer and None of Us Have the BRCA Gene - STYLECASTER

A majorityof cystic fibrosis patients who took part in an Instagram poll by BioNews Servicessaid they would be interested in moving from current treatments to Trikafta (elexacaftor,tezacaftor, andivacaftor), the newly approved and next-generation combinationtherapy by Vertex that is expected to treat 90% of all with CF.

Among those now using Symdeko (tezacaftor/ivacaftor, ivacaftor) orOrkambi (lumacaftor/ivacaftor),twoearlier Vertex treatments,93% of the 129 people who responded to this question said they would like to switch, largely because the benefits they felt from their current therapies were, at best, mixed.

My doctor told me that the new med blows Symdeko out of the water! said Christina Khoury of Pennsylvania, who was diagnosed at 3 weeks old.

Others, including Wendy Caroline of Wisconsin and Elizabeth Rogers of California, both diagnosed before age 2, simply noted that Orkambi and Symdeko hadnt work as hoped, and were a disappointment.

Drew Hanley of Florida, diagnosed at 13, was a bit more succinct: In medical lingo Symdeko and Orkambi were never considered highly effective. Trikafta is.

The informal, one-day poll,conducted Oct. 2223, asked seven questions largely to patients who follow Cystic Fibrosis News Today (a BioNews publication).

It also found thatmost were not surprised by the U.S. Food and Drug Administrations quick approval a little more thab two months since a request for approval was filed and given an accelerated review. Perhaps that is because of the positive results reported from clinical trials.

A slight majority, 54% of the 212 people who responded to this question, thought the FDAs speedy review was reasonable.

But a stronger majority 83% of 193 people responding were disappointed in Trikaftas expected $311,500 yearly list price in the U.S., equivalent to $23,896 for a 28-day supply, according to financial reports. That puts Trikaftas list price up with Kalydeco (ivacaftor), Vertexs most effective CF therapy to date, but a potentiator that treats only about 6% of all patients, as the most expensive of all of the companys CF medications.

Symdeko carries a yearly list price of about $292,000, and Orkambi of about $272,000. Financial analysts in the U.S. had speculated that Trikafta would enter the market at a list price similar to Symdeko. That it appears unlikely to do so has some patients worried.

FOR SURE, said respondent Bethany Schulberg of the United States, diagnosed at 18 months.The cost of this will make it difficult for people who have certain insurance access.

Insurance coverage and its quality could be key.

Caroline of Wisconsin, diagnosed at 6 weeks old, considered herself fortunate: Im lucky to have good insurance, so it shouldnt be an issue for me personally.

Keisha Hummel, also of the U.S., said shes a [h]ighly concerned adult with CF & married. Insurance is always a big issue for me. Always fighting.

Those from other countries expected a long wait, calling Trikaftas likely arrival at their home a dream. (Respondentswho could not be reached later to confirm use of their statements are not quoted.)

Trikafta, whose U.S. approval was based on two Phase 3 clinical trials in the AURORA program, is expected to be available soon for patients ages 12 and older with one F508del and one minimal function mutation in the CFTRgene, or with two F508del mutations, reflecting the patient groups evaluated in each trial NCT03525444for one F508del mutation, and NCT03525548for two.

An F508del defect in CFTR gene the most common CF mutation leads to faulty instructions being given for the creation of the CFTR protein. This protein regulates the production of mucus needed to lubricate organs, especially the lungs and digestive system, by controlling the transport of charged substances (chloride and sodium, especially) across cell membranes. Its failure results in a buildup of thick mucus that is difficult to clear and traps viruses and bacteria, promoting infections that weaken patients and damage their organs.

Previously approved Vertex therapies Kalydeco, Orkambi, and Symdeko were able to treat some people with one or two F508del mutations in CFTR, but not those with what are called minimal function or nonsense mutations. More than 1,700 mutations are known to exist in the CFTRgene, and nonsense mutations are those that prematurely stop the CFTR protein from forming.

Because this triple combination covers people with both the common F508del mutation and those with another minimal function mutation, it is expected to treat up to 90% of all CF.

Data fromboth AURORA studiesshowed significant gains in lung health in people on Trikafta, the primary goal of each trial, as assessed by the percent predicted forced expiratory volume in one second (ppFEV1, a widely used measure of lung function). ppFEV1 increased by an average of 13.8 percentage points in AURORA F/MF, which enrolled people with one F508del and one nonsense mutation,and by 10 percentage points in AURORA F/F, in which patients had two F508del mutations.

Trikafta-treated patients in AURORA F/MF also showed improvements in all secondary study goals, including a lower annual rate of pulmonary flares and diminishedsweat chloride levels.

Todays landmark approval is a testament to making a novel treatment available to most cystic fibrosis patients, including adolescents, who previously had no options, and giving others in the cystic fibrosis community access to an additional effective therapy, Ned Sharpless, MD, the FDAs acting commissioner, said in an agency releaseannouncing Trikaftas Oct. 21 approval.

The importance of this new option is evident: In this one-day poll on Instagram, where responses were limited by the nature of this social media platform, 47% of the 165 respondents a near majority said Trikafta would be a first CF treatment available to them.

Curiously, a follow-up question asking how they felt about having a first disease-modifying treatment was the only question to elicit no response.

Grace Frank worked as a copy editor, city editor, reporter and news designer for leading American newspapers, including The New York Times and The International Herald Tribune, for many years. She has won numerous journalism awards, and was nominated for a Pulitzer Prize for an investigative series into eye surgeries wrongly conducted outside a clinical trial.

View post:
CF Patients Voice Hopes and Expectations for Trikafta in Instagram Poll - Cystic Fibrosis News Today

Miriam didnt start out seeing herself as someone who could beat MCI. It didnt even feel like a possibility.

But early one day in September, she logged into a support group on Facebook to share the good news.

Heres exactly how she put it:

Miriams outcome, which took more than four years of hard work to achieve, isnt the most common for someone with mild cognitive impairment.

But it isnt the rarest either.

A recent study shows that over roughly that period of time, about half of the people diagnosed with MCI are likely to see their memory loss stabilize, and about a third will return to cognitively normal as Miriam did or at least fluctuate between MCI and cognitively normal.

So Miriam is not an outlier. Rather, shes an inspiration. She shows us that MCI can indeed be reversed. More importantly, she shows us how.

Thats why I tracked Miriam down after I saw her post on Facebook, and why Im glad she was willing to talk to me. I wanted to understand what worked for her how she did it.

Not because shes found some secret formula that anyone else can follow and get exactly the same result she did. But because Miriam took so many of the fundamental things people with MCI are encouraged to do, and threw herself into them.

For her, they worked. And shes convinced they can work for others, too.

When I started on this journey of recovery, my goal was to keep myself from getting worse; thats all I wanted, Miriam says.

But what happened was, I got better and it reversed, and I wasnt expecting that. I want people to know if that happened to me, it could happen to you.

For Miriam, the odyssey back to cognitively normal involved long, vigorous walks with her husband. It required her to radically improve her eating habits, giving up meat and eventually moving to an entirely plant-based diet. She had to learn ways to manage stress, and practice them faithfully.

So make no mistake about Miriams journey. It was a long, arduous one. And it began with memory problems that sent her stress level shooting off the charts, and a frightening diagnosis involving a condition she knew nothing about.

Miriam was 50 years old, married with three adult children and working as an accountant in the southwestern U.S. when her memory began to slip.

I was working a very stressful job, she says. The thing I remember most is that I would have to run meetings and when someone else was talking, I couldnt write down what people were saying because I couldnt remember what they said.

She wasnt the only one to notice. At one point, my manager said, Miriam, they just told you that, she recalls. But I couldnt write it down. It was gone. I thought, You didnt used to do this. Something is wrong. I started to get really stressed out.

Miriam immediately assumed the worst. Alzheimers runs strongly in her family, on both sides. But it really threw me, because I thought it was happening too soon, she says. It didnt hit my family until they were in their 70s, and I was 50.

She talked to her doctor, who sent her for an MRI and referred her to a neuropsychologist for cognitive testing. The following month, the results came in and she received her diagnosis mild cognitive impairment due to vascular disease and depression.

It wasnt the news she was hoping for. Even though I thought something was wrong, I had hoped it wasnt that bad, Miriam says. I hoped it was just me being too worried. I guess I was a little shocked, even though I wasnt completely shocked.

Based on her family history, Miriam knew all about Alzheimers. But MCI? Shed never heard of it.

I had no clue what MCI is, she says. I started reading everything I could find about it on the Internet. I think probably at that time I saw something about the percentage of people with MCI who went on to Alzheimers, and I knew I was at high risk. I thought, So this is how it starts.

If the concept of MCI was vague and confusing, the reality of living with it hit her in ways she has no trouble describing.

I was tired. I was fatigued, Miriam says. I tried to exercise but it felt like there was a weight on me. I couldnt focus properly. I couldnt think properly. I was scared. I had to write everything down, because I couldnt remember. I could not come home and cook dinner. I would come home and sit and watch TV. At that particular point, it was strictly that I wasnt able to thrive.

The company Miriam worked for at the time was a high-tech startup, and it was struggling. Her manager got laid off. Soon after that, she was laid off too.

During the time when I was let go, I was feeling so much anxiety, Miriam says. I decided I didnt want to start another job yet. I wanted to get some of this anxiety down. I started searching to see if I could find a doctor, someone who I could trust, who knew something about dementia. I knew there really was no cure, but I thought if I could find someone who was really into it, they would be on the front line and be aware of something if it did come up.

She was fortunate to find a memory specialist who was well-versed in MCI and dementia, and that helped put her on a better course. Miriam began to understand that even if theres no medicine approved for the treatment of MCI, theres ample evidence that lifestyle changes have the potential to slow or halt it.

She took up an exercise program, and coupled that with dramatic changes to her diet.

I started walking with my husband, Miriam says. We would walk three times during the week, three or four miles. On weekend days, wed walk four to eight miles each day. It was hard. I felt like I had weights on my legs.

But she persevered. Those regular walks turned into a healthy habit she continues today, and that fatigue has been replaced by a feeling of fitness. I still do about that much walking, but I walk a lot faster now, she says. Im not dragging. I have pep. I have energy. I feel a lot younger.

For Miriam, an even bigger turning point came when a physician assistant who worked for her memory specialist recommended a primarily plant-based diet, with no meat, but fish two or three times a week. She gave Miriam the book The Perfect Gene Diet, by Pamela McDonald, and told her to follow the diet recommended for people with the APOE4 gene. That gene is associated with a higher risk of Alzheimers.

Four months after being on The Perfect Gene Diet and I followed it strictly I was no longer on an anti-depressant, Miriam says. The diet cleared up my depression, so I continued doing the diet. I followed the diet, except no meat whatsoever. I only did fish.

While exercise and diet were beginning to benefit Miriam, that wasnt the whole picture. She was working a new job now, and she continued to struggle with work-related stress and the emotional toll of everything she was dealing with in her life. She realized that she had to address those things if she was going to get better.

Around mid-2016, I started going to a therapist, she says. I did individual therapy for two and a half years, and I also did about a year of group therapy. That helped me in this whole process of growing and changing things in my life, and moving forward and getting well.

She also learned a couple of stress-reduction techniques, and began to use them regularly.

One was a visualization technique that taught her how to leave her stress at work. I was bringing things home from work mentally, she says. So I would visualize putting whatever that concern was in a jar, putting the lid on the jar and setting that jar on the desk at my office before I left work.

She began using a very simple breathing technique as well. Breathe in, breathe out slowly, and letting go, just relaxing, she says.

All of these things were making a difference, though Miriam still had a ways to go. I felt a little bit better, my mind was a little clearer, she say, but I was still having some trouble.

The final turning point came when Miriam found a new neurologist. The memory specialist she worked with previously decided to stop taking patients and focus full-time on research. So Mariam had gone a while without seeing a specialist, and her general practitioner wanted her to go back to a neurologist again. I hadnt been able to find anyone else, Miriam says, so she recommended this nice young neurologist, right out of school.

Miriam found her new neurologist to be energetic and full of fresh approaches. About the same time, she discovered the teachings of Dr. Dale Bredesen, author of The End of Alzheimers. She read the book, and a lot of what Bredesen teaches made sense to her, so she asked her neurologist about his protocol. She had heard about it, and she said it was very expensive, but she said she believed in it, Miriam says.

Based on the expense and other considerations, Miriam choose not to seek out a medical specialist trained in the Bredesen protocol. Still, she felt there were parts of it she could incorporate into her life without that help. I decided I would just have to see if I could figure it out on my own, she says.

By then, Miriam had fully committed herself to a healthier lifestyle, and she had a lot of support and encouragement along the way. While she was dealing with MCI, her husband was diagnosed with a blood disorder, so they motivated each other to stick with the improvements in exercise and diet that both of them were making.

She had other family support as well. My half-brother, who is nine months older than me, was diagnosed with early onset Alzheimers, she says. He became another inspiration for me. Hes an electrical engineer, and by changing his diet, and exercise and all the extra things he does, he was still able to work, so he encouraged me. He was always reaching out to me to make sure I was following the protocol.

Yet even at this point, there still was one piece of the puzzle missing for Miriam. And the new neurologist helped her find it.

After I started seeing her, she began running all these different test, Miriam says. She told me, I have some blood work I want to do on you. Its called a dementia profile. She did my blood work in April. Because I was eating fish all the time, she wanted to be sure my mercury levels and my lead levels were OK.

The test results came back, and showed there indeed was a problem. Miriam had high levels of mercury, not to mention arsenic. Her neurologist moved immediately to address the problem. She told me, Stop eating that fish, Miriam says.

Her neurologist predicted it would take six months to a year for Miriam to flush the mercury from her body. But a month later, she says, my brain was clear.

And Miriam says once the mercury was completely out of her system, it was like a curtain being lifted. I noticed I was getting better and better, she says.

After that, all the indications began to turn positive for her.

Shed been working with a speech therapist on issues related to cognition, memory and speech, but her therapist told her that she didnt need further help with those. She said, You are not having any problems, Miriam remembers.

Miriam also had changed jobs, and found the new position to be less stressful. Now I was in a job thats perfect for me, and it was going well, Miriam says. I was having hour-long meetings, and I could talk about everything. I couldnt do that before. I am able to do that now.

The most encouraging indication, though, came this summer, when Miriams former memory specialist reached out to her. The specialist had found a study that she thought Miriam would be a good candidate for, and wanted to screen Miriam for it.

Miriam had always been open to participating in a clinical trial, but most studies are looking for people age 65 or older, so she hadnt been eligible. This one was open to people her age, who either had mild cognitive impairment or in some cases hadnt even received that diagnosis yet.

So Miriam volunteered to be screened for the study. But it turns out she didnt qualify for the best possible reason. They ran me through some of the testing, she says, and then they told me, Were sorry, but your memory is too good for our research.

I could tell even when I was being asked the questions, I was getting more answers right, she says. I was like, Wow, Im remembering more. I knew I was doing better, so I wasnt surprised.

I asked Miriam what it felt like to experience that, and she was giddy in her reply. She described one day at work, when she was so happy and doing so well, she found herself skipping along the corridor like a schoolgirl.

I am thrilled. Im just thrilled, she says. I knew how well I was doing. I was skipping down the hall because I felt so well.

I also invited Miriam to reflect back on all the hard work she had put in over those four-plus years, and all the ups and downs, and the fears and the frustrations of facing MCI. I asked her what she thought had made the difference for her.

The diet was a big piece of it a big, big, big piece of it, she says.

Asked to describe how she eats now, she says: Im on a whole-food, plant-based vegan diet. I strongly limit processed foods. I dont eat meat, fish, dairy, eggs, sugar or oil. I eat all fresh fruit, all vegetables and whole grains such as rice, oats, quinoa, bulgar, and beans, nuts and seeds. I limit bread and pasta.

And of course, there was a bigger picture than that, in terms of how she fought to defend her cognition.

It wasnt just the diet, she says. It also was the exercise and the help that I got with stress and overcoming the anxiety and just dealing with my whole thought process.

To put Miriams experience in perspective, its important to understand that no one can promise you the results she got. But remember, reversing MCI wasnt even her goal in the first place.

She was just hoping to slow it down or keep it from getting worse. And for people with MCI, its not an unrealistic goal. That is actually the more frequent outcome.

Earlier this year, researchers at the University of Pittsburgh published a study showing that across a broad general population of adults with mild cognitive impairment, relatively few of them went on to develop dementia over a period of five years.

Most people with MCI do not progress to dementia in the near term, but rather remain stable with MCI or revert to normal cognition, the study says.

In fact, according to the study, of nearly 900 adults with mild cognitive impairment:

There was a time when MCI was routinely referred to as a precursor to dementia, or an intermediate stage leading to dementia. We know better now.

For people with mild cognitive impairment, the odds of slowing, halting or reversing it are actually pretty good. And you can improve those odds even more by adopting healthy habits that promote brain health.

One of the quotes I like to share as often as I can comes from Dr. Joel Salinas, a neurologist at Massachusetts General Hospital. He told the Harvard Health Letter that only about 15 percent of people over the age of 65 who have MCI will progress to dementia.

Salinas says hes seen plenty of patients stay in the MCI stage for many years, even when we presume it was a neurodegenerative disease, and by that, he means even in cases where the doctors assumed the person had Alzheimers.

Salinas goes on to add: The people who spend the most time cognitively stable are often the ones who stick to lifestyle recommendations.

In other words, people like Miriam.

Again, its important to understand her experience is not a prescription for how to beat MCI. Its more of an allegory.

Its an example of what becomes possible when someone struggling with cognitive loss:

I had no earthly anticipation that I would be back to where I was before I began having this difficulty and getting this diagnosis, Miriam says.

I just want people to know that if you have mild cognitive impairment, theres something you can do and you dont have to spend a lot of money to do it, she says. I hope someone hears my story, and it inspires them to make the changes that are necessary. I hope it helps someone else. I really do.

Continued here:
She reversed her MCI, and here's how she did it - GoCogno.com

An unexpected early morning phone call from the hospital is never good news. When Joy Johnson answered, her first thought was that Sharon Birzer, her partner of 15 years, was dead. Her fears were amplified by the voice on the other end refusing to confirm or deny it. Just come in and talk to one of the doctors, she remembers the voice saying.

Johnson knew this was a real possibility. A few weeks earlier, she and Birzer sat in the exam room of a lymphoma specialist at Stanford University. Birzers cancer had grown, and fast first during one type of chemotherapy, then through a second. Out of standard options, Birzers local oncologist had referred her for a novel treatment called chimeric antigen receptor T-cell therapy or CAR-T. Birzer and Johnson knew the treatment was risky. They were warned there was a chance of death. There was also a chance of serious complications such as multi-organ failure and neurological impairment. But it was like warning a drowning person that her lifeboat could have problems. Without treatment, the chance of Birzers death was all but certain. She signed the consent form.

Two side-by-side PET scans from researchers at Fred Hutchinson Cancer Research Center show a large tumor mass in the kidneyprior to CAR-T cell therapy (left) and two months after CAR-T cells were injected. For this patient, the tumor almost completely regressed.

Visual: Fred Hutch News Service

Johnson hung up the phone that early morning and sped to the hospital. She met with a doctor and two chaplains in a windowless room in the cancer ward, where happy photos of cancer alumni smiled down from the walls. This is getting worse and worse, Johnson thought. As she remembers it, the doctor went through the timeline of what happened for 10 minutes, explaining how Birzer became sicker and sicker, before Johnson interrupted with the thought splitting her world in two: I need you to tell me whether shes alive or dead.

Birzer wasnt dead. But she was far from okay. The ordeal began with Birzer speaking gibberish. Then came seizures so severe there was concern she wouldnt be able to breathe on her own. When it took a few different medications to stop Birzer from seizing, her doctors sedated her, put a breathing tube down her throat, and connected her to a ventilator. Now, she was unconscious and in the intensive care unit (ICU).

Birzer was one of the early patients to receive CAR-T, a radical new therapy to treat cancer. It involved removing Birzers own blood, filtering for immune cells called T-cells, and genetically engineering those cells to recognize and attack her lymphoma. CAR-T made history in 2017 as the first FDA-approved gene therapy to treat any disease. After three to six months of follow-up, the trials that led to approval showed response rates of 80 percent and above in aggressive leukemias and lymphomas that had resisted chemotherapy. Patients on the brink of death were coming back to life.

This is something I often dream of seeing but rarely do. As a doctor who treats cancer, I think a lot about how to frame new treatments to my patients. I never want to give false hope. But the uncertainty inherent to my field also cautions me against closing the door on optimism prematurely. We take it as a point of pride that no field of medicine evolves as rapidly as cancer the FDA approves dozens of new treatments a year. One of my biggest challenges is staying up to date on every development and teasing apart what should and shouldnt change my practice. I am often a mediator for my patients, tempering theoretical promises with everyday realism. To accept a research finding into medical practice, I prefer slow steps showing me proof of concept, safety, and efficacy.

CAR-T, nearly three decades in the making, systemically cleared these hurdles. Not only did the product work, its approach was also unique among cancer treatments. Unlike our usual advances, this wasnt a matter of prescribing an old drug for a new disease or remixing known medications. CAR-T isnt even a drug. This is a one-time infusion giving a person a better version of her own immune system. When the FDA approved its use, it wasnt a question of whether my hospital would be involved, but how we could stay ahead. We werent alone.

Today, two FDA-approved CAR-T products called Kymriah and Yescarta are available in more than 100 hospitals collectively across the U.S. Hundreds of clinical trials are tinkering with dosages, patient populations, and types of cancer. Some medical centers are manufacturing the cells on-site.

The FDA approved CAR-T with a drug safety program called a Risk Evaluation and Mitigation Strategy (REMS). As I cared for these patients, I quickly realized the FDAs concerns. Of the 10 or so patients Ive treated, more than half developed strange neurologic side effects ranging from headaches to difficulty speaking to seizures to falling unconscious. We scrambled to learn how to manage the side effects in real time.

Johnson and Birzer, who I didnt treat personally but spoke to at length for this essay, understood this better than most. Both had worked in quality control for a blood bank and were medically savvier than the average patient. They accepted a medical system with a learning curve. They were fine with hearing I dont know. Signing up for a trailblazing treatment meant going along for the ride. Twists and bumps were par for the course.

Cancer, by definition, means something has gone very wrong within a cell has malfunctioned and multiplied. The philosophy for fighting cancer has been, for the most part, creating and bringing in treatments from outside the body. Thats how we got to the most common modern approaches: Chemotherapy (administering drugs to kill cancer),radiation(using high energy beams to kill cancer), and surgery (cutting cancer out with a scalpel and other tools). Next came the genetics revolution, with a focus on creating drugs that target a precise genetic mutation separating a cancer cell from a normal one. But cancers are genetically complex, with legions of mutations and the talent to develop new ones. Its rare to have that one magic bullet.

Over the last decade or so, our approach shifted. Instead of fighting cancer from the outside, we are increasingly turning in. The human body is already marvelously equipped to recognize and attack invaders, from the common cold to food poisoning, even if the invaders are ones the body has never seen before. Cancer doesnt belong either. But since cancer cells come from normal ones, theyve developed clever camouflages to trick and evade the immune system. The 2018 Nobel Prize in Physiology or Medicine was jointly awarded to two researchers for their work in immunotherapy, a class of medications devoted to wiping out the camouflages and restoring the immune systems upper hand. As I once watched a fellow oncologist describe it to a patient: Im not treating you. You are treating you.

What if we could go one step further? What if we could genetically engineer a patients own immune cells to spot and fight cancer, as a sort of best hits of genetic therapy and immunotherapy?

For patients, the dreaded c word is cancer. For oncologists, its cure.

Enter CAR-T. The technology uses T-cells, which are like the bouncers of the immune system. T-cells survey the body and make sure everything belongs. CAR-T involves removing a persons T-cells from her blood and using a disarmed virus to deliver new genetic material to the cells. The new genes given to the T-cells help them make two types of proteins. The first giving the technology its name is a CAR, which sits on the T-cells surface and binds to a protein on the tumor cells surface, like a lock and key. The second serves as the T-cells caffeine jolt, rousing it to activate. Once the genetic engineering part is done, the T-cells are prodded to multiply by being placed on a rocking device that feeds them nutrients while filtering their wastes. When the cells reach a high enough number a typical dose ranges from hundreds of thousands to hundreds of millions they are formidable enough to go back into the patient. Once inside, the cancer provokes the new cells to replicate even more. After one week, a typical expansion means multiplying by about another 1,000-fold.

Practically, it looks like this: A person comes in for an appointment. She has a catheter placed in a vein, perhaps in her arm or her chest, that connects to a large, whirring machine which pulls in her blood and separates it into its components. The medical team set the T-cells aside to freeze while the rest of the blood circulates back into the patient in a closed loop. Then, the hospital ships the cells frozen to the relevant pharmaceutical companys headquarters or transports them to a lab on-site, where thawing and manufacturing takes from a few days to a few weeks. When the cells are ready, the patient undergoes about three days of chemotherapy to kill both cancer and normal cells, making room for the millions of new cells and eradicating normal immune players that could jeopardize their existence. She then gets a day or two to rest. When the new cells are infused back into her blood, we call that Day 0.

CAR-T uses genetically modified T-cells that have been engineered to recognize and attack cancerous cells. Visual: Kotryna Zukauskaite (Animation by Paige Stampatori)

I remember the first time I watched a patient get his Day 0 infusion. It felt anti-climactic. The entire process took about 15 minutes. The CAR-T cells are invisible to the naked eye, housed in a small plastic bag containing clear liquid.

Thats it? my patient asked when the nurse said it was over. The infusion part is easy. The hard part is everything that comes next.

Once the cells are in, they cant turn off. That this may cause collateral damage was evident from the start. In 2009 working in parallel with other researchers at Memorial Sloan Kettering Cancer Center in New York and the National Cancer Institute in Maryland oncologists at the University of Pennsylvania opened a clinical trial for CAR-T in human leukemia patients. (Carl June, who led the CAR-T development, did not respond to Undarks interview request.) Of the first three patients who got CAR-T infusions, two achieved complete remission but nearly died in the process. The first was a retired corrections officer named Bill Ludwig, who developed extremely high fevers and went into multi-organ failure requiring time in the ICU. At the time, the medical teams had no idea why it was happening or how to stop it. But time passed. Ludwig got better. Then came the truly incredible part: His cancer was gone.

With only philanthropic support, the trial ran out of funding. Of the eligible patients they intended to treat, the Penn doctors only treated three. So they published the results of one patient in the New England Journal of Medicine and presented the outcomes of all three patients, including Ludwig, at a cancer conference anyway. From there, the money poured in. Based on the results, the Swiss pharmaceutical company Novartis licensed the rights of the therapy.

The next year, six-year-old Emily Whitehead was on the brink of death when she became the first child to receive CAR-T. She also became extremely ill in the ICU, and her cancer was also eventually cured. Her media savvy parents helped bring her story public, making her the poster child for CAR-T. In 2014, the FDA granted CAR-T a breakthrough therapy designation to expedite the development of extremely promising therapies. By 2017, a larger trial gave the treatment to 75 children and young adults with a type of leukemia B-cell acute lymphoblastic leukemia that failed to respond to chemotherapy. Eighty-one percent had no sign of cancer after three months.

As a doctor who treats cancer, I think a lot about how to frame new treatments to my patients. I never want to give false hope.

In August 2017, the FDA approved a CAR-T treatment as the first gene therapy in the U.S. The decision was unanimous. The Oncologic Drugs Advisory Committee, a branch of the FDA that reviews new cancer products, voted 10 to zero in favor of Kymriah. Committee members called the responses remarkable and potentially paradigm changing. When the announcement broke, a crowd formed in the medical education center of Penn Medicine, made up of ecstatic faculty and staff. There were banners and T-shirts. A remarkable thing happened was the tagline, above a cartoon image of a heroic T-cell. Two months later, in October 2017, the FDA approved a second CAR-T formulation called Yescarta from Kite Pharma, a subsidiary of Gilead Sciences, to treat an aggressive blood cancer in adults called diffuse large B-cell lymphoma, the trial of which had shown a 54 percent complete response rate, meaning all signs of cancer had disappeared. In May 2018, Kymriah was approved to treat adults with non-Hodgkin lymphoma.

That year, the American Society of Clinical Oncology named CAR-T the Advance of the Year, beating out immunotherapy, which had won two years in a row. When I attended the last American Society of Hematology meeting in December 2018, CAR-T stole the show. Trying to get into CAR-T talks felt like trying to get a photo with a celebrity. Running five minutes late to one session meant facing closed doors. Others were standing room only. With every slide, it became difficult to see over a sea of smartphones snapping photos. At one session I found a seat next to the oncologist from my hospital who treated Birzer. Look, she nudged me. Do you see all these non-member badges? I turned. Members were doctors like us who treated blood cancers. I couldnt imagine who else would want to be here. Who are they? I asked. Investors, she said. It felt obvious the moment she said it.

For patients, the dreaded c word is cancer. For oncologists, its cure. When patients ask, Ive noticed how we gently steer the conversation toward safer lingo. We talk about keeping the cancer in check. Cure is a dangerous word, used only when so much time has passed from her cancer diagnosis we can be reasonably certain its gone. But that line is arbitrary. We celebrate therapies that add weeks or months because the diseases are pugnacious, the biology diverse, and the threat of relapse looming. Oncologists are a tempered group, or so Ive learned, finding inspiration in slow, incremental change.

This was completely different. These were patients who would have otherwise died, and the trials were boasting that 54 to 81 percent were cancer-free upon initial follow-up. PET scans showed tumors that had speckled an entire body melt away. Bone marrow biopsies were clear, with even the most sensitive testing unable to detect disease.

The dreaded word was being tossed around could this be the cure weve always wanted?

When a new drug gets FDA approval, it makes its way into clinical practice, swiftly and often with little fanfare. Under the drug safety program REMS, hospitals offering CAR-T were obligated to undergo special training to monitor and manage side effects. As hospitals worked to create CAR-T programs, oncologists like me made the all too familiar transition from first-time user to expert.

It was May 2018 when I rotated through my hospitals unit and cared for my first patients on CAR-T. As I covered 24-hour shifts, I quickly learned that whether I would sleep that night depended on how many CAR-T patients I was covering. With each treatment, it felt like we were pouring gasoline on the fire of patients immune systems. Some developed high fevers and their blood pressures plummeted, mimicking a serious infection. But there was no infection to be found. When resuscitating with fluids couldnt maintain my patients blood pressures, I sent them to the ICU where they required intensive support to supply blood to their critical organs.

We now have a name for this effect cytokine release syndrome that occurs in more than half of patients who receive CAR-T, starting with Ludwig and Whitehead. The syndrome is the collateral damage of an immune system on the highest possible alert. This was first seen with other types of immunotherapy, but CAR-T took its severity to a new level. Usually starting the week after CAR-T, cytokine release syndrome can range from simple fevers to multi-organ failure affecting the liver, kidneys, heart, and more. The activated T-cells make and recruit other immune players called cytokines to join in the fight. Cytokines then recruit more immune cells. Unlike in the early trials at Penn, we now have two medicines to dampen the effect. Steroids calm the immune system in general, while a medication called tocilizumab, used to treat autoimmune disorders such as rheumatoid arthritis, blocks cytokines specifically.

Fortuity was behind the idea of tocilizumab: When Emily Whitehead, the first child to receive CAR-T, developed cytokine release syndrome, her medical team noted that her blood contained high levels of a cytokine called interleukin 6. Carl June thought of his own daughter, who had juvenile rheumatoid arthritis and was on a new FDA-approved medication that suppressed the same cytokine. The team tried the drug, tocilizumab, in Whitehead. It worked.

Still, we were cautious in our early treatments. The symptoms of cytokine release syndrome mimic the symptoms of severe infection. If this were infection, medicines that dampen a patients immune system would be the opposite of what youd want to give. There was another concern: Would these medications dampen the anti-cancer activity too? We didnt know. Whenever a CAR-T patient spiked a fever, I struggled with the question is it cytokine release syndrome, or is it infection? I often played it safe and covered all bases, starting antibiotics and steroids at the same time. It was counterintuitive, like pressing both heat and ice on a strain, or treating a patient simultaneously with fluids and diuretics.

The second side effect was even scarier: Patients stopped talking. Some, like Sharon Birzer spoke gibberish or had violent seizures.Some couldnt interact at all, unable to follow simple commands like squeeze my fingers. How? Why? At hospitals across the nation, perfectly cognitively intact people who had signed up to treat their cancer were unable to ask what was happening.

Our nurses learned to ask a standardized list of questions to catch the effect, which we called neurotoxicity: Where are we? Who is the president? What is 100 minus 10? When the patients scored too low on these quizzes, they called me to the bedside.

Joy Johnson (left) and her partner Sharon Birzer. Birzer was one of the early patients to receive CAR-T, a radical new therapy to treat cancer.

Visual: Courtesy of Sharon Birzer

In turn, I relied heavily on alaminated booklet, made by other doctors who were using CAR-T, which we tacked to a bulletin board in our doctors workroom. It contained a short chart noting how to score severity and what to do next. I flipped through the brightly color-coded pages telling me when to order a head CT-scan to look for brain swelling and when to place scalp electrodes looking for seizures. Meanwhile, we formed new channels of communication. As I routinely called a handful of CAR-T specialists at my hospital in the middle of the night, national consortiums formed where specialists around the country shared their experiences. As we tweaked the instructions, we scribbled updates to the booklet in pen.

I wanted to know whether my experience was representative. I came across an abstract and conference talk that explored what happened to 277 patients who received CAR-T in the real world, so I emailed the lead author, Loretta Nastoupil, director of the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. Fortuitously, she was planning a trip to my university to give a talk that month. We met at a caf and I asked what her research found. Compared to the earlier trials, the patients were much sicker, she said. Of the 277 patients, more than 40 percent wouldnt have been eligible for the very trials that got CAR-T approved. Was her team calling other centers for advice? They were calling us, she said.

Patients included in clinical trials are carefully selected. They tend not to have other major medical problems, as we want them to survive whatever rigorous new therapy we put them through. Nastoupil admits some of it is arbitrary. Many criteria in the CAR-T trials were based on criteria that had been used in chemotherapy trials. These become standard languages that apply to all studies, she said, listing benchmarks like a patients age, kidney function, and platelet count. But we have no idea whether criteria for chemotherapy would apply to cellular therapy.

Now, with a blanket FDA approval comes clinical judgment. Patients want a chance. Oncologists want to give their patients a chance. Young, old, prior cancer, heart disease, or liver disease without strict trial criteria, anyone is fair game.

When I was making rounds at my hospital, I never wandered too far from these patients rooms, medically prepared for them to crash at any moment. At the same time, early side effects made me optimistic. A bizarre truism in cancer is that side effects may bode well. They could mean the treatment is working. Cancer is usually a waiting game, requiring months to learn an answer. Patients and doctors alike seek clues, but the only real way to know is waiting: Will the next PET scan show anything? What are the biopsy results?

CAR-T was fundamentally different from other cancer treatments in that it worked fast. Birzers first clue came just a few hours after her infusion. She developed pain in her lower back. She described it as feeling like she had menstrual cramps. A heavy burden of lymphoma lay in her uterus. Could the pain mean that the CAR-T cells had migrated to the right spot and started to work? Her medical team didnt know, but the lead doctors instinct was that it was a good sign.

Two days later, her temperature shot up to 102. Her blood pressure dropped. The medical team diagnosed cytokine release syndrome, as though right on schedule, and gave her tocilizumab.

Every day, the nurses would ask her questions and have her write simple sentences on a slip of paper to monitor for neurotoxicity. By the fifth day, her answers changed. She started saying things that were crazy, Johnson explained.

One of Birzers sentences was guinea pigs eat greens like hay and pizza. Birzer and Johnson owned two guinea pigs, so their diet would be something Birzer normally knew well. So Johnson tried to reason with her: They dont eat pizza. And Birzer replied, They do eat pizza, but only gluten-free.

Johnson remembers being struck by the certainty in her partners delirium. Not only was Birzer confused, she was confident she was not. She was doubling down on everything, Johnson described. She was absolutely sure she was right.

Johnson vividly remembers the evening before the frightening early-morning phone call that brought her rushing back to the hospital. Birzer had said there was no point in Johnson staying overnight; she would only watch her be in pain. So Johnson went home. After she did, the doctor came by multiple times to evaluate Birzer. She was deteriorating and fast. Her speech became more and more garbled. Soon she couldnt name simple objects and didnt know where she was. At 3 a.m., the doctor ordered a head CT to make sure Birzer wasnt bleeding into her brain.

Fortunately, she wasnt. But by 7 a.m. Birzer stopped speaking altogether. Then she seized. Birzers nurse was about to step out of the room when she noticed Birzers arms and legs shaking. Her eyes stared vacantly and she wet the bed. The nurse called a code blue, and a team of more doctors and nurses ran over. Birzer was loaded with high-dose anti-seizure medications through her IV. But she continued to seize. As nurses infused more medications into her IV, a doctor placed a breathing tube down her throat.

Birzers saga poses the big question: Why does CAR-T cause seizures and other neurologic problems? No one seemed to know. My search of the published scientific literature was thin, but one name kept cropping up. So I called her. Juliane Gust, a pediatric neurologist and scientist at Seattle Childrens Hospital, told me her investigations of how CAR-T affects the brain were motivated by her own experiences. When the early CAR-T trials opened at her hospital in 2014, she and her colleagues began getting calls from oncologists about brain toxicities they knew nothing about. Where are the papers? she remembered thinking. There was nothing.

The CAR-T cells are invisible to the naked eye, housed in a small plastic bag containing clear liquid. Visual: Kotryna Zukauskaite (Animation by Paige Stampatori)

Typically, the brain is protected by a collection of cells aptly named the blood-brain-barrier. But with severe CAR-T neurotoxicity, research suggests, this defense breaks down. Gust explained that spinal taps on these patients show high levels of cytokines floating in the fluid surrounding the spine and brain. Some CAR-T cells circulate in the fluid too, she said, but these numbers do not correlate with sicker patients. CAR-T cells are even seen in the spinal fluid of patients without any symptoms.

What does this mean? Gust interprets it as a patients symptoms having more to do with cytokines than the CAR-T cells. Cytokine release syndrome is the number one risk factor for developing neurotoxicity over the next few days, she said. The mainstay for neurotoxicity is starting steroids as soon as possible. In the beginning we didnt manage as aggressively. We were worried about impairing the function of the CAR-T, she added. Now we give steroids right away.

But the steroids dont always work. Several doses of steroids didnt prevent Birzer from seizing. The morning after Johnsons alarming phone call, after the meeting at the hospital when she learned what had happened, a chaplain walked her from the conference room to the ICU. The first day, Johnson sat by her partners bedside while Birzer remained unconscious. By the next evening, she woke up enough to breathe on her own. The doctors removed her breathing tube, and Birzer looked around. She had no idea who she was or where she was.

Birzer was like a newborn baby, confused and sometimes frightened by her surroundings. She frequently looked like she was about to say something, but she couldnt find the words despite the nurses and Johnsons encouragement. One day she spoke a few words. Eventually she learned her name. A few days later she recognized Johnson. Her life was coming back to her, though she was still suspicious of her reality. She accused the nurses of tricking her, for instance, when they told her Donald Trump was president.

She took cues from the adults around her on whether her actions were appropriate. The best example of this was her I love you phase. One day, she said it to Johnson in the hospital. A few nurses overheard it and commented on how sweet it was. Birzer was pleased with the reaction. So she turned to the nurse: I love you! And the person emptying the trash: I love you! Months later, she was having lunch with a friend who asked, Do you remember when you told me you loved me? Birzer said, Well, I stand by that one.

When she got home, she needed a walker to help with her shakiness on her feet. When recounting her everyday interactions, she would swap in the wrong people, substituting a friend for someone else. She saw bugs that didnt exist. She couldnt hold a spoon or a cup steady. Johnson would try to slow her down, but Birzer was adamant she could eat and drink without help. Then peas would fly in my face, Johnson said.

Patients who experience neurotoxicity fall into one of three categories. The majority are impaired but then return to normal without long-term damage. A devastating handful, less than 1 percent, develop severe brain swelling and die. The rest fall into a minority that have lingering problems even months out. These are usually struggles to think up the right word, trouble concentrating, and weakness, often requiring long courses of rehabilitation and extra help at home.

Patients stopped talking. Some, like Sharon Birzer spoke gibberish or had violent seizures. Some fell into comas.

As Birzer told me about her months of rehab, I thought how she did seem to fall somewhere in the middle among the patients Ive treated. On one end of the spectrum was the rancher who remained profoundly weak a year after his infusion. Before CAR-T, he walked across his ranch without issue; six months later, he needed a walker. Even with it, he fell on a near weekly basis. On the other end was the retired teacher who couldnt speak for a week she would look around her ICU room and move her mouth as though trying her hardest and then woke up as though nothing happened. She left the hospital and instantly resumed her life, which included a recent trip across the country. In hindsight, I remember how we worried more about giving the therapy to the teacher than the rancher, as she seemed frailer. Outcomes like theirs leave me with a familiar humility I keep learning in new ways as a doctor: We often cant predict how a patient will do. Our instincts can be just plain wrong.

I asked Gust if we have data to predict who will land in which group. While we can point to some risk factors higher burdens of cancer, baseline cognitive problems before therapy the individual patient tells you nothing, she confirmed.

So we wait.

Doctors like me who specialize in cancer regularly field heart-wrenching questions from patients. They have read about CAR-T in the news, and now they want to know: What about me? What about my cancer?

So, who gets CAR-T? That leads to the tougher question who doesnt? That depends on the type of cancer and whether their insurance can pay.

CAR-T is approved to treat certain leukemias and lymphomas that come from the blood and bone marrow. Since the initial approval, researchers have also set up new CAR-T trials for all sorts of solid tumors from lung cancer to kidney cancer to sarcoma. But progress has been slow. While some promising findings are coming from the lab and in small numbers of patients on early phase trials, nothing is yet approved in humans. The remarkable responses occurring in blood cancers just werent happening in solid tumors.

Cancer is one word, but its not one disease. Its easier to prove why something works when it works than show why it doesnt work when it doesnt work, said Saar Gill, a hematologist and scientist at the University of Pennsylvania who co-founded a company called Carisma Therapeutics using CAR-T technology against solid tumors. That was his short answer, at least. The longer answer to why CAR-T hasnt worked in solid cancers involves what Gill believes are two main barriers. First, its a trafficking problem. Leukemia cells tend to be easier targets; they bob through the bloodstream like buoys in an ocean. Solid tumors are more like trash islands. The cancer cells stick together and grow an assortment of supporting structures to hold the mound together. The first problem for CAR-T is that the T-cells may not be able to penetrate the islands. Then, even if the T-cells make it in, theyre faced with a hostile environment and will likely die before they can work.

At Carisma, Gill and his colleagues look to get around these obstacles though a different immune cell called the macrophage. T-cells are not the only players of the immune system, after all. Macrophages are gluttonous cells that recognize invaders and engulf them for destruction. But studies have shown they cluster in solid tumors in a way T-cells dont. Gill hopes genetically engineered macrophages can be the stowaways that sneak into solid tumor and attack from the inside out.

Another big challenge, even for leukemias and lymphomas, is resistance, where the cancers learn to survive the CAR-T infusion. While many patients in the trials achieved remission after a month, we now have two years worth of data and the outlook isnt as rosy. For lymphoma, that number is closer to 40 percent. Patients celebrating cures initially are relapsing later. Why?

The CAR-T cells we use target a specific protein on cancer cells. But if the cancer no longer expresses that protein, that can be a big problem, and were finding thats exactly whats happening. Through blood testing, we see that many patients who relapse lose the target.

Researchers are trying to regain the upper hand by designing CAR-Ts to target more than one receptor. Its an old idea in a new frame: An arms race between our medicines and the illnesses that can evolve to evade them. Too much medical precision in these cases is actually not what we want, as it makes it easier for cancer to pinpoint whats after it and develop an escape route. So, the reasoning goes, target multiple pieces at once. Confuse the cancer.

Then theres the other dreaded c word: Cost. Novartis Kymriah runs up to $475,000 while Kite Pharmas Yescarta is $373,000. That covers manufacturing and infusion. Not included is the minimum one-week hospital stay or any complications.

They are daunting numbers. Some limitations on health care we accept maybe the patients are too sick; maybe they have the wrong disease. The wrong cost is not one we as a society look kindly upon. And drug companies shy away from that kind of attention.

Cost origins in medicine are notoriously murky. Novartis, confident in its technology, made an offer to offset the scrutiny in CAR-T. If the treatment didnt work after one month, the company said it wouldnt send a bill.

Not everyone agrees that cost is an issue. Gill, for example, believes the concern is over-hyped. Its not a major issue, he told me over the phone. Look, of course [with] health care in this country, if you dont have insurance, then youre screwed. That is no different when it comes to CAR-T as it is for anything else, he said. The cost conversation must also put CAR-T in context. Gill went on to list what these patients would be doing otherwise months of chemotherapy, bone marrow transplants, hospital stays for cancer-associated complications and the associated loss of income as patients and caregivers miss work. These could add up to far more than a one-time CAR-T infusion. A bone marrow transplant, for example, can cost from $100,000 to more than $300,000. The cancer-fighting drug blinatumomab, also used to treat relapsed leukemia, costs $178,000 a year. Any discussion of cost is completely irresponsible without weighing the other side of the equation, Gill said.

How the system will get on board is another question. Logistics will be an issue, Gill conceded. The first national Medicare policy for covering CAR-T was announced in August 2019, two years after the first product was approved. The Centers for Medicare and Medicaid Services has offered to reimburse a set rate for CAR T-cell infusion, and while this figure was recently raised, it remains less than the total cost. Despite the expansion of medical uses, at some centers referrals for CAR-T are dropping as hospitals worry its a net loss. And while most commercial insurers are covering CAR-T therapies, companies less accustomed to handling complex therapies can postpone approval. Ironically, the patients considering CAR-T are the ones for whom the window for treatment is narrowest. A delay of even a few weeks can mean the difference between a cure and hospice.

This, of course, poses a big problem. A breakthrough technology is only as good as its access. A major selling point of CAR-T besides the efficacy is its ease. Its a one-and-done treatment. Engineered T-cells are intended to live indefinitely, constantly on the alert if cancer tries to come back. Compare that to chemotherapy or immunotherapy, which is months of infusions or a pill taken indefinitely. CAR-T is more akin to surgery: Cut it out, pay the entire cost upfront, and youre done.

Birzer was lucky in this respect. I asked her and Johnson if cost had factored into their decision to try CAR-T. They looked at each other. It wasnt an issue, said Johnson. They remembered getting a statement in the mail for a large sum when they got home. But Birzer had good insurance. She didnt pay a cent.

One year after Birzers infusion, I met her and Johnson at a coffee shop near their home in San Francisco. They had saved a table. Johnson had a newspaper open. Birzer already had her coffee, and I noticed her hand trembling as she brought it to her mouth. She described how she still struggles to find exactly the right words. She sometimes flings peas. But shes mostly back to normal, living her everyday life. She has even returned to her passion, performing stand-up comedy, though she admitted that at least for general audiences: My jokes about cancer didnt kill.

People handed a devastating diagnosis dont spend most of their time dying. They are living, but with a heightened awareness for a timeline the rest of us take for granted. They sip coffee, enjoy their hobbies, and read the news while also getting their affairs in order and staying on the lookout, constantly, for the next treatment that could save them.

Hoping for a miracle while preparing to die are mutually compatible ideas. Many of my patients have become accustomed to living somewhere in that limbo. It is humbling to witness. They hold out hope for a plan A, however unlikely it may be, while also adjusting to the reality of a plan B. They live their lives; and they live in uncertainty.

I see patients in various stages of this limbo. In clinic, I met a man with multiple myeloma six months after a CAR-T trial that supposedly cured him. He came in with a big smile but then quietly began praying when it was time to view PET results. He asked how the other patients on the trial were doing, and I shared the stats. While percentages dont say anything about an individual experience, theyre also all patients have to go on. When someone on the same treatment dies, its shattering for everyone. Was one person the exception, or a harbinger anothers fate? Who is the outlier?

I look at these patients and think a sober truth: Before CAR-T, all would likely die within six months. Now, imagine taking 40 percent and curing them. Sure, a naysayer might point out, its only 40 percent. Whats the hype if most still succumb to their cancer? But there was nothing close to that before CAR-T. I agree with how Gill described it: I think CAR-T cells are like chemotherapy in the 1950s. Theyre not better than chemotherapy theyre just different. For an adversary as tough as cancer, well take any tool we can get.

There remain many questions. Can we use CAR-T earlier in a cancers course? Lessen the side effects? Overcome resistance? Streamline manufacturing and reimbursement? Will it work in other cancers? Patients will sign up to answer.

For now, Birzer seems to be in the lucky 40 percent. Her one-year PET scan showed no cancer. I thought of our last coffee meeting, where I had asked if she ever worried she wouldnt return to normal. She didnt even pause. If youre not dead, she said, youre winning.

Ilana Yurkiewicz, M.D., is a physician at Stanford University and a medical journalist. She is a former Scientific American Blog Network columnist and AAAS Mass Media Fellow. Her writing has also appeared in Aeon Magazine, Health Affairs, and STAT News, and has been featured in The Best American Science and Nature Writing.

Read more:
The CAR-T Revolution Is ... Messy - Undark Magazine

Breast cancer occurs in breast tissue, which both women and men have. Although its rare, male breast cancer does happen.

Its diagnosed and treated similarly in all genders, so early diagnosis remains key. The science around the cause of male breast cancer is unclear, according to the Mayo Clinic, same as most types of most cancer, though male breast cancer is even more mysterious.

People of all genders are born with some breast tissue and milk-producing glands (lobules) that transport milk to the nipples and fat. When a girl hits puberty, she develops more breast tissue, and boys do not. Boys, however, do still have the breast tissue with which they were born.

The most common type of breast cancer in men is ductal carcinoma, which begins in the milk ducts.

Just as with women, there is research indicating a family history of breast cancer increases the likelihood of a man getting the disease. Gene mutations like BRCA2 (the same mutation actress Angelina Jolie had that put her at a high risk of breast cancer) increases a mans risk of breast cancer and prostate cancer.

Older age remains a risk factor, as does exposure to estrogen, obesity or liver or testicular disease. Men who are born with Klinefelters syndrome, a genetic condition in which some boys have more than one copy of the X chromosome, also increase a mans likelihood of contracting breast cancer.

Early diagnosis and treatment is critical for best outcomes in male breast cancer, which can be harder since its not always the first condition tested for, so knowing the symptoms is important. These include a painless lump in or thickening of the breast tissue, changes to the nipple (redness, scaling or turning inward) or nipple discharge or changes to the skin covering the breast area. Men who see these symptoms should ask their doctor for further assessment.

According to the Mayo Clinic, diagnosis and treatment is similar to what women experience: clinical breast exams, medical imaging that enables the doctor to see problem areas, or a biopsy, during which the doctor extracts tissue from the suspected tumor and tests it.

Male breast cancer is often hormone-related, so doctors may recommend hormone therapy in addition to surgery, chemotherapy and radiation.

Originally posted here:
Breast Cancer in Men | Outlook - Big Bear Grizzly

New Detection and Treatment for Cancer

According to the American Cancer Society, the oldest description of cancer dates back to Egypt around 3000 BC. Weve been looking for answers ever since. The good news is that there are new detection and treatments for cancer that are providing the way forward to earlier detection and more targeted therapy.

GRAIL, Inc. has a new blood test in development that screens for numerous types of cancer. Investigators at Dana-Farber Cancer Institute confirmed the test has an overall specificity of 99.4%. Results of the multi-center trial were presented at the European Society for Medical Oncology 2019 Congress on September 18, 2019.

By looking for DNA rather than liquid biopsies, the test is able to focus in on portions of the genome where abnormal methylation patterns are found in cancer cells. The lead author, Geoffrey Oxnard, MD of Dana-Farber, commented that if the test was in wide use, it would increase the number of patients who could receive more effective treatments.

Non-Opioid Chronic Pain Management

With the rise of awareness of the dangers of opioids, doctors and patients are turning to alternative solutions for chronic pain management. Physical therapy, acupuncture, surgery, injections, and nerve blocks are some of those solutions. However, for Richard Hanbury, the solution to his personal chronic pain would not be found in opioids but in the experimentation of relaxation techniques, pulsing lights, and sound. As he tracked the decrease of his own pain, he began to raise seed funding, and in 2018, with the help of Stanford University and the United States Special Operations Command, put the device to the test.

In January, the Smithsonian Magazine identified Hanbury, founder of Sana, as an innovator to watch in 2019. Sana has developed a non-invasive bio-therapeutic to manage chronic pain while reducing health care costs. The company has created a device that--with the push of a button--the combination of deep relaxation with the promotion of hemispheric balance leads to pain relief in 16 minutes. As of July of 2019, the company had completed the engineering and testing required for review for FDA approval. Pending FDA approval, it will first be available for fibromyalgia treatment. Additional clinical studies are underway for Opioid Use Disorder, Severe Pain, Neuropathic Pain, and Oncology Pain. The aim, says Hanbury, is to create less suffering and a better status of care.

Virtual Reality is also being used for pain management. VR provides a safe, effective, drug-free alternative in the aftermath of an opioid epidemic. Its even being used to monitor Alzheimer's disease.

AI Applications

Fast Company identified Arterys as one of the Worlds 50 Most Innovative Companies of 2019 for scanning smartly. With long waiting lists and a shortage of radiology specialists, Arterys saw a need for AI to help doctors quickly detect, measure, and track tumor and lesions in CT scans of the lungs and in MRI and CT scans of the liver. In August, a major French hospital signed a five-year deal to deploy the AI platform. The purpose is not to replace human radiologists, but to let the system do manual tasks, allowing the radiologist to focus more on the patient and the experience.

But Arterys isnt the only company providing AI assistance. Machines are being used to predict, comprehend, learn, and act. From surgery-assisting robots to faster diagnoses, AI has multiple applications in the life science industries. For more read 32 Examples of AI in Healthcare and Would You Trust An Automated Doctor?

Neurological Advancements

By 2050, the cost and diagnosis of neurological disorders is expected to nearly double. The good news is that innovation is happening at a rapid pace as scientists are discovering more about the function of the nervous system on molecular and genetic levels. According to an article in Americas Biopharmaceutical Companies, there are 537 medications currently being developed for the treatment of chronic pain, brain tumors, Alzheimers disease, Parkinsons disease, epilepsy, headaches, and migraines. The article highlights disease-modifying treatments for Alzheimers that have the potential to stop or slow down the progression of the disease.

According to Doug Williamson, chief medical officer and vice president of U.S. drug development at Lundbeck, hope is right around the horizon. Just as cancer has progressed from being a death sentence to often being treatable and in some cases curable, the next few decades will see far more effective treatments for a variety of neurological diseases.

It is not only in medication that we are seeing advancements for neurological diseases, like Alzheimers and Parkinsons disease. Earlier this year The Norman Fixel Institute for Neurological Diseases at the University of Florida Health in Gainesville opened its doors. Neurologists, neurosurgeons, neuropsychologists, physical therapists, occupational therapists, speech and swallowing specialists, nutritionists, psychiatrists and social workers are all working together under one roof, providing comprehensive and advanced care.

We are thinking broadly and establishing a coordinated approach to improvement of clinical care, drug discovery, as well as gene and neuromodulatory therapy, said David R. Nelson, M.D., senior vice president for health affairs at UF and president of UF Health. Our outstanding team of experts will continue to push the boundaries in identifying new, game-changing approaches to treating neurologic disease.

Direct to Consumer Hearing Aids

InnerScope Hearing Technologies Inc.(innd.com) received the Best Hearing Aid Manufacturer 2019 USA & GHP Award for its innovation in direct-to-consumer hearing aid delivery. The company is working to serve 1.2 billion people worldwide who have hearing loss by providing accessible and affordable solutions. There are five hearing aid manufacturers that control 97% of hearing aids sold globally. The company plans to disrupt this existing product with its patented self-fitting hearing aid that will be distributed through global big box retailers. InnerScope is also conducting a 510K FDA clinical trial on treatment for tinnitus. The goal is to provide quality care to people who previously have been unable to afford hearing devices.

2019/ 2020 Potential Jobs and Opportunities

As we finish out 2019 and enter 2020, the future of biotechnology and pharmaceuticals is promising. Innovations, small biotech startups, and clinical tests are advancing towards earlier diagnosis and more effective treatments. As more advances are made in the life sciences, additional opportunities will open. This is good news for those seeking employment, meaning its time to pitch your dream position into markets where they need you, but dont quite know why.You can check out current openings within the life sciences industry here.

Stay ahead of your competitors. Read Creating a Life Sciences Jobs Where One Doesnt Exist. Twenty years ago, would you have thought strapping on a headset would be an effective pain management strategy or that a cure for the HIV infection was possible? Go start tomorrow's innovations today. The future is waiting.

Continue reading here:
5 Biotech and Pharmaceutical Innovation Trends in 2019 - BioSpace

Adrienne Moore knew something was wrong. After being diagnosed and successfully treated for ovarian cancer a decade earlier, she recognized the pain and bleeding she began to experience during intercourse, and the sudden irregularity of her periods, as signs of a potentially serious problem with her reproductive health.

Moore, a 45-year-old respiratory nurse from Atlanta, was terrified that her cancer had returned. But when she sought help from her doctors in 2012, she left her appointments with a series of misdiagnoses: perimenopause, cysts, fibroids. Being in the medical world, I thought I knew how to communicate with my caregivers, she says. But even as she pressed her fears, it felt like no one was listening.

She returned to her doctors repeatedly over the next three years, but her symptoms didnt improve. When her employers switched her health insurance plan, and her monthly premium jumped, Moore became unable to afford specialist care. As the pain grew unbearable, she requested sick leave from work. Instead, she was laid off. Her family paid out of pocket for scans and tests that Moore herself ordered. Still, doctors found nothing wrong.

But growing in Moores pelvic cavity, across her ovaries and into the endometriumthe lining of her wombwas a disease that could kill her.

Endometrial cancer is the most common type of gynecological cancer in the United States. Four times more common than cervical cancer, and the fourth most common cancer in women, its one of the few cancers in the country for which diagnoses and deaths are on the rise. The American Cancer Society estimates that at least 57,000 women will be diagnosed this year, and more than 11,000 will die.

Black women are just as likely to get endometrial cancer as white women, but they are more likely to die from it. Within every age, within every stage of diagnosis, within every tumor type, black women do worse, says Dr. Kemi Doll, a gynecologic oncologist at the University of Washington.

Doll has spent the past seven years researching gynecological cancers and investigating the cause of the disparity. She believes that, as with racial discrepancies in other medical conditions, the difference in the endometrial cancer death rate is the result of how the medical establishment treats black women.

To start, black women are less likely than white women to receive an early diagnosis for the disease. As a result, thousands discover they have the cancer only after it has spread, when they have less chance of survival.

That could be because doctors miss early signs of the disease, or because many black women are more reluctant or less able than their white counterparts to seek help from doctors. For many black women, confidence in the health care system has been undermined by decades of difficult experiences. Studies have found that doctors are more likely to view black patients as medically uncooperative, and that diagnostic and treatment decisions are influenced by patients race. Black patients consistently report higher levels of dissatisfaction with their care and mistrust of their doctors. Doll says that patients she speaks with frequently describe feeling dismissed, ignored, or overwhelmed. If you consider a black woman in the US who has had a lifetime of experiences of subpar reproductive health care, Doll says, it might not be that a couple of drops of postmenopausal bleeding has you running to the doctor.

And even those, like Moore, who seek help early for endometrial cancer receive less aggressive care. A recent study conducted by Dolls team found that black women with health insurance or access to medical care were less likely than white women to receive biopsies that could confirm their cancer earlier. Another found that 40 percent of the black-white mortality gap in endometrial cancer may be due to inequitable surgery rates: research shows that black women are less likely to receive surgery than white women at every stage of the disease, and they are also less likely to receive chemotherapy.

For further proof, Doll points to the racial discrepancies that exist in other diseases. Black women are less likely than white women to be tested for hereditary genetic mutations linked to breast cancer. Black patients with end-stage renal disease are less likely to be considered appropriate candidates for kidney transplants. Compared with white patients, black patients are more likely to die from breast, prostate, and stomach cancer, more likely to develop Alzheimers, and more likely to have a stroke. When it comes to maternal care, black women are almost four times more likely to die a pregnancy-related death than white women, and more likely to experience pregnancy complications like preeclampsia, placental abruptions, and postpartum hemorrhage.

You can either approach it from the standpoint that there is something fundamentally wrong with black womens bodies, or theres something wrong with the way we treat black women and their bodies, Doll says. We are not going to help women, and we are not going to solve this problem, if we dont deal with the problem of race and racism.

Not everyone agrees entirely with Dolls prognosis. Dr. Rodney Rocconi, interim director of the University of South Alabama Mitchell Cancer Institute, believes that biology plays an important part in endometrial cancers mortality disparity. Rocconi points to the fact that black women are more likely to be diagnosed with an aggressive form of endometrial cancer, regardless of how early she is diagnosed.

Rocconis research has found that women with a higher percentage of African ancestry are significantly more likely to have a genetic mutation that allows tumors to grow unchecked. Other research corroborates this idea: certain genetic mechanisms that help suppress tumors are less active in black women. Studies of kidney disease and hypertension suggest that genetics may also play part in increasing black peoples risk of developing the illnesses.

Critics argue that research linking race, genetics, and disease veers troublingly close to endorsing theories of eugenics and promoting pseudo-scientific racism. Rocconi agrees that theres no such thing as a black gene. But identifying a concrete link between black womens genetics and the aggressive tumors they suffer could be the first step in finding a cure. Whats most exciting to me is that we can target the biological cause of the disease, Rocconi says. Once the research is confirmed, we can add a targeted therapy to inhibit that immune pathway, and make patients more likely to respond to therapy.

But progress is hampered by another racial discrepancy, this time in clinical trials. Black enrollment numbers for early-phase endometrial cancer clinical trials, Rocconi notes, are dismal: For even one white person enrolled, 0.04 black people are. That first phase in clinical trials helps set the pipeline for agents that can be used in patients, Rocconi says. We are self-selecting [therapies] that work in the majority white population. This is a widespread problem. A recent ProPublica investigation found that in trials for 18 drugs targeting cancers that occur at least as frequently in black people as white, on average only 4.1 percent of participants were black.

To increase participation, Rocconi says, doctors must find a way to garner black patients trust in medical institutions. In Alabama, where the infamous Tuskegee syphilis experiment remains in living memory, Rocconi has had success enrolling more black patients in cancer treatment trials thanks to a University of South Alabama peer support program that helps patients understand treatment plans and medications and access things like medical insurance, hospital transportation, and community services. These were black women who were talking to people from the same community, Rocconi says. They were advocates for them.

Rocconis and Dolls research converge in another way, too: Both researchers believe epigenetics, the idea that social, economic, and cultural inequalities can alter our DNA, might also have a role in explaining why more black women are dying from endometrial cancer. Since the inequalities black women face persist throughout lifetimes, the resulting epigenetic changes keep accumulatingresulting in poorer health outcomes, including cancer, among certain racial and ethnic groups, a study co-written by Rocconi asserts. In other words, black womens genes may predispose them to aggressive endometrial cancer. But those genes have been influenced by generations of inequality.

This is why Doll believes that her patients experiences are key. The genetic information that youre getting comes from a person who had an experience, she says. And if you dont look at that experience you simply wont ever know how it may be influencing what youre seeing on the genetic level.

Back in Atlanta, Adrienne Moore was determined to find answers to what was ailing her. When she started a new job, a year after being laid off, she used her reinstated health benefits to order a biopsy on one of her cysts. It confirmed what she thought she already knew: She had cancer. But when the oncologist described the disease, she was shocked. She had never heard of endometrial cancer before. Her disease was so advanced, she was diagnosed at Stage 3. She was lucky to survive.

As she finished chemotherapy, Moore joined the Endometrial Cancer Action Network for African-Americans, a national support group founded by Doll. The organization hosts an online community for survivors and an education arm that informs black women about the disease, and its members serve as a research pool for ongoing studies into the cancers causes and treatments. Moore, whose cancer is now in remission, is a patient advisor for ECANA and conducts outreach to black women across Georgia.

Theres such a silence around our reproductive health, says Moore. She feels she had a lucky escape. When black women tell me theyve never heard of endometrial cancer, she says, its probably because weve lost so many to this disease.

See the article here:
Why Are More Black Women Dying From the Most Common Reproductive Cancer? - Mother Jones

Oct. 21, 2019 05:00 UTC

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib.

Safety for the combination of Tecentriq and Avastin was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. Data from the IMbrave150 study will be presented at an upcoming medical meeting.

We are very pleased with the results of our study testing the combination of Tecentriq and Avastin, which marks the first treatment in more than a decade to improve overall survival in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. HCC is a major cause of death globally and particularly in Asia, making this study an important step in our mission of addressing unmet medical needs for patients around the world. We will submit these data to global health authorities as soon as possible. Our hope is to bring a new treatment to people with this aggressive disease who currently have limited options.

In July 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Tecentriq in combination with Avastin in HCC based on data from an ongoing Phase Ib trial.

Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies, across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

About the IMbrave150 study

IMbrave150 is a global Phase III, multicenter, open-label study of 501 people with unresectable HCC who have not received prior systemic therapy. People were randomized 2:1 to receive the combination of Tecentriq and Avastin or sorafenib. Tecentriq was administered intravenously, 1200 mg on day 1 of each 21-day cycle, and Avastin was administered intravenously, 15 mg/kg on day 1 of each 21-day cycle. Sorafenib was administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle. People received the combination or the control arm treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Co-primary endpoints were OS and PFS by independent review facility (IRF) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Secondary efficacy endpoints included overall response rate (ORR), time to progression (TTP) and duration of response (DoR), as measured by RECIST v1.1 (investigator-assessed [INV] and IRF) and HCC mRECIST (IRF), as well as patient-reported outcomes (PROs), safety and pharmacokinetics.

About hepatocellular carcinoma

According to the American Cancer Society, it is estimated that more than 42,000 Americans will be diagnosed with liver cancer in 2019. Liver cancer incidence has more than tripled since 1980 and HCC accounts for approximately 75% of all liver cancer cases in the United States. HCC develops predominantly in people with cirrhosis due to chronic hepatitis (B and C) or alcohol consumption, and typically presents at an advanced stage where there are limited treatment options.

About the Tecentriq and Avastin combination

There is a strong scientific rationale to support further investigation of Tecentriq plus Avastin in combination. Avastin, in addition to its anti-angiogenic effects, may further enhance Tecentriqs ability to restore anti-cancer immunity by inhibiting vascular endothelial growth factor (VEGF)-related immunosuppression, promoting T-cell tumor infiltration and enabling priming and activation of T-cell responses against tumor antigens.

About Tecentriq (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Avastin (bevacizumab)

Avastin is a prescription-only medicine that is a solution for intravenous infusion. It is a biologic antibody designed to specifically bind to a protein called VEGF that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumors ability to grow and spread in the body (metastasize).

Tecentriq U.S. Indications

Tecentriq is a prescription medicine used to treat adults with:

A type of bladder and urinary tract cancer called urothelial carcinoma. Tecentriq may be used when your bladder cancer:

The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.

A type of lung cancer called non-small cell lung cancer (NSCLC).

A type of breast cancer called triple-negative breast cancer (TNBC).

Tecentriq may be used with the medicine paclitaxel protein-bound when your breast cancer:

The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients disease worsened. Continued approval for this use may depend on results of an ongoing study to confirm benefit.

A type of lung cancer called small cell lung cancer (SCLC).

It is not known if Tecentriq is safe and effective in children.

Important Safety Information

What is the most important information about Tecentriq?

Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life threatening and can lead to death.

Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse.

Tecentriq can cause serious side effects, including:

Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment with Tecentriq if patients have severe side effects.

Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:

The most common side effects of Tecentriq when used in triple-negative breast cancer with paclitaxel protein-bound include:

Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.

These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information. Patients should call their doctor for medical advice about side effects.

Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Report side effects to Genentech at 1-888-835-2555.

Please visit http://www.Tecentriq.com for the Tecentriq full Prescribing Information for additional Important Safety Information.

Avastin is approved for:

Avastin in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (prOC) in women who received no more than two prior chemotherapy treatments.

Avastin, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (psOC)

Possible serious side effects

Everyone reacts differently to Avastin therapy. So, its important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Their doctor will stop treatment if any serious side effects occur. Patients should contact their health care team if there are any signs of these side effects.

Side effects seen most often

In clinical studies across different types of cancer, some patients experienced the following side effects:

Avastin is not for everyone

Patients should talk to their doctor if they are:

Patients should talk with their doctor if they have any questions about their condition or treatment.

Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Report side effects to Genentech at 1-888-835-2555.

For full Prescribing Information and Boxed WARNINGS on Avastin please visit http://www.avastin.com.

About Genentech in personalized cancer immunotherapy

For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. Today, were investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Genentech is currently studying more than 10 cancer immunotherapy medicines across 70 clinical trials alone or in combination with other medicines. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines. For more information visit http://www.gene.com/cancer-immunotherapy.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191020005095/en/

See original here:
Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular...